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Abstract
Abstract
Human papillomaviruses type 16 (HPV-16) is one of a number of HPV types 
specifically associated with the development of carcinoma in the anogenital 
tract and HPV-16 is the most commonly found subtype in cervical 
carcinomas worldwide. The early HPV proteins are expressed throughout 
epithelial differentiation, but expression of the late proteins is tightly linked to 
the differentiation status of the host cell, being found only in cells in the 
process of keratinisation in the granular layer of stratified epithelia. For HPV- 
16, a 79 nt negative regulatory element (NRE), overlapping the 3’ end of the 
L1 stop codon and extending into the late 3’ untranslated region, is an 
important post-transcriptional regulator of viral late gene expression. 
Unsurprisingly, the HPV-16 NRE has previously been shown to bind a range 
of RNA processing factors in vitro, including the auxiliary splicing factor 
U2AF65, the polyadenylation factor CstF-64, and the elav-like HuR protein.
I carried out saturating site-directed mutagenesis of the HPV-16 NRE and 
found that no individual short sequences are responsible for the activity of 
this inhibitory element, or its ability to interact with cellular factors. I have 
used an affinity-chromatography based RNA binding assay to show that the 
NRE can also bind the splicing-related (SR) protein, ASF/SF2, a member of 
the Sm protein family, and the U1A subunit of UlsnRNP. Furthermore, using 
a novel monolayer culture differentiation system and organotypic rafts to 
generate undifferentiated and differentiating populations of HPV-16 positive 
epithelial cell lines, I have shown by Western blot analysis that the level of 
expression of the NRE-binding proteins is differentially regulated, and is 
influenced by the status of the viral genome in the infected cell. I suggest 
that the inhibitory activity of the HPV-16 NRE is overcome as a result of the 
upregulation of cellular factors that bind the NRE.
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Introduction
CHAPTER 1: INTRODUCTION
1.1.1 History
The infectious nature of animal and human warts was established in the 
1890s but it was not until 1933 that the first papillomavirus was described by 
Shope, who determined that cutaneous papillomatosis in the cottontail rabbit 
was caused by the cottontail rabbit papillomavirus (CRPV) (Shope, 1933, 
reviewed in Howley, 1996, zur Hausen et al., 1994). Shope showed that 
inoculation of a wart extract onto scarified skin of cottontail or domestic 
rabbits resulted in transmission of the disease (Shope, 1933, Breitburd et al., 
1997). Wart regression occurs in most infected animals within 6 months, 
however, malignant transformation of certain warts occurs after this time in 
25% of animals, and metastatic tumours are observed in the majority of 
these malignancies (Breitburd et al., 1997). CRPV was one of the first 
experimental examples of a mammalian cancer virus and of an oncogenic 
DNA virus. Since then it has emerged that papillomaviruses are widespread 
in nature and, while they have been described primarily in higher 
vertebrates, papillomavirus infection in lower vertebrates has also been 
reported (reviewed in Howley, 1996).
Papillomavirus virion production requires full epithelial differentiation, 
consequently, studies on papillomaviruses have, until recently, been 
hampered by the lack of a suitable in vitro tissue culture system. Initial 
studies, therefore, focused on bovine papillomavirus (BPV) since this virus, 
unlike most HPV-types, causes large productive lesions, in the natural host, 
from which large quantities of BPV virions can be isolated. BPV induces 
fibropapillomas and is the only papillomavirus known to cross the species 
barrier, giving rise to sarcoids in horses, although these lesions do not 
produce infectious virions (Olson eta!., 1951). BPV-4 infects the upper 
gastrointestinal tract and induces squamous epithelial papillomas. However, 
in cattle grazing on bracken fern these papillomas can transform and
1
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progress to squamous cell carcinoma (Beniston et al., 2001). Bracken fern 
contains immunosuppressants and a number of mutagens, including 
quercetin. BPV virions are also capable of transforming a variety of rodent 
cells in tissue culture and by the late 1970s a quantitative transformation 
assay had been developed for BPV-1 that opened the way for the analysis of 
viral genes involved in the induction of cellular proliferation (Dvoretzky et al., 
1980, reviewed in Howley, 1996). This development, together with the 
successful cloning of the BPV-1 genome in bacteria in 1980 (Howley et al., 
1980), led to extensive study of this virus, which has served as the molecular 
prototype of the papillomaviruses, particularly in the study of viral DNA 
replication and transcriptional regulation. Interest in the study of BPV and 
other PVs has recently been renewed by the development of anti­
papillomavirus vaccines in naturally occurring animal models including cattle, 
rabbits and dogs. A number of anti-HPV vaccines, based on vaccines 
developed in these animal models, are now in clinical trials (Stanley et al., 
1997, Morgan et al., 2000, Nicholls et al., 2000).
Gradual improvements in molecular cloning and cell culture techniques 
made the direct study of HPVs less problematic, and by the late 1970s the 
plurality of human papillomavirus (HPV) types was beginning to emerge 
(reviewed by zur Hausen et al., 1994, Howley, 1996). The major stimulus for 
the interest in HPVs at this time originated from the discovery of their causal 
relationship with a common form of human cancer, carcinoma of the cervix. 
Surprisingly, this relationship had not been considered prior to 1974 despite 
the fact that CRPV was known to be carcinogenic in rabbits, and BPV could 
malignantly transform rodent cells in tissue culture and infected cells in vivo 
in association with bracken fern (zur Hausen et al., 1994). By 1983 however, 
specific HPV types had been isolated directly from cervical cancer biopsies 
and a preponderance of evidence now supports a causal link between 
human papillomavirus infection and cervical neoplasia (Durst etal., 1983, 
Boshart et al., 1984, Canavan etal., 2000).
2
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1.1.2 Taxonomy
Until very recently, the papillomaviruses were grouped together with the 
polyomaviruses to form the papovavirus family on the basis of small size, a 
non-enveloped virion, an icosahedral capsid, a double-stranded circular DNA 
genome, and the nucleus as a site of replication (Howley, 1996). However, 
the papovavirus family has now been divided into two families, the 
Polyomaviridae and the Papillomaviridae, as a result of the fundamental 
differences in the genomic organisation, size and biology of these viruses 
(de Villiers, 2001): Polyomaviruses are generally smaller in size than 
papillomaviruses (40nm versus 55nm), with a smaller genome (5000 bp 
versus 8000 bp). In addition, the molecular biology of polyomaviruses differs 
considerably; for example, both strands of the genome serve as templates 
for transcription (Dimmock and Primrose, 1994). The taxonomic 
classification of papillomaviruses, based on the degree of genome 
relatedness has been a controversial issue, and has to date, not been 
accepted by the International Committee on the Taxonomy of Viruses (ICTV) 
(de Villiers, 2001). However, 86 complete genomes of the human 
papillomaviruses and 16 animal papillomaviruses have been characterized 
so far and more than 120 putative novel HPV types have been partially 
characterized (de Villiers, 2001). The definition of a new papillomavirus type 
has changed over the years as more information from newly characterized 
types has become known. Since 1995, a new papillomavirus type has been 
defined as one sharing less than 90% DNA homology within only the L1 
open reading frame (ORF) of the closest related type (reviewed in Howley, 
1996, de Villiers, 2001). Based on nucleotide sequences the 
Papillomaviridae can be divided into at least five subgroups, classified as 
Papillomavirinae A to E, and it is likely that additional subfamilies will be 
identified in the future. Papillomavirinae A to C are further divided into 
genera A1 to A14, B1 and B2, and C1 to C3 respectively (de Villiers, 2001)
3
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(Fig. 1.1). Demarcation of genera within the remaining subfamilies is not 
possible at present due to a lack of information.
1.1.3 Sites of HPV-lnfection
Thus far, all types of HPV identified appear to be strictly epitheliotropic; they 
infect epithelial cells either of the skin or of the anogenital and oropharyngeal 
mucosa (reviewed in Beutner etal., 1997). Because of this, papillomaviruses 
have historically been grouped according to tissue tropism, i.e. the location 
of the lesion from which the virus was originally isolated and subsequently 
detected in. Therefore, HPV types are generally grouped as either 
mucosal/genital or cutaneous groups, however, this division is not absolute. 
Infection with HPV, whether mucosal or cutaneous, is associated with a wide 
variety of clinical manifestations ranging from laryngeal papillomatosis to 
intra-epithelial neoplasia (reviewed by Shah etal., 1996) Table 1.1. This 
table clearly demonstrates that while papillomaviruses have a strict tropism 
for epithelial cells, this tropism extends beyond merely host and tissue 
specificity to an affinity for specific anatomical sites, HPV-1 is commonly 
found on the soles of the feet or the fingers and hands, whereas HPV-16 is 
generally associated with the anogenital region. This preference for 
anatomical sites is most likely related to differences in transcriptional 
requirements of different HPV types as well as the mechanisms of 
transmission (Meyers et al., 1994a).
1.1.4 Differentiation of normal epithelia
The productive viral life cycle of HPVs is tightly linked to epithelial 
differentiation (Stanley, 1994). In normal epithelia, only the basal cells in the 
lower layers are mitotically active and divide to produce two daughter cells, 
one of which may migrate from the basal layer and become committed to 
differentiation (Fuchs et al., 1994). If this happens, this daughter cell moves 
from the basal layer to the spinous layer, in which cells are postmitotic but
4
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metabolically active, and devote much of their protein synthesizing activity to 
manufacturing two keratins, K1 and K10 (Fuchs et a/., 1993). In addition, 
cells in the upper spinous layer and granular layer make lysine-rich envelope 
proteins such as involucrin, which are deposited on the inner surface of the 
plasma membrane of each cell (reviewed in Fuchs, 1990). As cells reach the 
upper granular layers, they stop generating keratin proteins and switch to 
production of loricrin, which is a glycine-rich insoluble protein, and a major 
component of the cornified envelope. Filaggrin, a matrix protein for keratin 
filaments is also expressed at this time (Fuchs et al., 1994). During the 
transition from the granular to the cornified layer there is a rather abrupt 
onset of intracellular degradation leading to the loss of nuclei and cellular 
organelles. By the time the daughter cell reaches the skin surface it has 
undergone a series of biochemical and morphological changes that 
culminate in the production of dead, flattened, enucleated squames, which 
are sloughed from the surface and continually replaced by inner cells 
differentiating outward. This is a continuous, life-long process in humans 
which for skin takes approximately 3 to 4 weeks for completion (Fuchs et al., 
1994) (Fig. 1.2). Non-keratinizing epithelia such as the cervix may have a 
more rapid turnover time but this is unlikely to be less than 7-10 days (Fuchs 
etai ,  1993).
1.1.5 HPV-lnfection of Epithelia
It is generally accepted that papillomavirus growth requires the infection of 
cells in the basal layer of the epithelium, since these contain the necessary 
transcription machinery for viral protein expression and replication. The most 
likely route of infection by papillomaviruses is through tiny abrasions and 
microtraumas in the epithelial architecture (Meyers et al., 1994a). Only the 
primary target cells of cottontail rabbit papillomavirus (CRPV) have been 
identified to date, and are thought to be present in hair follicles, where they 
colocalize with a subpopulation of keratinocytes with properties of epidermal
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stem cells (Schmitt et al., 1996). However, unlike CRPV, a number of PVs 
specifically target epithelial sites that lack hair follicles, such as mucosal 
epithelium. Nevertheless, cells with features of stem cells have been 
identified in discrete areas of mucosal epithelium, for example, at intervals in 
the basal layer of the pluristratified epithelium of the cervix, and so these 
stem-like cells may serve as target cells for this subset of PVs (Stanley, 
1994). However, the question remains as to whether these target cells carry 
a specific receptor molecule for PV or alternatively provide unique 
transcription machinery for PV gene expression. BPV-1 virions and HPV-11 
virus-like particles (VLPs) have been shown to bind both to human 
keratinocytes and cell lines of epithelial and fibroblast origin suggesting that 
the PV receptor molecule(s) are ubiquitously expressed (Roden, et al.,
1994). Despite this, the identity of the cell surface receptor(s) for PVs 
remains controversial and several candidates have been proposed to date. 
The integrin alpha-six beta-four protein complex (a6 integrin) is expressed 
primarily during wound healing which makes it a logical candidate, and while 
no functional studies have yet shown it to mediate HPV entry, a recent report 
using HPV-16 VLPs indicated that the degree of VLP binding was directly 
proportional to the level of expression of a6 integrin (Yoon et al., 2001). In 
contrast, it has been shown that ot6 integrin is not the obligatory cell receptor 
for BPV-4, which, like all HPVs, is strictly epitheliotropic. BPV-4 virions were 
found to bind cells lacking a6 integrin to similar, saturatable levels as normal 
keratinocytes (Sibbet et al., 2000). Nor does it appear that oi6 integrin is 
involved in HPV-33 pseudovirion infection (Giroglou et al., 2001).
Additional reports have implicated the ubiquitous polysaccharide, heparan 
sulphate, as the cell surface receptor for PV (Combita et al., 2001, Giroglou 
et al., 2001). A recent study has also presented evidence suggesting that 
heparan sulphate may be the initial attachment point, and this is followed by 
association with a secondary receptor complex prior to internalisation, similar 
to the situation for certain herpes and adenoviruses, as well as dengue, 
Sindbis and vaccinia viruses (Giroglou et al., 2001). Moreover, it has been
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postulated that this secondary receptor may be L2-specific; L2 is the minor 
viral capsid protein and results suggest that an interaction between a 
conserved N-terminal domain of L2 and an, as yet unidentified, cell surface 
protein plays an important role in papillomavirus infection (Kawana et al., 
2001). It has been well established that the incorporation of L2 increases the 
infection efficiency of pseudovirions and that antibodies to L2 can be 
neutralising, indicating that L2 is important for infection (Cornelison, 2000).
Following entry into the basal cell, HPV genomes are established as 
extrachromosomal elements in the nucleus and copy number is increased to 
approximately 20-100 copies per cell, with viral DNA replication occuring in 
synchrony with DNA replication in the infected cell (Stanley, 1994). As 
infected cells divide, viral DNA is distributed between both daughter cells. 
One daughter cell may withdraw from the cell cycle, migrate from the basal 
layer and initiate a programme of differentiation. The remaining daughter cell 
continues to divide in the basal layer and provides a reservoir of viral DNA 
for further cell divisions, but the virus continues to maintain its genome at a 
low-level in these cells. Production of mature virus is restricted to suprabasal 
cells, consequently, the cells in the basal layer are not lysed by virion 
production but continue to proliferate and can persist for extensive periods. 
As the differentiating infected daughter cell migrates upward, viral early 
proteins continue to be expressed in all layers of the epithelium. However, 
expression of late viral proteins and activation of productive viral replication 
is blocked very effectively until the infected cells undergo terminal 
differentiation (Meyers, etai ,  1994b). This is an unusual infection strategy 
since, in order to replicate its genome in the unfavourable environment of the 
differentiated cell, HPV must reactivate the quiescent cellular DNA 
replication machinery, similar to the polyomaviruses and adenoviruses. It 
has been reported that HPV-16 can switch replication mode during its life 
cycle. In the mitotically active basal cells, the virus replicates bidirectionally, 
via theta structures, and is highly dependent on host cellular factors,
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however in terminally differentiated cells, the virus switches to a rolling circle 
mode of replication which is unidirectional, and one initiation event leads to 
the generation of multiple copies of the genome and so fewer cellular factors 
are required (Lambert et al., 1991, Flores etal., 1997). Mature virus particles 
are observed in the granular layers of the epithelium but little is known about 
papillomavirus assembly or release, although the virus does not appear to 
be cytolytic. It seems highly likely that virions are transmitted from the layers 
of desquamated cornified cells (DCCs), which are continuously shed from 
the stratum corneum, the uppermost epithelial layer. DCCs normally have a 
very durable structure, and therefore virion release from these cells would 
require the cornified cell envelope to break apart. Interestingly, it has 
previously been reported that the envelope of DCCs from HPV-11-infected 
genital epithelium are unusually thin and fragile and it has since been shown 
that DCCs serve as vehicles for the efficient, concentrated delivery of virions 
in an HPV-11 infection (Bryan et al., 2001). If other HPVs use a similar 
mechanism for virion release then it seems highly likely that virion 
transmission and subsequent infection is a local event.
1.2.1 HPV- associated Disease
For the purposes of this discussion I have divided HPV-associated diseases 
on the basis of anatomical site of infection i.e. skin, respiratory tract and 
anogenital tract, as shown in Table 1.1:
Skin
The soles of the feet and the hands appear to be the favoured sites for wart 
formation and specific HPV types are associated with each location and wart 
morphology: for example, common warts are generally found on the hands 
and are associated with HPV-2 and -A, while deep plantar warts, associated 
with HPV-1, are more commonly found on the soles of the feet. Butcher’s 
warts are associated with HPV-7 and might be considered an occupational
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hazard since they are found almost exclusively on the hands of butchers and 
meat and fish handlers. The majority of warts regress spontaneously within 2 
years and are rarely associated with the development of malignancy 
(reviewed in Shah eta!., 1996).
Epidermodysplasia verruciforms (EV) is a rare genetic skin condition 
involving a lifelong predisposition to HPV-infection, leading to chronic 
nongenital HPV lesions on sun-exposed sites, which can develop into 
squamous cell carcinomas overtime (reviewed in Shah et al., 1996). Two 
types of warts occur in EV patients, flat warts and reddish-brown macular 
plaques and although HPV types -5, -8 , -17 and -20 are most frequently 
found in EV patients, a large number of other HPV-types have also been 
associated with EV lesions including -3, -9, -10, -12, -14, -15, -17, -19, -20 
and -25 (reviewed in Shah et al., 1996).
There has been a great deal of data published recently regarding the 
potential role of human papillomavirus infection in the genesis and 
progression of non-melanoma skin cancers (NMSC), which are the most 
commonly diagnosed carcinomas among Caucasians worldwide (de Villiers 
et al., 1999). The importance of ultraviolet radiation (UVR) in the 
development of these cancers has previously been well established and is 
now considered the most important etiologic factor. However, a growing 
body of evidence suggests that certain types of HPV, similar to those 
associated with EV lesions, either alone or in conjunction with UVR, may 
play a role in the pathogenesis of these cancers (reviewed in Kiviat, 1999).
HPV infection has also been implicated in the development of head and neck 
squamous cell carcinoma as a result of the presence of HPV DNA, 
particularly HPV-16, in tumour tissue. However, the results of various 
retrospective and prospective case studies have been inconclusive and it 
remains possible that the development of cancer simply improves the 
detection of virus in these lesions (Mork et al., 2001 ).
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Respiratory Tract
The best-characterised HPV infections of the respiratory tract are laryngeal 
papillomas, also known as recurrent respiratory papillomatosis (RRP) 
(Mounts et al., 1984). These papillomas result from transmission of HPV-6 
and - 11 , commonly found in genital warts, to the respiratory tract and so in 
most cases, virus transmission is believed to occur vertically during the 
birthing process (reviewed in Shah e ta i, 1996). In addition, it has been 
suggested that viral transmission may occur in utero, but this appears to be 
an infrequent event (Fredericks et al., 1993). A striking characteristic of 
laryngeal papillomas is the frequency of recurrence following surgery or 
treatment. Recurrence most likely results from the reactivation of latent viral 
DNA in histologically normal epithelium adjacent to the papillomas (Ferenczy 
e ta i, 1985).
Two HPVs appear to exclusively infect the oral cavity, HPV-13 and -32, and 
both are associated with the well-characterised condition, focal epithelial 
hyperplasia (FEH), which, although it has a worldwide distribution, is 
particularly common in the indigenous populations of Central and South 
America and of Alaska and Greenland (reviewed in Shah et al., 1996). FEH 
is characterised by self-limiting multiple nodules on the oral mucosa, which 
do not undergo malignant transformation.
HPV infection is also frequently detected in tonsillar carcinoma; however, 
unlike the examples mentioned above, some reports suggest that the 
presence of HPV in these cases is a prognostically favourable factor for 
patient survival and also for low risk of relapse by making the tumours more 
susceptible to radiation treatment (Friesland et al., 2001). However, a 
previous study reported the presence of integrated HPV-6a DNA in a 
tonsillar carcinoma; this is very unusual since HPV-6 is generally considered 
a low-risk virus and rarely integrates into the host genome (Bercovich et al., 
1991).
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Genital Tract
One of the most well studied sites for HPV infections is the genital tract. 
Approximately 40 different HPV types are known to infect the anogenital 
tract where infection can give rise to a range of clinical outcomes from 
benign genital warts through to cancer of the cervix, penis and vulva. 
Papillomaviruses were first recognised as the etiologic agents of genital 
warts in the late 1960s and further study led to the recognition of the causal 
role of HPV-infection in carcinomas of the genital region (reviewed in zur 
Hausen et al., 1994).
Genital warts are the most commonly recognized clinical lesions of genital 
HPV infections and are typically transmitted through sexual contact. HPV-6 
and HPV-11 are most commonly associated with condyloma acuminata and 
these warts generally regress either spontaneously or following treatment 
and rarely progress to malignancy. Therefore, HPV types - 6  and -11 are 
generally regarded as low-risk types due to their lack of oncogenic potential 
Beutner et al., 1997). Conversely, a subset of genital HPVs are frequently 
detected in anogenital cancer biopsy specimens: The main representatives 
are HPV types -16, -18, -31, -33, -39, -45, -52, -58, and -69, which 
specifically possess cell-immortalising and transforming properties and are 
considered as high-risk types (reviewed in Kaufman et al., 2000). These 
high-risk viruses are associated with carcinoma at a number of lower genital 
sites, however, the most extensively studied anogenital cancer is cervical 
carcinoma, which is second only to breast cancer in terms of the number of 
women affected worldwide (Canavan et al., 2000). The high incidence of 
invasive cervical cancer as compared to the lower incidence of cancer at 
other sites in the female genital tract is ascribed to the high susceptibility of 
the cervical transformation zone to carcinogens (Shah et al., 1996). The 
transformation zone is located at the lower end of the cervix where the 
columnar cells of the endocervix meet the stratified squamous epithelium of
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the ectocervix; cells in this zone are subject to rapid turnover (reviewed in 
Stanley et al., 1992).
1.2.2 Development of Cervical Carcinoma
The natural history of invasive squamous cell carcinoma of the cervix has 
been well documented, and it is generally accepted that the majority of 
invasive neoplasms arise from a focus of intraepithelial neoplasia that may 
have been present within the cervix for many years (reviewed in Stanley, 
1994). For example, detectable HPV-16 DNA persists in the female genital 
tract for a mean time of approximately a year, and the median time to 
develop an anti-HPV-16 capsid antibody response in serum is also 
approximately 1 year (Galloway et al., 1996). Following detection of viral 
DNA, the earliest pre-invasive changes, which are squamous intraepithelial 
lesions, are asymptomatic and can develop in as little time as 2 years, 
although additional co-factors may influence this time interval (Galloway et 
al., 1996). Currently it is assumed that squamous cell carcinoma of the 
cervix develops through a continuum of progressive cervical intraepithelial 
neoplasia (CIN) lesions (Stanley, 1994) (Fig. 1.3). These lesions are graded 
according to the proportion of the epithelium occupied by undifferentiated 
cells of basal type: In CIN grade I, the cells in the upper and middle third of 
the epithelium undergo differentiation. In CIN grade II, cells with an 
undifferentiated basal phenotype extend beyond the lower third of the 
epithelium but not into the upper third and some abnormal mitotic figures are 
also present in the lower two thirds. In CIN grade III, undifferentiated 
nonstratified cells occupy more than two thirds, and often the full thickness, 
of the epithelium. These abnormal cells remain intraepithelial but if invasion 
occurs, the neoplastic cells penetrate the underlying basement membrane 
and invade the stroma with the potential for widespread dissemination 
(reviewed in Stanley, 1994).
12
Introduction
1.2.3 Integration of Viral DNA into the Host Genome
Increasing CIN grade is often accompanied by integration of the viral 
genome into the host DNA (Durst et al., 1985). This integration event 
frequently disrupts the early viral coding region, resulting in the loss of 
expression of all the viral proteins with the exception of the viral oncoproteins 
E6 and E7, which actually become overexpressed (Durst et al., 1991). 
However, given that the average age of patients with CIN III in the United 
States is 29, and the median age of invasive cervical cancer patients is 49, 
the additional changes required for invasion and metastasis appear to be 
acquired slowly over time and may not be a direct consequence of the 
overexpression of viral oncoproteins (reviewed in Galloway et al., 1996). A 
substantial body of evidence now exists which supports the hypothesis that 
while high-risk oncogenes are necessary for cell immortalisation and 
tumourigenesis, they are not sufficient for the development of the malignant 
phenotype, which requires the interruption of host cell genes that normally 
suppress the tumorigenicity of immortalised cells. For example, somatic cell 
hybridisation of individual clones of HPV-immortalised human keratinocytes 
frequently results in senescence of the cell hybrids despite the continued 
expression of viral oncogenes (reviewed in zur Hausen, 1999). Moreover, a 
number of specific chromosomal aberrations have been observed in HPV- 
immortalised cells and in cervical carcinomas; cytogenetic analyses have 
frequently reported changes in chromosome 3 as well as chromosome 18, 
corresponding to loss of the fragile histidine triad (FHIT) gene (Butler et al.,
2000 ) and the putative tumour suppressor gene, deleted in colon cancer 
(DCC) (Klingelhutz et al., 1995), respectively. Surprisingly, however, HPV 
genomes do not appear to integrate at any specific locus on the host 
genome, for example close to tumour suppressor genes or proto-oncogenes, 
as observed for other oncogenic viruses such as certain retroviruses and 
hepatitis B viruses. Therefore, it appears that in addition to expression of 
high-risk HPV oncogenes, other factors contribute to specific alterations
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within the host-cell DNA, which collectively result in malignant progression 
(Fig. 1.4).
1.2.4 Epidemiology
In 1995 the International Agency for Research on Cancer (IARC) stated that 
there was no doubt that infection with certain types of HPV is the main cause 
of cervical cancer (reviewed in Munoz, 2000). The IARC also concluded that 
there was sufficient evidence to categorize HPV types -16 and -18 as 
human carcinogens but the existing evidence was limited or inadequate to 
allow a similar categorization of other HPV types (Munoz, 2000). However, 
subsequent extensive worldwide studies have led to the recognition of a 
large number of additional carcinogenic HPV types including HPV-31, -33, - 
35, -39, -45, -51,-52, -54, -56, -58, -59, -6 6 , -69 and -70 (Munoz, 2000). A 
comparison of 1000 cases of histologically confirmed invasive cervical 
carcinomas from 22 countries worldwide revealed that 99.7% of cases were 
HPV-positive: 53% HPV-16, 15% HPV-18, 9% HPV-45, 6% HPV-31 and 3% 
HPV-33 (reviewed in Munoz, 2000). HPV-16 was found to be the most 
prominent type world wide although there were geographical variations; in 
Indonesia and South East Asia, in general, HPV-18 was the most common 
type, while in Western Africa HPV 45 was frequently found, whereas HPV 
types -33, -39 and -59 were found more often in Central and South America 
than in other regions (reviewed in Munoz, 2000). Higher rates of HPV 
prevalence in certain geographical regions also correlates well with the 
differences in cervical cancer incidences worldwide. African countries and 
Latin America have a high HPV prevalence and large numbers of cervical 
cancer cases, other countries such as Thailand and the Philippines report an 
intermediate prevalence of HPV infection and intermediate numbers of 
cervical carcinoma patients, while most European countries have a much 
lower HPV prevalence and fewer cases of cervical carcinoma (Bosch, 1999).
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The mean age of cervical cancer patients worldwide is 52 years and the 
distribution of cases is biphasic with peaks at 35-39 and 60-64 years, 
although a recent study in Argentina surprisingly revealed no second peak of 
incidence (Munoz, 2000). The majority of all cervical carcinomas are 
squamous cell carcinoma (85-90%) and the second most common type is 
adenocarcinoma (10-15%), which arises from the columnar epithelium, lining 
the endocervical canal and glands (Tjiong et al., 2001). Adenocarcinoma is 
generally more rapid and aggressive that squamous cell carcinoma (SCC) 
and is more frequently associated with HPV-18 than HPV-16 (reviewed in 
Beutner et al., 1997).
Most HPV infections are transient in immunocompetent woman and the 
prevalence of infection is age-related, such that in woman aged 20-25 years 
the reported HPV prevalence is 20-46% while in women over 30 this 
decreases to 6% (Melkert et al., 1993). Moreover, it appears that in most 
women the immune system can successfully overcome an HPV infection 
even when cervical intraepithelial neoplasia (CIN) has developed; data from 
a number of retrospective studies indicates that only 1 % of CIN I progress to 
invasive lesions, this increases to 5% for CIN II and to 12% for CIN III 
lesions (Arends et al., 1998), which are widely believed to be the immediate 
precursors of invasive carcinoma. Clearly, cervical cancer is a multi-step 
process as indicated by the low number of high-risk HPV infected woman 
that develop cervical cancer and the low rate of progression from high-grade 
cervical lesions to invasive carcinoma. Further viral and non-viral factors 
must play a role in cervical carcinogenesis.
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1.2.5 Risk Factors
HPV-associated risk factors for invasive cervical carcinoma include infection 
with certain high-risk types particularly HPV-16, -18, -45, and -56 (reviewed 
in Canavan et al., 2000). Most genital HPV infections are cleared within 6 to 
12 months of infection, and infections not cleared within this time are 
considered to be persistent and only persistent infections progress to 
neoplasia (Einstein etai., 2001). Naturally occurring HPV variants may also 
be important co-factors. Variants are defined as having less than 2% 
variation in their genome. For example, infection with Non-European HPV-16 
variants is more likely to indicate an increased risk of cervical cancer 
development compared to infection with European variants (reviewed in 
Nindl, 2002). It is likely that naturally occurring variants such as these have 
different biological and biochemical properties that result in differences in 
viral pathogenicity.
Sexual activity is considered the most important non-viral risk factor. Genital 
HPV infection is primarily a sexually transmitted disease and therefore 
factors such as the age at first intercourse (Parazzini et al., 1992), the 
number of sexual partners and the frequency of sexual intercourse influence 
the risk of acquiring such an infection (Tijong et al., 2001). However, it has 
been argued that a lower age at first intercourse is not a true co-factor but 
instead exerts its effect by influencing the lifetime number of sex partners 
(reviewed in Koutsky, 1997). Individuals, who have previously been infected 
with a sexually transmitted disease, including HPV, also appear to be at 
greater risk of acquiring a persistent HPV infection (Parazzini et al., 1992).
The use of oral contraceptives has long been the subject of great 
controversy with several reports presenting contradictory data including one 
report suggesting that while oral contraceptive use had no effect on the 
incidence of low-grade cervical lesions, the risk of high-grade lesions did 
increase, implying that oral contraceptives, possibly by varying hormone
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levels, act by altering disease progression rather than by increasing the risk 
of HPV infection (Negrini et al., 1990). The hormonal and physiological 
changes that occur during pregnancy might also explain the higher rates of 
HPV infection detected in pregnant women, in some studies (Schneider et 
al., 1990). Reports relating to the influence of cigarette smoking are also 
contradictory and less convincing, partly because it is difficult to establish if 
this type of activity influences the risk of acquiring infection or simply 
improves the efficiency of detection of latent infections (reviewed in Koutsky, 
1997).
A number of reports have also suggested that women with HLA class II 
DQw3 are at an increased risk of developing cervical cancer (Wank et al., 
1991), however, a further report disputed this and the matter remains 
unresolved (Glew et al., 1993). A similar impasse has been reached with 
regards to the influence of the p53 codon 72 polymorphism on progression 
of cervical neoplasia, with some reports suggesting that an arginine/arginine 
genotype at codon 72 in the p53 gene predisposes individuals to tumour 
progression (Storey et al., 1998), and yet others convincingly arguing that 
there is no correlation between HPV infection, p53 codon 72 arginine 
polymorphism and the development of squamous cell carcinoma (O’Connor 
et al., 2001 ).
In contrast, the immune status of the host appears to have a significant 
impact on the ability to detect genital HPV infection and on the progression 
of HPV-induced lesions. In immunocompromised individuals, such as, 
human immunodeficiency virus (HlV)-infected women and organ transplant 
recipients, the presence of HPV infections and anogenital neoplasia is higher 
than in the general population. In one study persistent HPV infections were 
detected in 24% of HIV-seropositive women but only in 4% of the control 
group (Sun et al., 1997). Moreover, approximately 50% of symptomatic HIV- 
infected women in a number of studies appeared to have abnormal cervical
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cytology suspect for squamous intraepithelial lesions (Schafer etai., 1991).
In a comparison of immunosuppressed renal transplant patients and normal 
controls, a 17-fold greater incidence of genital HPV infection and a 9-fold 
increase in HPV-related CIN lesions were found in the immunosuppressed 
group (Halpert et al., 1986). Immunosuppression could result in a higher 
prevalence of HPV infection either by increasing the risk of infection or by 
impairing the body’s ability to suppress latent infection.
1.2.6 Infection with multiple HPV types
A recent study comparing HPV-types in NMSC lesions of immunocompetent 
and immunosuppressed patients revealed that 59.1% of transplant tumours 
compared to 13.04% of immunocompetent tumours contained multiple HPV- 
types (Harwood et al., 2000). This observation also extends to anogenital 
warts. Christensen et al., (1997) reported several genital HPV types detected 
within a single anal wart from a renal transplant patient, however, localisation 
by in situ hybridisation suggested that each HPV type maintained regional 
separation within the lesion. Similarly Unger et al., (1997) reported the 
presence of multiple HPV types clustered in geographically distinct areas 
within anogenital warts in immunocompromised HIV-positive patients. 
Coinfection with multiple types of genital HPV in immunocompetent 
individuals has also been reported, but the frequency of occurrence and 
whether prior infection with specific HPV types inhibits subsequent infection 
by related types is not known. A recent report found that concurrent 
acquisition of multiple HPV types occurred more often than expected by 
chance, however, no two types were more or less likely to be acquired 
concurrently, and prior infection with a phylogenetically related type did not 
decrease the risk of subsequent infection with a new type (Thomas et al.,
2000). Fife et al., (2001) have suggested that the number of HPV-types in a 
multiple infection correlates with increasing cervical dysplasia.
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1.2.7 Immune Response to HPV-lnfection
The reasons for the enormous diversity of HPV types as well as the 
restriction of viral propagation to external skin or specific internal mucosal 
sites are presently unknown. The possibility exists however, that both of 
these observations are interrelated. The replication of viral DNA and the 
subsequent particle formation in external differentiated epithelial cells of skin, 
anogenital, and oral mucosa may expose these infections to less 
immunologic interference (reviewed in zur Hausen, 2000). The absence of 
immunologic interference could be the major reason for reduced evolutionary 
restraints, permitting the adaptation of new HPV variants to different types of 
differentiated epithelia. It has been reported that the rate of seroconversion 
following infection with either HPV 16, 18 or 6 varies, such that the timing of 
seroconversion was markedly delayed for HPV-16 compared with HPV-6  
infections and it seems likely that this is due to differences in the nature of 
these viral infections (Carter et al., 2000). HPV-6 capsid proteins may be 
more immunogenic and therefore the infections are eliminated more quickly. 
Conversely, high-risk HPV infections employ strategies that may delay the 
recognition of the viral proteins such as interference with the interferon 
response pathways: Stat-1 and interferon genes have recently been 
identified as transcriptional targets of HPV-31 through microarray analysis 
(Chang et al., 2000). HPV-16 E6 and E7 proteins have also been shown to 
inhibit the transcriptional activity of interferon regulatory factor 3 (IRF-3) 
(Ronco et al., 1998). Therefore, it appears that high risk HPVs can affect 
both the synthesis of interferon and also the interferon response pathway.
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1.2.8 Latency
HPV restricts expression of its most immunogenic proteins, the capsid 
proteins, to the upper layers of the skin, which not only helps efficient 
transmission of mature virions but may also enable the virus to establish 
latent infections in the lower layers of the epithelium. While it is not yet clear 
if papillomaviruses have a true latent phase, as has been well documented 
for a number of other viruses such as HSV-1, EBV or varicella zoster, 
evidence exists to suggest that CRPV can induce a latent infection 
(Stubenrauch et al., 1999). Infection of rabbits with low doses of CRPV 
results in the development of papillomas at a small number of sites (10- 
20%), sites that do not develop papillomas are positive for viral DNA and can 
be induced to form papillomas following treatment with photosensitizers 
indicating that these infections are truly latent and not abortive (Amelia et al.,
1994). In addition, several clinical observations suggest that a latent state 
also exists for HPV infections in vivo. The rapid appearance of genital and 
cutaneous papillomas in immunosuppressed renal transplant and HIV- 
positive patients, despite the absence of obvious lesions before treatment, 
provides support for such a state (Sillman et al., 1984). In addition, the 
persistent reappearance of HPV-11 papillomas in the larynx of children 
indicates that even in immunocompetent individuals this viral type can exist 
latently (Ferenczy et al., 1985). True HPV latency can be defined as the 
presence of viral DNA in the absence of differentiation-dependent virion 
production and therefore, the presence of HPV DNA in basal cells cannot be 
called a true latent state (Stubenrauch et al., 1999). However, if an infected 
stem cell failed to divide a state of latency could be achieved, and the level 
of expression and activity of viral proteins such as E6 and E7 could 
potentially prevent the cell cycle progression of infected cells. In support of 
this, a comparison of HPV-11 transcripts in respiratory papillomas and 
latently infected tissue showed that this tissue lacked correctly processed 
mRNAs encoding the E6 and E7 proteins and had only low levels of
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expression of the early viral proteins, E1 and E2, suggesting that a limiting 
amount of key viral proteins may be a factor in latent infections (Maran et al.,
1995). Whether a true latent state exists for these viruses remains an 
important question for the development of therapeutics to treat HPV 
infections.
1.2.9 HPV Diagnosis
In light of the recognition of the strong causal relationship between infection 
with certain types of HPV and the development of cervical carcinoma, 
accurate diagnosis of HPV infection is an important source of information. 
Observation together with colposcopic examination is a useful conventional 
method for the detection of clinically apparent infection, manifesting as 
distinctive anogenital warts, however due to low diagnostic specificity this 
approach is more useful as an investigative, rather than a diagnostic, tool 
(Trofatter, 1997). Moreover, since the majority of individuals have no clinical 
manifestation of HPV-infection, detection and diagnosis of HPV in these 
cases can be problematic. The most common method of cytologic testing is 
the Papanicolaou test, generally referred to as the Pap smear (Trofatter, 
1997). Exfoliated genital cells are stained and examined for evidence of 
abnormal cells, such as koilocytes, which are considered characteristic of 
low-grade CIN. However, although the Pap smear has been very successful 
at reducing the incidence of cervical cancer in most countries, it has been 
shown that the sensitivity of this test does not exceed 70%, with a false- 
negative rate ranging from 20 to 30% (Fahey et al., 1995).
It has been proposed that HPV testing in combination with the Pap smear 
may help lower the false-negative rate of the latter (Wright et al., 1995, 
Harper et al., 2001). Recent studies have shown that HPV testing combined 
with a Pap smear has a promising future in primary screening, particularly in 
women over the age of 30 (Cox et al., 1995, Nobbenhuis et al., 1999).
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The most commonly used methods for detecting HPV in tissue are PCR and 
solution hybridisation, also known as Hybrid Capture. These tests have 
similar sensitivity and specificity but PCR is more difficult to use routinely, 
whereas Hybrid Capture is a rapid test and is available as a kit. PCR is 
considered the gold standard research-based test for HPV (reviewed in 
Lorincz et al., 2001). Different types of primers can be used, including 
consensus primers, which hybridise to a common HPV nucleotide sequence 
and can detect many HPV-types, while type-specific primers can be used to 
identify the type of HPV involved. The Hybrid Capture (HC) method is the 
most commonly used test for HPV detection in clinical practice, (reviewed in 
Lorincz et al., 2001). It is a simple, amplification-based chemiluminescent 
assay using RNA probes specific for the genomes of the 13 viral types, HPV- 
16, -18, -31,-33, -35, -39, -45, -51,-52, -56, -58, -59 and -69, etiologically 
connected to the pathogenesis of cervical cancer (reviewed in Lorincz et al.,
2001). Recent studies using HC II, the current version of HC test, have 
consistently documented a sensitivity of about 90% or greater for the 
presence of high-grade CIN, (reviewed in Cuzick, 1999).
1.2.10 HPV Vaccines
As a viral disease, HPV infection is a candidate for preventative vaccination, 
with current efforts targeted at the development of both prophylactic and 
therapeutic vaccines. Prophylactic vaccines could theoretically prevent HPV 
infection by inducing a protective antibody response in the genital mucosa 
against the viral capsid proteins L1 and L2. A number of vaccines based on 
high-risk virus-like particles (VLPs) are currently in Phase 1 trials and the 
potential success of such vaccines is supported by results using animal 
papillomavirus models of infection, (reviewed in Cornelison, 2000, Harro et 
al., 2001). One possible shortcoming of these VLP-vaccines, however, is 
that they are unlikely to have a therapeutic effect because the capsid 
proteins are not detected in the proliferating cells of the infected epithelia or
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in cervical carcinomas. Immunisation by combination strategies using 
chimeric VLPs containing both early and late HPV gene products offers 
increased potential for both prophylaxis and therapy (reviewed in Kaufman et 
al., 2000, Cornelison, 2000).
Two types of therapeutic vaccines are being considered: The first is aimed at 
suppressing the replicating virus in infected individuals, and so the early viral 
proteins E1 and E2 are possible immunological targets for this (Selvakumur 
et al., 1995). The second vaccine type is aimed at counteracting established 
neoplastic processes and therefore the oncogenic proteins E6 and E7, and 
possibly E5, could potentially be used as tumour vaccine candidates, and a 
number of preliminary studies addressing this have given encouraging 
results (Liu et al., 2000, Muderspach et al., 2000). There has also been 
considerable recent interest in the development of oncolytic viruses that 
specifically target high-risk HPV-induced tumours, such as adenovirus 
mutants that efficiently replicate only in tumour cells with defective p53. 
High-risk E6 is constitutively expressed in cervical tumour cells and 
degrades p53 in these cells, therefore, mutant adenoviruses should be able 
to replicate in these neoplastic cells and bring about selective cell death.
This work is still at an early stage but preliminary results are promising 
(Balague et al., 2001).
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1.3.1 Genomic Organisation
Papillomaviruses are small, 52-55nm in diameter, nonenveloped DNA 
viruses. The capsid is of icosahedral symmetry and comprises 72 
capsomers and contains within it a single molecule of double-stranded 
circular DNA composed of approximately 8,000bp (Howley, 1996). The 
prototype HPV-16 sequence was first published in 1985 and is now one of 
more than 100 papillomaviruses that have been fully sequenced (Seedorf et 
al., 1985, de Villiers, 2001). The genomic organization of each 
papillomavirus is remarkably similar: The genetic information is localized on 
one strand of the viral DNA and the genome can be divided into three 
regions: the early region (E), the late region (L), and the non-coding region, 
also called the untranslated region (UTR) (Fig. 1.5). HPV genomes are 
transcribed into polycistronic messages through the use of multiple 
promoters, early and late polyadenylation signals, and extensive splicing 
(reviewed in Howley, 1996, Ozbun etai., 1998a). Polycistronic messages 
are uncommon in eukaryotes yet seem to be prevalent in both high and low- 
risk HPV infections (Hummel et al., 1992). It is known that differential splicing 
of early RNAs in all PVs generates a variety of polycistronic messages, 
which vary considerably in relative abundance (Hummel et al., 1992, 
Barksdale etai., 1995).
1.3.2 Early Viral Proteins
The early region represents approximately 45% of the genome and encodes 
up to eight viral proteins, although their open reading frames overlap 
extensively. HPV-16, like most HPVs characterised to date, expresses only 
the E1, E2, E4, E5, E6 and E7 proteins.
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E1 is the largest ORF in all PVs and is essential for viral replication (Ustav et 
al., 1991). E1 exhibits ATPase and helicase activity and binds with low 
affinity to the A/T-rich origin of replication within the UTR of papillomaviruses 
(Hughes et al., 1993). The subsequent binding of the second viral replication 
protein, E2, to its binding sequences flanking the origin of replication, and 
interactions between E1 and E2, strengthen the binding of E1 to the origin 
(Frattini et al., 1994). E1 is responsible for recruiting the cellular DNA 
replication initiation machinery and mediates the formation of a stable, 
multimeric complex (Park et al., 1994). Following the assembly of this protein 
complex, E2 is released from the origin and is free to fulfil its primary 
function as a regulator of viral transcription (Spalholz et al., 1985), however, 
the possibility remains that the role of E2 in viral replication extends beyond 
the recruitment and stabilisation of E1 (Li et al., 1993).
E2
The E2 protein is highly conserved among PV types and comprises three 
functional domains: The N-terminal 200 amino acids which function in 
transactivation and replication are linked by a flexible ‘hinge’ region to the C- 
terminal domain responsible for sequence-specific DNA-binding and 
dimerisation (McBride et al., 1989). E2 binds the consensus sequence 
ACCNeGGT and has been shown to control early viral gene expression 
through E2-responsive elements located within the viral UTR, flanking the 
early promoter (Androphy et al., 1989). E2 can therefore control expression 
of itself as well as the other early viral proteins and consequently modulate 
viral genome copy number. E2 is also required for genome maintenance and 
segregation and the amino terminus transactivation domain is necessary and 
sufficient for association of the E2 protein with mitotic chromosomes, thus 
ensuring efficient segregation of viral DNA to daughter nuclei (Bastien et al.,
2000).
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E5
Transforming activity has been demonstrated for the E5 protein of BPV and 
some HPVs, including HPV-16 (Di Maio et al., 2001). BPV E5 transforms 
cells by binding to and activating the platelet-derived growth factor (PDGF) p 
receptor in a ligand-independent fashion leading to the recruitment of cellular 
signalling proteins (Petti et al., 1991). HPV E5 also appears to act via 
receptor tyrosine kinase signalling pathways and most reports have 
implicated the epidermal growth factor receptor (EGFR), moreover HPV-16 
E5 also enhances the keratinocyte response to endothelin-1, suggesting 
interactions with a variety of growth factor receptors (Straight et al., 1993, 
Venuti et al., 1998). The E5 protein of both human and bovine 
papillomaviruses has been shown to interact with the 16kDa subunit of 
vacuolar H+-ATPase (V-ATPase) and this interaction is believed to be 
responsible for the downregulation of gap junction intercellular 
communication and for the prevention of the acidification of endosomes and 
Golgi apparatus (Goldstein et al., 1991, Conrad et al., 1993). However, a 
recent report has suggested that the binding of E5 to V-ATPase does not 
affect the activity or function of this enzyme and that binding is due simply to 
a chaperone function of the 16kDa subunit (Ashby et al., 2001). It has also 
been reported that HPV-16 E5 may act as a survival factor, protecting cells 
from apoptosis by enhancing the P13K-Akt and ERK1/2 MAPK signal 
pathways (Zhang et al., 2002). However, the E5 open reading frame is 
frequently deleted in cervical carcinoma cells suggesting that the role of this 
hydrophobic protein may lie in the initiation of tumourigenesis (reviewed in 
DiMaio et al., 2001). The function(s) of the E5 protein in naturally occurring 
infections remains poorly understood.
E6
In contrast, much more is known about the early viral proteins E6 and E7, 
both of which play multiple roles during HPV-infection. However, unlike E1 
and E2, the activities of E6 and E7 differ depending on whether they are
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expressed from low-risk or high-risk HPVs (reviewed in Howley, 1996). Both 
proteins are invariably retained and expressed in anogenital tumours and 
high-risk E6 and E7 can transform keratinocytes in vitro, and are now 
recognised as oncogenes (reviewed in Mantovani et al., 2001, Munger et al.,
2001). High-risk HPV E6 , (HR E6 ), can bind the cellular protein p53 and 
mediate the degradation of this protein through the ubiquitin-ligase pathway 
in conjunction with the E6-associated protein (E6-AP) (Werness et al., 1990, 
Scheffner et al., 1990). The removal of p53 in this way allows cells to bypass 
the G-i/S checkpoint, which normally serves as a control for DNA-damaged 
cells. High-risk E6 also mediates the degradation of another proapoptotic 
protein, Bak, a member of the Bcl-2 family (Thomas et al., 1998, Thomas 
and Banks, 1999). Moreover, high-risk E6 has also been shown to activate 
host-cell telomerase (Klingelhutz et al., 1996). The ability to complex with 
p53 is a feature of other viral oncoproteins including the SV40 T Ag and the 
adenovirus (Ad) E1B 55k protein, however unlike E6 , these viral proteins 
inactivate p53, at least in part, by sequestering it into stable complexes 
(Sarnow et al., 1982, reviewed by Howley, 1996). The E6 protein of low-risk 
HPVs cannot bind p53 and is unable to mediate the degradation of this 
cellular protein. Moreover, low-risk E6 is unable to transform keratinocytes, 
although it does appear to have similar transcriptional activation properties to 
its high-risk counterpart (Scheffner etai., 1990, Sedman etai., 1991). 
Another characteristic HR E6 , not shared with the low-risk protein, is the 
ability to inhibit terminal differentiation of epithelial cells (reviewed in 
Mantovani et al., 2001). Although this mechanism is not fully understood, HR 
E6 can interact with the calcium-binding protein ERC 55 (Chen etai., 1995), 
the focal adhesion protein paxillin (Tong et al., 1997), and the human 
homologue of the Drosophila discs large tumour suppressor protein, which is 
required for regulation of cell adhesion and proliferation in epithelial tissues 
(Kiyono et al., 1997, Mantovani et al., 2001). Each of these interactions 
could potentially interfere with epithelial differentiation.
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E7
E7 was the first oncogene of high-risk HPVs to be discovered (Bedell et al.,
1989). In addition to functional similarities, HPV-16 E7 shares amino acid 
sequence similarity with portions of two other oncogenic viral proteins, 
adenovirus (Ad) 12S E1A product and the SV40 large T Ag (reviewed by 
Howley, 1996). A key observation for the function of E7 was the 
demonstration of its binding to the retinoblastoma protein, pRb (Dyson et al.,
1989), and retinoblastoma protein (Rb)-related pocket proteins, p107 and 
p130 (Dyson et al., 1992), an observation that has also been made for Ad 
12S E1A and SV40 T Ag (Dyson et al., 1992, DeCaprio et al., 1988, 
reviewed in Howley, 1996). This binding results in phosphorylation of pRb, 
leading to its degradation by ubiquination, and the subsequent release of 
transcription factors of the E2F family from the pRb complex, thereby 
activating transcription of genes regulating cell proliferation and permitting 
progression into the S phase of the cell cycle (Boyer et al., 1996). Low-risk 
E7 binds pRb with a ten-fold lower efficiency that high-risk E7 (Gage et al.,
1990). Surprisingly, this reduced binding efficiency has been attributed to a 
single amino acid difference between high and low-risk E7 proteins (Sang et 
al., 1992). High-risk E7 can also inactivate the cyclin-dependent kinase 
inhibitors p21cip'1 and p27KIP'1 thus uncoupling cdk activity and cdk inhibitors, 
and contributing to the increased growth of HPV-infected cells (reviewed in 
zur Hausen, 2000). High-risk E7 proteins have also been identified in cyclin 
A and cyclin E complexes and this interaction may allow HPV-positive cells 
to bypass the Gi/S checkpoint, independent of the E6 mediated bypass of 
this checkpoint (Zerfass et al., 1995).
Productive Infections
The amount of E6 and E7 proteins produced during a productive viral 
infection is very low, and in the case of E7 in particular this is a consequence 
of its relatively short half-life of less than 2h (Munger et al., 2001). In the 
course of a productive HPV-infection, the replicative phase is confined to the
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unfavourable environment of differentiated cells. The ability of both high and 
low-risk E7 to interact with pRb, albeit with reduced affinity for the latter, is 
thought to be important in preventing the cell cycle exit of HPV-infected cells 
upon differentiation, thereby permitting vegetative viral DNA amplification in 
suprabasal cells, a process that is tightly controlled both in low and high-risk 
viruses (reviewed in Howley, 1996). Moreover, the combined action of E6 ,
E7 and possibly E5 is believed to result in a delay of differentiation leading to 
a lateral expansion of the infected cell in the basal layer giving rise to a 
clonal population, consequently resulting in numerous virus-producing cells 
at the surface of the developing lesion following differentiation (reviewed in 
zur Hausen et al., 1994). Studies on high-risk HPV-31 and low-risk HPV-11 
have also suggested that E6 and E7 are required for the stable maintenance 
of viral episomes and act to modify the cellular environment in such a way as 
to prevent the removal of these extrachromosomal elements, an activity that 
is independent of their role in immortalisation, in the case of high-risk viruses 
(Thomas et al., 1999, 2001). Thus, both low and high-risk E6 and E7 work 
cooperatively during a productive infection to create a favourable 
environment for viral replication whilst bypassing the cellular checkpoints 
that would normally prevent such re-initiation of DNA replication in 
differentiating cells.
Non-productive Infections
In light of this, however, it is not difficult to imagine how overexpression of 
these cellular proteins in a non-productive infection could initiate processes 
that lead to immortalisation and ultimately to full transformation of the cell. 
Integration of high-risk viral genomes, as seen in many cervical tumours, 
leads to increased steady state levels of viral mRNAs transcribed from the 
E6 and E7 oncogenes (Jeon et al., 1995b, Desaintes et al., 1996). This 
increased mRNA stability is believed to result in part from the replacement of 
the viral early 3’UTR, containing an mRNA instability element, with cellular 
sequences (Jeon et al., 1995b). The combined action of the E6 and E7
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proteins of high-risk HPVs in a non-productive infection essentially result in 
deregulated cellular growth and genomic instability and allow the infected 
cells to bypass the cell cycle checkpoints, avoid apoptosis and proceed to 
malignancy (Fig. 1.6 ). It should be clear, however, that this is not the 
preferred outcome of an HPV infection, representing instead the most 
unfortunate result of a progressive and multifunctional process that occurs 
only on some rare occasions.
1.3.3 Late Viral Proteins
E4
The E4 ORF is located within the early coding region but is considered to 
encode a late protein by virtue of the differentiation-inducible promoter from 
which it is transcribed, see below (reviewed in Howley, 1996). A transcript 
containing a few codons spliced from the beginning of the E1 ORF to E4 
appears to be the major RNA in HPV-11, -16 and -31-induced lesions 
(Nasseri etal., 1987, Doorbar etal., 1990, Hummel etal., 1995, Ozbun et 
ai, 1997). E1AE4 has been found in cells expressing L1 in the upper layers 
of the epithelium both in natural lesions and athymic mouse grafts of HPV-11 
and HPV-16 and its appearance coincides closely with the onset of 
vegetative viral amplification (Doorbar et al., 1989, Crum et al., 1990, Brown 
et al., 1994, Doorbar et al., 1997). E1AE4 has also been found to co-localise 
with cytokeratins, and in the case of human keratinocytes expressing HPV- 
16 E1AE4, this interaction results in the collapse of the keratin network, at 
least in vitro, suggesting a potential role for HPV-16 E1AE4 in viral egress 
(Doorbar etal., 1991, Doorbar etal., 1996). HPV-16E1AE4 has also been 
implicated in the posttranscriptional control of viral gene expression as a 
result of its interaction with a DEAD box helicase, potentially involved in 
regulating mRNA stability and degradation (Doorbar et al., 2000). Recently, 
expression of HPV-16 E1AE4 in a HPV-16 immortalised line, SiHa, appeared 
to arrest the cells in the G2 phase of the cell cycle. E1AE4, through its
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interaction with the cytokeratin network, was found to sequester components 
of the mitosis promoting complex, specifically cyclin B and Cdc2, and 
prevent the shuttling of these factors between the nucleus and cytoplasm 
thereby effectively stalling the cells in G2 (Davy et al., 2001). The authors of 
this work propose that this E1AE4 induced G2 arrest, coupled with E6/E7 
mediated bypass of the Gi/S checkpoint, will create a pseudo S-phase 
environment conducive to viral genome amplification (Davy et al., 2001) (Fig. 
1 .6 ).
The capsid proteins. L1 and L2
The designated late coding region accounts for approximately 40% of the 
viral genome and encodes two viral proteins, L1 and L2. The major capsid 
protein L1, has a molecular weight of approximately 57kDa, and comprises 
more than 95% of the capsid; this protein is highly conserved among 
papillomaviruses (Kaufman et al., 2000). The minor capsid protein, L2, forms 
less than 5% of the capsid, its molecular weight is approximately 70kDa, and 
portions of L2, namely 200 amino acids in the N-terminus and 30 amino 
acids in the C-terminus are greatly conserved (Kaufman et al., 2000). The 
icosahedral capsid of papillomaviruses is composed of 72 capsomers 
arranged in a T=7 symmetry (reviewed in Howley, 1996). The capsomers are 
pentamers of the L1 protein, and while L2 represents only a small proportion 
of the total viral capsid protein, its exact position in the capsid remains 
unknown (Baker et al., 1991). However, a recent three-dimensional 
reconstruction of the BPV capsid suggested that L2 could be located in the 
centre of the capsomeres at the 12 pentavalent vertices (Trus et al., 1997). 
The tight association between late gene expression and terminal 
differentiation of epithelial cells has hampered the in vitro study of PV late 
proteins. Nevertheless, a number of groups have demonstrated the 
formation of HPV-like particles (VLPs) by expressing either recombinant L1, 
or L1 and L2, using the baculovirus, vaccinia virus or yeast expression 
systems (Zhou, et al., 1991, Kirnbauer et al., 1993). These studies showed
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that L1 is sufficient for the formation of VLPs, which are bound and 
internalised efficiently and appear morphologically and immunologically 
similar to mature virions. However, further studies in BPV-1 and HPV-18 
indicated that L2, through its N-terminal DNA-binding domain, is required for 
the encapsidation of viral DNA, although there appears to be no requirement 
for specific DNA sequences, nor is the size of DNA critical (Roden et al., 
1996, Stauffer, etal., 1998). VLPs have been shown to induce levels of 
neutralizing antibodies that are comparable to those induced by authentic 
virions and this, together with the ability to produce preparative amounts in 
non-mammalian cells, has led to the use of VLPs in several vaccine trials 
(Kirnbauer etal., 1992, Pastrana etal., 2001).
The L2 capsid protein is also reportedly targeted to distinct nuclear bodies 
known as promyelocytic leukaemia oncogenic domains (PODs) or ND10 
domains, and has been shown to recruit L1 and E2 to these structures (Day 
et al., 1998). Initially, it was suggested that this co-localization might 
enhance encapsidation by bringing together viral DNA and the capsid 
proteins. Recently, however, HPV-33 L2 expression has been shown to 
result in a complete loss of the cellular factor Sp100 from PODs and a 
redistribution of an additional cellular protein, Daxx, exclusively to PODs, 
both in cell culture and in naturally occurring lesions; potentially indicating 
that these L2-induced cellular changes may be involved in viral DNA 
encapsidation (Florin et al., 2001).
1.3.4 Viral Promoters
Early promoter
Transcripts encoding the early proteins of HPV-16 are initiated from an early 
promoter within the E6 ORF, which has been mapped to position 97, P97 
(Smotkin et al., 1986, Doorbar et al., 1990). The early promoter of a number 
of other genital HPVs has been mapped to a similar position e.g. P105 in 
HPV-18 and Pggin HPV-31 (Schneider-Gadicke etal., 1986, Ozbun etal.,
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1998a). Previous extensive transcription studies in BPV-1 identified 7 
promoters, six of which appeared to be active throughout the viral life cycle 
and could be grouped together as early promoters (Baker et al., 1987b). 
Recent studies on the temporal usage of promoters during the life cycle of 
HPV-31b identified 4 viral promoters including the major early promoter Pgg, 
a novel minor early promoter P77, the previously identified late promoter P742, 
and another novel promoter P332o(Ozbun et al., 1998a). With the exception of 
P742, each of the promoters appeared to be constitutively active during the 
viral life cycle (Ozbun et al., 1998a, Ozbun et al., 1999). RNA initiation sites 
analogous to P77have been described for HPV-16 also, although they have 
not yet been accurately mapped (Grassmann et al., 1996). Therefore, it 
seems likely that additional early promoters exist within the HPV-16 genome. 
HPV-16, like the other genital papillomaviruses, contains four E2-binding 
sites in conserved relative positions, flanking the early promoter, Pg7 
(Romanczuk et al., 1990). Specific binding of E2 to one or more of these 
sites results in the transcriptional repression of the early viral promoter, 
probably by interfering with the assembly of the transcription pre-initiation 
complex (McBride et al., 1991). The level of early mRNAs initiated at the 
early promoter does not appear to be affected by differentiation and so early 
proteins are expressed throughout the strata of the differentiating epithelium 
in a productive infection (Frattini et al., 1994, Desaintes et al., 1996, Ozbun 
et al., 1998a). However, in many non-productive infections integration of the 
viral genome leads to loss of E2-mediated transcriptional repression of the 
early viral promoter and an overexpression of the oncogenic E6 and E7 viral 
proteins (Jeon etal., 1995a and b).
Late promoter
The level of expression of the HPV-16 late viral proteins E1AE4, L1 and L2 
increases substantially in the suprabasal layers of the epithelium and the 
activation of a differentiation-inducible late promoter, mapped to position 670 
within the E7 ORF, P670, is partly responsible for this (Grassmann et al.,
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1996). Differentiation-inducible promoters have also been identified in BPV- 
1, P7250, and other HPVs, including P742 in HPV-31 and in HPV-11 an exact 
nucleotide has not yet been mapped (Baker et al., 1987b, Hummel et al., 
1992, Stubenrauch et al., 1999). Unlike the early promoter, this late region 
lacks a consensus TATA box and it has previously been shown that many 
genes, particularly housekeeping genes which lack TATA sequences are 
regulated during differentiation (Azizkhan et al., 1993, reviewed in Smale,
1997). Upstream of P670 lies a potential binding site for the CCAAT 
enhancer-binding protein, (C/EBP), which promotes terminal differentiation 
of adipocytes and may also be important in differentiation of other tissues 
including skin, through the regulated activation of differentiation-specific 
genes (Johnson et al., 1989, Umek et al., 1991). Moreover, this CCAAT 
motif appears to be conserved in PVs and is present upstream of the 
differentiation-inducible promoter of HPV-6, -11, and -31 and BPV-1 (Baker 
et al., 1987b, Hummel et al., 1992, Ozbun et al., 1998a, Ai et al., 1999, Zhao 
1999).
The mechanisms regulating activation of the late viral promoter and 
consequently late viral gene transcription are not yet understood. However, 
in HPV-31 it appears that upon differentiation the region surrounding the late 
promoter within the E7 ORF becomes accessible to DNase I, indicating that 
chromatin remodelling in this region makes the late promoter available for 
transcription factor binding following differentiation, (Del Mar Pina et al.,
2001). Moreover, Kukimoto et al., (2001) have shown that a differentiation- 
specific transcription factor, hSkn-1a, can displace YY1 from the late 
promoter region of HPV-16, thus relieving the repression of this late 
promoter in differentiated cells (reviewed in Desaintes et al., 1996).
1.3.5 Viral Polyadenylation Signals
It is widely believed that the majority of late messages are terminated at a 
late polyadenylation signals within the late 3’ UTR, however, some
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transcripts, e.g. E4-coding transcripts, may be terminated at as yet 
unidentified poly(A) sites (Higgins etal., 1992, Hummel et al., 1992, 1995, 
Ozbun et al., 1998a, Terhune et al., 1999). Nonetheless, since these late 
transcripts initiate at a promoter within the early region they must read- 
through the early polyadenylation site in order to terminate at a poly(A) site 
in the late 3’UTR. This phenomenon has mostly been studied in HPV-31 and 
it has been determined that, while there is significant read-through both in 
undifferentiated and differentiated cells, read-through increases by 50% 
following differentiation (Terhune etal., 1999). This difference has been 
attributed to the weakness of the HPV-31 early polyadenylation site for 
binding of the polyadenylation factor CstF, since insertion of a high-affinity 
CstF binding site into the early poly(A) signal significantly reduced read- 
through (Terhune etal., 1999, 2001). By extension, the early polyadenylation 
signal of HPV-16 is also probably very weak due to the lack of a good 
consensus downstream GU/U-rich region. In contrast, the HPV-16 late 
polyadenylation region has a good consensus downstream GU/U-rich region 
and would therefore be predicted to bind CstF strongly and act as a strong 
polyadenylation signal (Seedorf etal., 1985, Kennedy etal., 1990); however, 
this has not yet been established experimentally for HPV-16. Nevertheless, 
the tandem arrangement of early and late polyadenylation signals, as seen 
in most papillomaviruses, suggests that a read-through mechanism may be 
conserved in this family (Baker et al., 1987a, Kennedy et al., 1990).
However, unlike HPV-31 or any other sequenced HPV, analysis of the 
prototype HPV-16 sequence indicates that there are three putative late 
polyadenylation signals in the 3’ untranslated region of this virus: LP1 at 
nt7260, LP2 at nt7330, and LP3 at nt7660 (Kennedy et al., 1985, Seedorf et 
al., 1990). Yet, while each of the putative sites contains the conserved 
AAUAAA hexanucleotide, the downstream GU-rich element, characteristic of 
many 3’ processing signals is weak for both LP1 and LP3, whereas 
downstream of LP2 the consensus GU-rich sequence, YGUGUUYY, where
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Y is a pyrimidine, is present (McLauchlan et al., 1985, Seedorf et al., 1985). 
In light of this, it is unsurprising that only the LP2 polyadenylation site was 
found to function efficiently in basal epithelial cells, in vitro, and while LP1 
functioned with low efficiency, LP3 did not function at all (Kennedy et al.,
1990). However, when the GU-rich element downstream of the LP1 site, 
TGTGTAAC, was altered to resemble the LP2 GU-rich sequence, 
TGTGTTGT, the first polyadenylation signal was found to function as 
efficiently as LP2, indicating that lack of utilization of LP1 and LP3 is most 
likely due to weak downstream GU-rich elements (Kennedy et al., 1990).
It remains possible though, given the small differences in the LP1 and LP2 
GU-rich elements, that the virus uses this tandem arrangement of late 
polyadenylation signals to facilitate differential usage in specific cell types in 
order to control viral late protein expression. In support of this, it has recently 
been shown that both LP1 and LP2 are functional, in vivo, in the context of 
genuine late transcripts and are in fact utilised in a differentiation stage- 
specific manner, such that LP2 appears to be the site of choice in 
undifferentiated cells while poly(A) site usage switches to LP1 upon 
differentiation (McGuire et al., 2002).
1.3.6. HPV-16 Splicing Patterns
In most HPV-16 positive cervical carcinomas and cell lines derived from 
such tumours, such as the SiHa and CaSki lines, the viral genome is 
integrated into the host DNA, the E1/E2 coding region is frequently disrupted 
and while the virus remains transcriptionally active, transcription is limited to 
the E6 and E7 ORFs (Smotkin etal., 1986, Durst et al., 1987, Meissner,
1999). Two major and one minor type of E6/E7 transcripts have been 
identified in cervical carcinomas, all of which are fused at their 3’ ends with 
cellular sequences (Schwarz etal., 1985, Smotkin etal., 1986). This 
observation lends support to the proposed role of high-risk E6 and E7 
proteins in the establishment and maintenance of a malignant phenotype.
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Information about the HPV-16 splicing pattern in pre-cancerous lesions was 
limited until the derivation of the W12 line, which was established from a low- 
grade cervical lesion and maintains up to 100 copies of the viral genome 
extrachromosomally (Stanley et al., 1989). Analyses of cDNAs obtained from 
these cells led to the identification of 6 novel mRNA species (Doorbar et al.,
1990) (Fig. 1.7). A number of previously uncharacterised splice donor and 
acceptor sites were also identified which may be involved in the generation 
of HPV-16 late proteins (Doorbar et al., 1990). This study suggested that the 
episomal state of the viral DNA in the W12 cell line dictated a different 
programme of gene transcription than that previously observed in cervical 
carcinomas. Furthermore, it was suggested that alterations in the splicing 
patterns of specific mRNAs might be related to tumour stage and the 
physical state of the viral genome. Surprisingly however, while no mRNAs 
encoding the late proteins of HPV-16 were detected in high-grade lesions or 
the majority of carcinomas, the frequency and size of early transcripts did not 
appear to be related to tumour stage or physical state of the viral genome 
(Sherman et al., 1992). Viral anti-sense RNAs, corresponding to sequences 
in the untranslated region, and the early and late coding regions, were 
detected in a number of cervical carcinoma samples but not in any pre- 
malignant lesions (Vormwald-Dogan etal., 1992). This suggests that 
integration of the viral genome into transcriptionally active regions of the host 
genome, as frequently observed in invasive carcinomas, most likely results 
in fusion transcripts, initiated from a cellular promoter, which could potentially 
give rise to anti-sense viral mRNAs (Vormwald-Dogan et al., 1992). It is 
probable that such anti-sense transcripts by binding to complementary viral 
transcripts could inhibit gene expression but the possible consequences of 
this for tumour progression remains unknown.
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1.4.1 Regulation of HPV-16 late gene expression
Several groups have reported the presence of late viral transcripts in 
undifferentiated HPV-16 infected cells. Stoler et al., (1989) noted the 
presence of HPV-16 L1 and L2 transcripts by in situ hybridisation in the 
nuclei of less differentiated cells in the lower layers of squamous 
intraepithelial lesions. HPV-16 late gene transcripts were also detected by 
PCR in monolayer cultures of W12 cells by Doorbar et al., (1990) and again 
using Northern blot analysis of undifferentiated monolayer cultures of W12 
cells, Koffa et al., (2000) reported the nuclear localisation of HPV-16 late 
mRNAs, which appeared to be fully processed. Nevertheless, despite the 
presence of late viral transcripts in undifferentiated cells, HPV-16 late 
proteins are detected exclusively in differentiating keratinocytes (Sterling et 
al., 1991, Sterling etal., 1993, Doorbar et al., 1997). These observations 
strongly suggest that viral late gene expression is regulated post- 
transcriptionally, possibly via a number of RNA processing mechanisms, 
such as mRNA splicing, polyadenylation, nuclear export, and cytoplasmic 
mRNA stability (Kennedy ef al., 1991, Dietrich-Goetz etal., 1997, Koffa et 
al., 2000, McGuire et al., 2002). Control mechanisms such as these most 
likely depend on interactions between cellular or viral trans-acting factors 
that are responsive to cell differentiation and act on viral c/'s-acting DNA and 
RNA elements (Schwartz et al., 1999, Koffa et al., 2000). Given the small 
size of papillomavirus genomes, and their limited coding potential, it seems 
highly likely that the virus has evolved in such a way as to exploit the 
differential changes in the cellular environment in order to help control viral 
late gene expression. Positive factors that antagonise the inhibitory activity 
of elements within late protein mRNAs may be upregulated with 
differentiation; alternatively, negative factors mediating the inhibitory activity 
might be downregulated during differentiation (Tan etal., 1995b, Koffa et al.,
2000).
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1.4.2 RNA Processing -  a summary:
In order to understand more fully the mechanisms potentially involved in the 
post-transcriptional control of HPV-16 late gene expression I will briefly 
discuss the steps involved in RNA processing. Processing of pre-mRNA 
transcripts involves a number of steps: pre-mRNAs must be spliced to 
remove introns, polyadenylated to confer stability, and then when processing 
is complete, the mRNAs must be efficiently exported from the nucleus to the 
cytoplasm for translation.
Splicing
Pre-mRNAs are spliced in a two-step pathway: in the first step, the pre- 
mRNA is cleaved at the 5’ splice site, generating a linear first exon RNA 
species and an intron-second exon RNA species in a lariat configuration.
The second step involves cleavage at the 3’ splice site followed by ligation of 
the two exons and release of the intervening intron. Splicing occurs in a 
large multicomponent complex called the spliceosome; formation of a 
commitment complex between a pair of splice sites triggers the sequential 
interaction of splicing factors that collectively make up the spliceosome 
(reviewed in Green, 1991). Critical to this assembly process is the initial 
recognition of the 5’ and 3’ splice sites and it appears that the exon acts as 
the unit of recognition, hence this model is termed exon definition (Niwa et 
al., 1992) (Fig 1. 8). U2AF65 initially recognises a branch site upstream of 
the exonic 3’ splice site, leading to the recruitment of U2 small nuclear 
ribonucleoprotein (U2 snRNP), followed by UlsnRNP (reviewed in Zhao et 
al., 1999). U1 snRNP is primarily involved in the recognition of 5’ splice sites 
and binding of this protein to the 3’ splice site poises U1 snRNP to search 
across the exon in a 3’ to 5’ direction for a downstream 5’ splice site 
(reviewed in Green, 1991, Zhao et al., 1999). Interactions between splicing 
factors bound at the 5’ and 3’ splice sites are believed to be mediated by
39
Introduction
serine-arginine (SR) proteins, through a bridging interaction between U2AF35 
and the U1 snRNP 70K protein subunit (reviewed in Chabot, 1996). In the 
case of a terminal exon, i.e. an exon beginning with a 3’ splice site and 
ending in a polyadenylation signal, this model predicts that factors bound at 
the 3’ splice site can interact with the polyadenylation complex, and an 
increasing body of evidence exists to support a direct physical linkage 
between the processes of splicing and polyadenylation (Niwa et al., 1992, 
Lutz et al., 1996, reviewed in Zhao et al., 1999).
Cleavage and Polyadenylation
In mammalian cells, three elements define the core polyadenylation signal: 
The highly conserved AAUAAA hexanucleotide located 10 to 30 nts 
upstream of the cleavage site, a less well conserved GU/U-rich element 
located downstream of the cleavage site, and the cleavage site itself, which 
since it becomes the point of poly(A) addition, is generally referred to as the 
poly(A) site (reviewed in Wahle et al., 1999) (Fig.1.9). Formation of 3’ ends 
in pre-mRNAs is also a two-step reaction. The cleavage and polyadenylation 
specificity factor (CPSF) recognizes the AAUAAA hexanucleotide and 
binding of this factor is greatly enhanced by a cooperative interaction with 
the cleavage-stimulating factor (CstF), which binds to the downstream GU/U- 
rich region (reviewed in Zhao et al., 1999). While it seems that CPSF is 
involved both in polyadenylation and cleavage, CstF and the cleavage 
factors Im  and I Im  are involved only in cleavage; it also appears that the 
carboxyl- terminal domain (CTD) of RNA polymerase II (pol II) is required for 
cleavage and may act by stabilizing the cleavage complex through 
interactions with CPSF and CstF, alternatively, the CTD of RNA pol II may 
exert its effect through the donation of CstF or CPSF to the assembling 
polyadenylation complex (Hirose et al., 1998, Hirose et al., 2000). Following 
endonucleatic cleavage at the poly(A) site, adenosine residues are added to 
the 3’ end of the fragment to form a poly(A) tail through the action of poly (A) 
polymerase (PAP) (reviewed in Colgan etal., 1997). Rapid elongation and
40
Introduction
control of poly(A) tail length are mediated by the poly(A)-binding protein II 
(PAB II) (reviewed in Colgan etal., 1997). Additional less well defined 
sequence elements, acting in a position and orientation-dependent manner, 
have been shown to regulate polyadenylation efficiency in a number of viral 
poly(A) signals (Gilmartin etal., 1995, Lutz et al., 1994, Moreira et al., 1998). 
The action of these upstream sequence elements (USE) is often dependent 
on the binding of RNA processing factors (Gilmartin et al., 1995, Lutz et al., 
1996, Moreira et al., 1998). A stable polyadenylation complex is the 
consequence of multiple, cooperative interactions between the basic 
cleavage and polyadenylation factors, an arrangement which affords many 
targets for regulation.
RNA Nuclear Export
Only after the pre-mRNA has been fully processed can it be exported from 
the nucleus to the cytoplasm. It has been shown that formation of a correct 
3’ end appears to be important for export (reviewed in Wahle et al., 1999), 
and it is possible that the spliceosome or polyadenylation complex retains 
pre-mRNAs in the nucleus by preventing interactions with the nuclear pore, 
alternatively, binding of the pre-mRNA by the spliceosome and/or 
polyadenylation machinery may prevent binding of transport factors to 
specific export signals on pre-mRNAs (Green, 1991). Several reports have 
suggested that RNA binding proteins, collectively known as heterogenous 
ribonucleoproteins (hnRNPs), are actually deposited onto pre-mRNAs during 
3’ end formation. Many hnRNPs have been shown to actively shuttle 
between the nucleus and cytoplasm, suggesting that RNA transcripts are 
passively exported through the binding of these shuttling proteins (Zhao et 
al., 1999). Binding of shuttling proteins which facilitate the efficient nuclear 
export of mRNAs are believed to be important in overcoming the negative 
effects of destabilising elements found throughout many mRNAs (reviewed 
in Ross, 1995).
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1.4.3 Negative Regulatory Elements within the Viral Untranslated 
Region
A c/'s-acting negative regulatory element (NRE) has been identified in the 
late 3’ UTR of HPV-16, upstream of the LP2 signal; this element can repress 
reporter gene expression following transient transfection in HeLa cells, used 
as a model for basal epithelial cells (Kennedy etal., 1990). Similar inhibitory 
sequences have also been identified in the late 3’ UTRs of BPV-1, HPV-1, 
and HPV-31 and it has been proposed that these elements, like the HPV-16 
NRE, may regulate HPV expression in a differentiation dependent manner, 
such that the inhibitory activity is alleviated as the infected cells undergo 
terminal differentiation (Furth etal., 1991, Tan et al., 1995b, Cumming et al., 
2002a). However, while these inhibitory elements share some degree of 
sequence homology, reports to date suggest that these regions act via 
distinctly different mechanisms (Kennedy etal., 1991, Furth et al., 1994, 
Sokolowski etal., 1997).
BPV-1
A 53nt sequence located immediately upstream of the poly(A) signal in the 
BPV-1 late 3’UTR acts in an orientation-dependent manner to reduce the 
levels of cytoplasmic, polyadenylated mRNAs (Furth et al., 1991). The 
inhibitory activity of this element is determined by a 9nt sequence, 
AAGGUAAGU, with perfect homology to a consensus 5’ splice site. This 
sequence binds U1 small nuclear riboprotein (U1 snRNP), effectively 
uncoupling the processes of splicing and polyadenylation as a result of the 
direct interaction of the 70kDa subunit of U1 snRNP with poly(A) polymerase, 
(PAP), thus reducing the 3’ end processing efficiency of late mRNA 
transcripts (Furth et al., 1994, Gunderson etal., 1998).
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HPV-1
A negative regulatory RNA element located within the HPV-1 late 3’ UTR 
acts in an orientation- dependent manner to reduce late mRNA levels in the 
nucleus and cytoplasm (Tan et al., 1995a, Zhao et al., 1996, Sokolowski et 
al., 1997). This 57nt element contains 97% A+U residues, and can be 
divided into two parts: the 5’ half contains two AUUUA motifs and the 3’ half 
contains three UUUUU motifs, characteristic of mRNA instability elements 
(Sokolowski et al., 1997). AU-rich RNA elements (AREs) in mRNAs 
generally contain AUUUA pentamers in an AU-rich environment and target 
these messages for rapid degradation, probably as a result of their 
interaction with cellular factors (Ross, 1995). The HPV-1 element can bind a 
number of cellular proteins including hnRNP C1 and C2 and the shuttling 
protein, HuR (Sokolowski et al., 1997, Sokolowski et al., 1999). It has been 
proposed that HPV-1 late messages are retained in the nucleus and 
prematurely degraded in undifferentiated cells as a consequence of hnRNP 
C1 and C2 binding; a differential increase in the expression of HuR, 
however, overcomes this negative effect by stabilising late messages and 
mediating their export to the cytoplasm (Schwartz et al., 1999).
HPV-31
Recently an element within the late 3‘ UTR of HPV-31 has been identified 
that inhibits late gene expression in undifferentiated epithelial cells 
(Cumming et al., 2002a). Unlike the negative elements described previously 
in HPV-1, -16 and BPV-1 this element is surprisingly complex, comprising a 
major 130nt inhibitory element upstream of the late polyadenylation signal 
and a novel minor element of 110nt downstream of the poly(A) site 
(Cumming et al., 2002a). A portion of the sequence of the major element 
closely resembles the HPV-16 NRE and not surprisingly, both elements bind 
the same cellular proteins in vitro, including U2AF65, CstF-64 and HuR (Koffa 
et al., 2000, Cumming et al., 2002a). While the minor element also binds a 
number of cellular proteins these differ to those bound by the major element.
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It has been proposed that these elements act together, possibly via a 
number of post-transcriptional mechanisms, to disrupt polyadenylation at the 
late site in undifferentiated cells (Cumming et al., 2002a).
1.4.4 Mapping of the HPV-16 NRE
The HPV-16 NRE was mapped by cloning fragments of the 3’ UTR 
downstream of a chloramphenicol acetyltransferase, (CAT), reporter gene 
under the control of the HSV 1 immediate early reporter in a plasmid lacking 
polyadenylation signals called pLW1 (Kennedy et al., 1990). Mutational 
analysis initially mapped this inhibitory region to within nts 7008 and 7226 of 
the HPV-16 UTR and showed that, while it had a negative effect on the level 
of expression of CAT mRNA, it did not appear to affect 3’ end processing, at 
least in vitro (Kennedy et al., 1990) (Fig 1.10). Further mutation studies 
mapped this negative regulatory element (NRE) specifically from nts 7128 to 
7206, with the 5’ end lying just upstream of the L1 stop codon and the 3’ end 
extending into the late 3’ UTR (Kennedy et al., 1991). This c/s-acting 79nt 
RNA element can be divided into two portions: The 5’ half portion, nts 7128 
to 7176, comprises a putative stem loop structure and four weak 5’ splice 
sites. The 3’ portion, nts 7177 to 7206, contains a GU-rich region (Kennedy 
etal., 1991) (Fig. 1.10, Fig.4.1B). However, additional studies carried out in 
another laboratory mapped the HPV-16 NRE to the first 51 nts of the NRE (nt 
7128-7178) (Furth et al., 1994). Functional tests of this element were carried 
out in the context of the SV40 early polyadenylation site, and in this context, 
the second of the four weak 5’ splice sites appeared to be important for the 
inhibitory activity of this element (Furth et al., 1994). However, this shorter 
element lacks most of the GU-rich region, which has now been shown to 
have independent inhibitory activity (Cumming et al., 2002b). Moreover, 
when the NRE is functionally tested in the context of its own late 
polyadenylation region it appears that the four 5’ splice sites actually act
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cooperatively to mediate the inhibitory activity of the 5’ portion of this 
negative element (Cumming et al., 2002b).
1.4.5 The HPV-16 NRE acts as a general regulator of polyadenylation
Work published in the early 1990’s reported that the inhibitory effect of the 
NRE was neither species, tissue nor cell-type specific and suggested that 
this element may act to destabilise polyadenylated RNA, in vitro at least 
(Kennedy et al., 1991). However, in vivo studies have so far failed to support 
this observation and it now appears that the NRE may in fact act as a 
general regulator of polyadenylation (McGuire etal., 2002). A recent report 
has shown that the NRE can act as an upstream efficiency element (USE) to 
control polyadenylation site usage in a position and orientation-dependent 
manner, both in the context of the HPV-16 late 3’UTR and also in a 
heterologous poly(A) competition assay utilising a tandem arrangement of 
weak and strong poly(A) sites, similar to the arrangement of LP1 and LP2 in 
HPV-16 (McGuire et al., 2002). Furthermore, it appears that, unlike the 
situation in vitro, both the LP1 and LP2 poly(A) sites are functional in vivo, 
and that a large proportion of the late transcripts induced upon differentiation 
are polyadenylated at the LP1 site (McGuire et al., 2002). This observation 
would appear to support the hypothesis that differential usage of the tandem 
late polyadenylation sites in HPV-16 helps to control the expression of late 
viral proteins, with the NRE acting as a possible differential regulator of 
poly(A) site choice (McGuire et al., 2002).
Moreover, it seems that the NRE can further influence polyadenylation by 
acting as DNA element and pausing transcription (McGuire et al., 2002). 
Transcription pause sites are generally located downstream of the 
polyadenylation signal and it is conceivable that since the NRE lies upstream 
of the late poly(A) signals that stalling transcription at this point in the exon 
would result in the rapid degradation of late messages due to the lack of a 
suitable upstream polyadenylation site (Yonaha et al., 1999, McGuire et al.,
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2002). This would be an extremely efficient mechanism of preventing late 
protein expression in undifferentiated cells. This type of inhibition could be 
overcome with differentiation as a result of the increased rate of transcription 
through the late region leading to efficient 3’ end processing.
1.4.6 Protein binding to the NRE
The 79nt NRE has also been shown to bind a range of cellular proteins, 
three of which have been identified as proteins specifically involved in RNA 
processing: The auxiliary splicing factor U2AF65, the 64kDa subunit of the 
cleavage stimulation factor, CstF-64, and the elav-like shuttling protein HuR 
(Dietrich-Goetz et al., 1997, Koffa etal., 2000). Furthermore, the level of 
expression of these cellular factors appears to be differentially regulated 
such that U2AF65 levels decrease upon differentiation, CstF-64 expression is 
upregulated with differentiation, and HuR undergoes a differential 
redistribution from the nucleus to the cytoplasm (Koffa et al., 2000).
The presence of weak 5’ splice sites in the 5’ portion of the HPV-16 NRE 
together with the ability of this element to interact with U2AF65 has lead to 
analogies being drawn between the HPV-16 NRE and the negative element 
in the late 3’UTR of BPV-1 (Furth et al., 1994, Dietrich-Goetz et al., 1997). 
However, it appears that, unlike BPV-1, the four weak 5’ splice sites in the 
HPV-16 NRE act together to exert a negative effect (Cumming et al., 2002b). 
Binding of U1 snRNP to the NRE has not been reported, although our data 
strongly suggests that U1 snRNP-associated proteins do bind to the NRE 
(Chapter 5). However, it remains to be determined if the HPV-16 NRE 
regulates 3’ end processing via a mechanism similar to that used by BPV-1. 
Alternatively, the NRE may fulfil a function similar to that of the upstream 
efficiency element (USE) in the late polyadenylation region of SV40 (Lutz et 
al., 1994). Binding of the U1A subunit of U1 snRNP to this USE actually 
serves to enhance polyadenylation of late messages by coupling
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polyadenylation and splicing through the direct interaction of U1A with the 
160kDa subunit of the cleavage-polyadenylation specificity factor (CPSF) 
(Lutz etal., 1996).
The polyadenylation protein CstF-64 normally binds to the GU/U-rich region 
downstream of a polyadenylation signal, stabilising formation of the 
polyadenylation and cleavage complex (Takagaki et al., 1990, Takagaki et 
al., 1997). The GU-rich 3’ region of the NRE may compete for CstF binding 
with the downstream GU/U-rich region, thereby inhibiting efficient 
polyadenylation of late messages in undifferentiated cells. Differential 
changes in the level of expression of CstF-64 could promote binding of this 
cleavage factor to the stronger GU/U binding site, downstream of the poly(A) 
sites, and improve the efficiency of late mRNA polyadenylation upon 
differentiation (Terhune etal., 1999). As mentioned previously, the HPV-16 
NRE acts as an USE to regulate differential late poly(A) site usage (McGuire 
et al., 2002). In this scenario, CstF-64 binding to the NRE in differentiated 
cells could promote use of the NRE-proximal LP1 site, similar to the situation 
in the C2 complement polyadenylation region where binding of CstF-64 to a 
GU-rich region upstream of the poly(A) signal stimulates cleavage and 
polyadenylation at this site (Moreira et al., 1998).
Unlike the negative element of HPV-1, the HPV-16 NRE lacks the AUUUA 
tandem repeat characteristic of AU-rich elements, however, it does contain a 
GUUUG tandem repeat, which may be sufficient for HuR-binding (Seedorf et 
al., 1985, Koffa et al., 2000). HuR binding to the HPV-16 NRE might promote 
nuclear export of late mRNAs and improve the cytoplasmic stability of these 
late messages, similar to the situation in HPV-1 (Sokolowski et al., 1999).
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1.4.7 Inhibitory Elements within the Viral Coding Region
While the inhibitory elements described above in BPV-1, HPV-1, -16 and -31 
are located within the non-coding region of the virus, c/s-acting negative 
elements have also been identified within the HPV-16 L1 and L2 coding 
regions as well as the L2 coding region of HPV-31 (Tan et al., 1995a, 
Sokolowski et al., 1998, Terhune etal., 2001, Collier etal., 2002). At 
present, negative elements within late coding sequences have been 
identified only in these two high-risk viruses, both of which produce small 
numbers of mature virions in productive infections, leading to the suggestion 
that intragenic negative elements determine the levels of virus produced 
from specific HPV types (Schwartz et al., 1999).
HPV-16 L1 and L2
The HPV-16 L1 element is located within the 5’ end of the ORF (nt 5813- 
6150) and acts in an orientation dependent manner to post-transcriptionally 
inhibit L1 expression (Tan et al., 1995a, Collier et al., 2002). The inhibitory 
region in the HPV-16 L1 coding sequence contains seven AUUUA 
pentanucleotides, which are a general feature of mRNA instability elements 
and have been identified in several cellular mRNAs also under post- 
transcriptional regulation, including c-fos and c-myc (Chen etal., 1995,
Ross, 1995). The HPV-16 L2 coding region also contains strong negative 
elements that act in an orientation-dependent manner to reduce the levels of 
L2 encoding mRNAs in the nucleus and the cytoplasm (Sokolowski et al., 
1998). A region within the 5’ half of the L2 ORF appears to act in cis to 
reduce mRNA half life, however, while this region does not contain any 
AUUUA or UUUUU motifs it does have a 60% A+U content. A weaker 
element has also been identified in the 3’ end of the L2 coding sequence and 
may affect the efficiency of utilisation of L2 mRNAs. This element has been 
shown to bind a number of cellular proteins, including the polyC binding 
proteins 1 and 2 (PCBP-1 and -2) and hnRNP K (Collier et al., 1998).
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Interestingly, the 5’ element of HPV-16 L1 also specifically binds these 
factors, suggesting that both late proteins are subject to the same control 
mechanisms; however, the role of these cellular proteins in the virus life 
cycle remains to be investigated (Collier et al., 1998).
HPV-31 L2
The negative element of HPV-31 L2 is located within the first 800nt of the 
ORF and may function either as a single large element or cooperatively 
through multiple redundant elements (Terhune et al., 2001). Disruption of 
this region in the context of the whole viral genome results in a significant 
reduction in genome replication and loss of stable maintenance in primary 
foreskin keratinocytes (Terhune et al., 2001). These observations tend to 
suggest that the mechanism of action of the HPV-31 L2 negative element 
differs to that of the HPV-16 L1 and L2 elements, which appear to act 
primarily at the level of mRNA instability.
The regulation of viral late-gene expression caused by negative regulatory 
elements within protein coding regions appears to be a common strategy 
used by many viruses. For example, human immunodeficiency virus type 1 
(HIV-1) contains inhibitory sequences in the Gag, Pol and Env coding 
regions (Cochrane etal., 1991, Maldarelli etal., 1991, Schwartz etal., 1992), 
and human T-cell leukaemia virus type 1 (HTLV-1) contains inhibitory 
sequences in the 5’ UTR and in the Env and Pol coding regions (Seiki et al., 
1990, Saiga et al., 1997). Hepatitis B virus also contains a c/'s-acting RNA 
element shown to regulate the expression of surface gene transcripts 
(Huang et al., 1994). The presence of inhibitory sequences on mRNAs 
encoding structural proteins may allow tight regulation of virus production, 
which probably contributes to the ability of HIV-1, HTLV-1 hepatitis B and 
papillomaviruses to persist in their hosts even in the presence of specific 
immune responses against the infection.
49
Introduction
1.4.8 In Vitro Study of Papillomaviruses
History
Until relatively recently it has been virtually impossible to study the life-cycle 
of PVs outwith the natural host, due to the lack of a reproducible cell culture 
system permissive for vegetative viral replication. A number of characteristic 
features of papillomavirus biology have hampered the development of such 
an in vitro system: Given the tight association between keratinocyte 
differentiation and expression of the late viral proteins, the biggest hurdle 
has been finding a system that can faithfully mimic the epithelial 
differentiation programme as seen in vivo. Furthermore, human 
papillomaviruses have a specific tropism for epithelial cells, and a 
predilection for certain anatomical sites, thus precluding the use of animal 
models for HPV-infection.
However, since the mid-1980s xenografting in the athymic mouse system 
has been successfully used to recreate HPV infections outwith the natural 
host. Kreider et al., (1985) first grafted normal cervical tissue infected with 
HPV-11, i.e. condyloma acuminata-derived material, onto the flanks of 
athymic mice and showed that the resulting lesions displayed morphological 
transformation similar to that of low-grade cervical lesions. Furthermore, 
when neonatal foreskin epithelium, infected with HPV-11 DNA extracted 
from human vulvar condyloma acuminata, was grafted under the renal 
capsule of athymic mice and organotypic raft cultures, the xenografts and 
rafts were able to support the vegetative replication of papillomaviruses, and 
the virions produced were infectious (Kreider et al., 1986, Dollard et al., 
1992). In the case of the former, this was the first time a HPV type had been 
produced in the laboratory.
Following this, focus shifted to the derivation of HPV-positive cell lines from 
low-grade cervical lesions, in an attempt to recreate a productive HPV- 
infection in an in vitro tissue culture system. Eventually after a number of 
failed attempts in which the viral genome consistently became integrated, a
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HPV-16 line which maintained episomal copies of the viral genome was 
reported and was called W12 (Stanley et al., 1989). Grafting of this line onto 
granuloma beds in the flanks of nude mice resulted, with time, in the 
formation of a stratified epithelium that displayed morphological 
characteristics of low-grade lesions (Sterling et al., 1990). In the upper layers 
of the structure, viral DNA amplification was detected together with capsid 
protein expression and formation of mature virions (Sterling et al., 1991, 
Sterling et al., 1993). However, for reasons that remain unknown, the mature 
virions shed from the epithelium were not infectious.
HPV-positive keratinocyte cell lines are also amenable to study in monolayer 
culture. Rheinwald and Green first reported in 1975 that a feeder layer of 
irradiated mouse 3T3 fibroblast cells supported the clonal growth of 
keratinocytes but not other cell types (Rheinwald & Green, 1975). 3T3 cells 
treated in this way are no longer able to replicate but continue to secrete 
soluble factors such as insulin-like growth factor I (IGF-1), human growth 
factor (HGF) or keratinocyte growth factor (KGF), which sustain keratinocyte 
proliferation (Taichman, et al., 1986, Parkinson, et al., 1992, Meyers etal., 
1994a). This system is very useful for the clonal growth and serial cultivation 
of epithelial cell lines, however, while the feeder support system does allow 
limited stratification, keratinocytes grown using this technique do not 
undergo complete differentiation, therefore this system cannot support the 
complete life cycle of HPV-infected cell lines.
Calcium
Keratinocytes can be induced to differentiate in the absence of a fibroblastic 
feeder layer. One factor that regulates many aspects of epidermal 
differentiation, including desmosome formation, stratification and 
transglutamine activation, is extracellular calcium. In medium with a calcium 
concentration below 0.1 mM, keratinocytes maintain a basal cell phenotype, 
while an increase in extracellular calcium to 1.2mM leads to differentiation;
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cells stratify within 1-2 days and terminally differentiate with cell sloughing by 
4 days (Hennings et al., 1980).
Suspension in Semi-Solid Medium
In 1977 Green et al., first demonstrated that suspension of keratinocytes in 
semisolid medium resulted in their differentiation (Green et al., 1977). 
Suspension of HPV-positive keratinocytes in semisolid medium, such as 
methylcellulose, is a simplified differentiation method, which allows for the 
analysis of differentiation-dependent activities as a function of time. A recent 
study reported that, following 24 h in methylcellulose, approximately 25% of 
HPV-31-positive cells expressed high levels of the late viral protein E1AE4 
and appeared to have amplified levels of viral DNA. However, synthesis of 
the viral capsid protein L1 could not be detected in these cells, suggesting 
that this method does not induce faithful terminal differentiation (Ruesch et 
al., 1998a and b). Nevertheless, suspension of HPV-16 positive cells in 
methylcellulose has been used to show that the mechanism of viral DNA 
replication switches upon differentiation (Flores etal., 1997), and this 
method continues to be used extensively, particularly in studies addressing 
differential changes in HPV-promoter usage and polyadenylation (Terhune et 
al., 1999, Terhune etal., 2001).
Organotypic Raft Culture
It appears that, in vitro, the complete keratinocyte differentiation programme 
can best be obtained by culturing keratinocytes on organotypic raft cultures 
(Fig. 1. 11). This system has been proven to accurately mimic the in vivo 
physiology of the epidermis. Epithelial cells are placed on top of a dermal 
equivalent, grown to sub-confluence, and raised to an air-liquid interface for 
growth and differentiation (Meyers etal., 1994a). The dermal equivalent 
used most widely now for the cultivation of HPV-infected lines was first 
described by Bell et al., in 1979 and further modified by Asselineau and 
Prunieras in 1984 (Bell etal., 1979, Asselineau et al., 1984, Asselineau et
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al., 1986). In this system, living mesenchymal cells, e.g. murine 3T3 cells, 
are incorporated into a collagen matrix, which solidifies to form the dermal 
equivalent. Epithelial cells are plated on top of the collagen-fibroblast matrix, 
allowed to attach, and grown to confluence while remaining submerged. Air 
exposure is generally accomplished by placing the matrix on metal grids so 
that the medium feeds the confluent culture with nutrients and growth factors 
through the collagen and ventral surface of the epithelium. The rafts are 
incubated in this way usually for 2-3 weeks during which time the epidermal 
cells stratify and differentiate (Bell et al., 1979, Asselineau et al., 1984, 1986, 
Meyersef al., 1994a).
This system has been used to successfully propagate a number of HPV- 
positive cell lines. The CIN 612 9E line was derived from a low-grade 
cervical lesion and maintains episomal copies of the HPV-31 genome 
(Bedellef al., 1991). When this cell line was applied to the organotypic raft 
culture system it stratified and differentiated efficiently, resulting in a lesion 
similar to the one from which the line was originally derived (Bedellef al., 
1991). However, in agreement with previous reports, the differentiation of the 
CIN 612 reconstructed epithelium appeared incomplete and this was 
believed to account for the low level of detection of viral capsid transcripts 
and the lack of mature virion production in these cultures (Asselineau et al., 
1986, Bedell etal., 1991). Treatment of CIN 612 raft cultures with an activator 
of the protein kinase C (PKC) pathway, 12-0-tetradecanoylphorbol-13- 
acetate (TPA) resulted in a more complete differentiation programme as 
indicated by an increase in expression of the differentiation markers keratin 
10 and filaggrin (Meyersef al., 1992). Moreover, late viral capsid proteins 
were detected in the suprabasal layers of TPA-treated CIN 612 rafts and 
mature, infectious HPV-31 virions were produced (Meyersef al., 1992,
Meyers et al., 1994). This was the first demonstration of the production of 
mature virions from an in vitro system using a biopsy-derived continuous cell 
line.
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Recent modifications of the organotypic raft culture system have involved the 
use of epithelial lines containing cloned viral DNA. Cloned, recircularlised 
HPV-11,-18, and -31 DNA was co-transfected with a neomycin resistance 
plasmid (pSV2neo) into monolayers of normal human foreskin keratinocytes 
(HFKs) (Frattini etal., 1996, Frattini etal., 1997, Meyersef al., 1997, 
Thomasef al., 2001). In each case, clones that maintained episomal copies 
of the viral DNA were expanded, seeded onto organotypic rafts, and allowed 
to differentiate at the air-liquid interface. For the HPV-18 and -31 lines 
mature virions were produced, while in the HPV-11 line, late viral protein 
expression and viral DNA amplification was detected in the suprabasal 
layers and it should be noted that phorbol ester treatment was not required 
(Frattini et al., 1996, Meyers et al., 1997, Thomas et al., 2001). The 
establishment of epithelial lines containing cloned viral DNA permits genetic 
manipulation of the viral genome and allows more complete genetic and 
biochemical studies of HPV than previously afforded by biopsy-derived cell 
lines. However, working with HFKs in cell culture can be problematic due to 
their limited lifespan, which can make it difficult to select for stable 
transfectants before they senesce. Therefore, the recent identification of a 
spontaneously immortalised HFK cell line called BC-1-Ep/SL may prove to 
be more useful in these types of studies (Flores et al., 1999). BC-1-Ep/SL 
cells are primarily diploid but contain a duplication in the small arm of 
chromosome 8. Nevertheless, they exhibit many characteristics of normal 
HFKs and differentiate well on the organotypic raft culture system (Flores et 
al., 1999, Allen-Hoffmann et al., 2000). These cells are capable of 
maintaining episomal copies of HPV-16 and -31 DNA following stable 
transfection and can support the productive viral life cycle when seeded onto 
raft cultures (Floresef al., 1999, Allen-Hoffmann et al., 2000).
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1.5 Aims and Objectives
The main objective of this work was to understand the molecular 
mechanisms regulating the tight linkage of viral late gene expression and 
epithelial differentiation.
The biopsy-derived HPV-16 positive W12 cell line contains episomal copies 
of the HPV-16 genome and is considered to be operationally equivalent to a 
basal epithelial cell latently infected with HPV-16, this line can also be 
induced to differentiate. The W12 cell line therefore represents a good model 
system in which to study the expression of HPV-16 late proteins in response 
to epithelial differentiation, however, this line has remained relatively 
uncharacterised. The first aim of this project, therefore, was to characterise 
the growth of HPV-16 infected epithelial cell lines both in monolayer culture 
and on the organotypic raft culture system.
The negative regulatory element (NRE) of HPV-16 is believed to play a 
central role in the post-transcriptional control of HPV-16 late gene 
expression. Therefore, the second aim of this project was to attempt to 
elucidate the mechanisms through which the NRE exerts its inhibitory effect 
in undifferentiated cells, and conversely, establish how the virus overcomes 
NRE-mediated inhibition of late gene expression upon differentiation. In 
order to do this, saturating site-directed mutagenesis of the NRE was carried 
out. Each NRE mutant was tested both for its ability to bind nuclear proteins 
and also its ability to repress reporter gene expression, compared to a 
wildtype control. Furthermore, I attempted to identify cellular factors that 
interact with this negative element and ascertain the effects of epithelial 
differentiation, both in the presence and absence of HPV-16 infection, on the 
level of expression of these NRE-bound proteins.
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Fig. 1.1. Phylogenetic tree containing sequences of 
103 papillomaviruses. Adapted from de Villiers, 2001
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Fig, 1.3. Progression to dysplasia. The histological changes that occur 
during the develop of invasive carcinoma. Adapted from Bennett Jenson 
et al., 1990.
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Fig. 1.5. Genomic map of HPV-16. The individual ORFs of the early 
(E) and late (L) regions are shown as areas outside the double­
stranded circular genome. LCR designates the long control region. 
The early promoter, P97 and late promoter, P differentiation inducible, a r e  
indicated. AE and AL denotes the early and late polyadenylation sites, 
respectively. Adapted from Desaintes et al., 1996.
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Fig. 1.6. HPV oncogenes and the cell cycle. In normal cells DNA damage 
induces cell cycle arrest in G1 and G2. In HPV-infected cells, E6 bypasses G1 
arrest by degrading p53 and also gradually attenuates the G2 checkpoint. Rb is 
inactivated by E7 which also inhibits the cdk inhibitor, p21, and bypasses the 
G1 checkpoint. Also shown is the putative inhibition of cyclin B by HPV-16 
E1AE4, resulting in G2 arrest. Adapted from Galloway and McDougall, 1996.
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Fig.1. 7. HPV-16 mRNA species and coding potentials. A. Linear diagram of 
the HPV-16 genome and positions of open reading frames. The nucleotide 
positions of the 5’ and 3’ ends of each cDNA clone are indicated. Also shown 
are the positions of the early, P97, and late, P670, promoters and early, AE, and 
late, Al , polyadenylation sites. B. RNA species isolated from HPV-16 cervical 
carcinoma and the W12 cell line (Smotkin et al., 1989, Doorbar et al., 1990). 
Open boxes represent potential coding regions; coding capacity of each species 
is indicated on the right. Positions of common splice sites are shown. Adapted 
from Sherman et al., 1992, Vormwald-Dogan et al., 1992.
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Fig. 1.8. Exon definition and splicing leading to the formation of an 
export-competent mRNA. CBP, cap-binding proteins: U1, U2, the U1 and 
U2 snRNPs: SR; members of the serine and arginine-rich family of splicing 
factors; U2AF, U2 snRNP auxiliary factor; SF-U1A, snRNP-free U1A 
complex; CPC, cleavage/polyadenylation complex; PAB II, poly (A)-binding 
protein II. The identity of factors directly contacting splicing factors during the 
bridging of terminal exons is not yet certain. Adapted from Zhao et a l ., 1999.
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Fig. 1.9. Cleavage and polyadenylation. A. A model of the cleavage 
complex. CPSF recognises the AAUAAA hexanucleotide while CstF 
binds downstream at the GU/U-rich region. The positions of CF I, CF II 
and PAP in the complex are not yet known. B. A model of the 
polyadenylation complex. CPSF remains bound to the AAUAAA 
sequence while PAP2 binds the poly(A) tail. Adapted from Wahle et al., 
1999.
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Pst\
TTCTGCAGACCTAGATCAGTTTCCTTTAGGACGCAAATTTTACTACAAG
CAGGATTGAAGGCCAAACCAAAATTTACATTAGGAAAACGAAAAGCTACA
❖
CCCACCACCTCATCTACCTCTACAACTGCTAAACGCAAAAAACGTAAGCT
GTAAGTATTGTATGTATGTTGAATTAlGTGTTGTTTGTTGTGTATATGTTT
GTATGTIGCTTGTATGTGCTTGTAAATATTAAGTTGTATGTGTGTTTGTAT
Ssp I
GTATGGTATAATAAACACGTGTGTATGTG I ITT IAAATGCTTGTGTAACT 
ATTGTGTCATGCAACATAAATAAACTTATTGTTTCAACACCTACTAATTG 
GTGGGTGGTTATTCATTGTATATAAACTATATTTGCTACATCCTGTTTTT 
GTTTTATATATACTATATTTTGTAGCGCCAGGCCCATTTTGTAGCTTCAA
CCGAATTCGG
Eco Rl
5’ portion CAAAAAAC Loop of putative stem loop
3’ portion TAA L1 stop
❖ Weak 5’ splice sites AATAAA LP1
AATAAA LP2
Fig. 1.10. P/E Fragment. The sequence of a 445 nt Pst I-Eco Rl fragment 
from the L1 ORF/3’ UTR of the HPV-16 genome. Features are highlighted 
and listed above.
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Fig. 1.11. Organotypic raft culture system. Epithelial cells are plated onto 
a submerged collagen matrix containing fibroblast feeders in the presence of 
medium. When cells reach confluence the matrix is raised onto a metal grid 
at the air-liquid interface and subsequent feeding occurs from underneath. 
Cells stratify and differentiate over a 2-week period. Adapted from Meyers et 
al., 1994.
Site HPV-associated
disease
HPV Types
Skin Wart 1 ,2 ,3 , 4, 7, 10, 26, 27, 28, 
29,41,48, 60, 63, 65, 75, 
76, 77, ...
Epidermodysplasia 
verruciforms (EV)
5,8,9,12,14,15,17,19,20,21,
22,23,24,25,36,37,38,46,
47,50,...
Respiratory tract Laryngeal
papillomatosis
6, 11
Focal epithelial 
hyperplasia (FEH)
13, 32, 57, 72, 73
Genital tract Genital warts 6, 11
Intraepithelial
neoplasia
34, 40, 42, 43, 44, 53, 55, 
61,62, 64, 67, 68, 71,74
Intraepithelial 
neoplasia and 
invasive carcinoma
16, 18, 31, 33, 35, 39, 45, 
51, 52, 54, 56, 58, 66, 69, 
70
Table 1.1: Sites of HPV-infection and associated diseases.
Adapted from Howley, 1996 and zur Hausen, 1996.
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CHAPTER 2: MATERIALS AND METHODS
2.1 Materials
2.1.1. Enzymes
All restriction enzymes were purchased from New England Biolabs. T4 DNA 
ligase, T3 RNA polymerase, T7 RNA polymerase, Klenow polymerase, 
RNasin, and RNase-free DNase 1 were purchased from Promega. TAQ 
polymerase was purchased from ABgene.
2.1.2. Radiochemicals
Radiochemicals were purchased from the following sources at the stated
specific activity:
a - [35 S] dATP 
a - [32 P]dATP 
a - [32 P]UTP 
[3H] chloramphenicol
12.5mCi/ml
3000Ci/mmol
800Ci/mol
58.5mCi/mmol
Amersham 
DuPont NEN 
DuPont NEN 
Amersham
2.1.3. PlasmidsA/ectors
pGem®-T Vector -  a cloning vector used to clone PCR products. The vector 
was supplied pre-cut with EcoR V and with a 3’ terminal thymidine added to 
both ends thus providing a compatible overhang for PCR products 
generated using Taq polymerase, which adds an additional deoxyadenosine 
residue to the 3’ ends of amplified fragments. Insertion of the PCR product 
within the a-peptide coding region of the p-galactosidase enzyme causes 
inactivation of this enzyme and allows blue/white selection of recombinant 
clones on Xgal/IPTG plates (Promega). Map in Appendix 1.
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pLW1 -  an expression vector containing a chloramphenicol 
acetyltransferase (CAT) reporter gene under the control of the Herpes 
Simplex Virus type 2 (HSV-2) immediate early promoter. This vector lacks 3’ 
end processing signals. Inserts were cloned downstream of the reporter 
gene between the Pst \/Hin6 III sites (Gaffney etal., 1985) (Fig. 4.2).
pBS -  a cloning vector derived from a pUC plasmid that contains 
bacteriophage T3 and T7 promoters into which the M13 origin of replication 
has been inserted in opposite orientations (Stratagene). Map in Appendix 1.
pBS PE445 -  this plasmid contains a 445nt Pst I-Eco Rl (PE) fragment from 
the 3’ coding region of HPV-16 L1 extending into the late 3’UTR (7008nt to 
7453nt), Fig. 1.10, (McGuire etal., 2002).
pBS 114KI pBS 114B — full-length HPV-16 DNA derived from a cervical 
condyloma acuminatum cloned into the Bam HI site of pBS (Kirnbauer et al., 
1993).
pBS HPV31EcoRI -  full-length HPV-31 DNA from the CIN 612 9E cell line 
cloned into the Eco Rl site of pBS (Ozbun et al., 1997).
2.1.4. Antibodies
Name, source and dilution of all antibodies used in this study are listed in 
Table 2.1.
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Primary Antibody 
and type
Western blot 
dilution
Immunocyto
chemistry
dilution
Source and 
Reference
HPV-16 L1 
CamVir 1 
Mouse
1:10000 1:250
Abeam 
McClean et al., 
1990
HPV-16 E1AE4 
TVG 402 
Mouse
1:500 1:50
J. Doorbar 
Doorbar et al., 
1992
Involucrin 
SY5 clone 
mouse
1:5000 1:100 Sigma
K10 
K8.60 clone 
Mouse
1:500 1:100 Sigma
U2AF65
MC3
mouse
1:100 Not attempted
M. Carmo- 
Fonseca 
Gama-Carvalho et 
al.. 1997
CstF-64
a64k
mouse
1:100 Not attempted
J. Manley 
Takagaki etal., 
1990
HuR
16A5
mouse
1:250 Not attempted
H. Ferneaux 
Levy et al., 1998
ASF/SF2 
aSF2 96 
mouse
1:1000 Not attempted
A. R. Krainer 
Hanamura et al., 
1998
Sm
Y12
mouse
1:1000 Not attempted
Lab Vision 
Lerner etal., 1981
U1A 
Anti-U1A 
antiserum 
rahhit
1:1000 Not attempted I. M. Mattaj
U1 70K 
H111 
mouse
1:1000 Not attempted
Euro Diagnostica 
Kastner et al., 
1992
GAPDH
6CS
mouse
1:1000 Not attempted BiodesignInternational
Table 2.1. Antibodies used in the course of this work.
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2.1.5. Bacterial Culture
The E. Coli strains DH5a and XL1 Blue were used for maintenance and 
propagation of plasmid DNA. Both strains were grown in L-Broth (10g NaCI, 
16g Bactopeptone, 5g yeast extract in 11 water, pH 7.5). Agar plates were 
made with 1.5% (w/v) agar in L-Broth. When necessary, L-Broth and LB agar 
plates were supplemented with 100pg/ml ampicillin.
2.1.6. DNA Probes
Full-length HPV-16 genomic probes were prepared by linearising plasmid 
pBS114K by digestion with Bam HI.
Full-length HPV-31 genomic probes were prepared by digesting plasmid 
pBS HPV31Eco Rl with Eco Rl to release the viral genome.
2.1.7. Cell Lines
HaCaT -  Spontaneously immortalized aneuploid human keratinocyte cell 
line (Boukamp etal., 1988)
HeLa -  HPV-18-positive epithelial line derived from an aggressive cervical 
lesion (Griffiths, 1953)
J2 3T3 -  J2 clone of random-bred Swiss mouse 3T3 cells (Rheinwald et al., 
1975)
NHFK -  Pooled normal human epidermal keratinocytes (neonatal skin) 
(Clonetics/BioWhittaker)
W12 -  HPV-16-positive cervical epithelial cell line established from a low- 
grade lesion (Stanley et al., 1989)
20863 -  Subclone of the parental W12 cell line harbouring 
extrachromosomal copies of HPV-16 (Jeon et al., 1995a)
20861 - Subclone of the parental W12 cell line harbouring integrated copies 
of HPV-16 (Jeon etal., 1995a)
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2W12 -  Subclone of 20863 cell line harbouring episomal HPV-16 (Ozbun 
and Meyers, unpublished data)
CIN 612 9E - HPV-31-positive cervical epithelial cell line established from a 
low-grade lesion (Bedell etal., 1991)
2.1.8. Common Reagents. Chemicals and Solutions
30% Acrylamide 29% (w/v) acrylamide, 1% (w/v) N, N’- 
methylene bis-acrlyamide
40% Acrylamide 38% acrylamide (w/v), 2% bis-acrylamide
5x agarose gel loading buffer 1x TAE, 1% SDS (w/v), 50% glycerol (v/v),
1 mg/ml bromophenol blue
Coomassie Blue stain 0.02% (w/v) Coomassie Brilliant Blue, 
50% (v/v) methanol, 43% (v/v) water, 7% 
(v/v) acetic acid
50x Denhardts solution 5g Ficoll, 5g polyvinyl-pyrrolidone, 5g
bovine serum albumin, H2O to 500ml. 
Filter and aliquot at -20°C
Diethyl Pyrocarbonate (DEPC) 
treated dH20
300pl DEPC added to 500ml dH20, 
Incubated overnight at room temperature 
and baked overnight at 80°C to inactivate 
DEPC
Destain 5% (v/v) methanol, 7% (v/v) acetic acid, 
88% (v/v) water
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HEPES extract buffer 50mM HEPES, 50mM NaCI, 0.1% (v/v)
NP40, pH7.5
PBS 170mM NaCI, 3.4mM KCI, 10mM
Na2HP04, 1.8mM KH2P 04, pH7.2
PBS-Tween PBS plus 0.05% (v/v) Tween 20
11.1x PCR buffer 4.5mM TrisCI pH8.8, 11mM (NH4)2S04,
4.5mM MgCI2, 6.7mM (3-mercaptoethanol, 
4.4mM EDTA, 100mM dATP, dCTP, 
dGTP, dTTP, 113pg/ml BSA
7x Protease Inhibitor Cocktail One tablet (Roche) dissolved in 1.5ml
distilled water
3x Protein gel loading buffer 150mM Tris HCI, 300mM dithiothreitol,
6% (w/v) SDS, 0.3% (w/v) bromophenol 
blue, 30% (v/v) glycerol, pH 6.8
Protein gel running buffer 50mM Tris base, 50mM glycine, 0.1% 
(w/v) SDS
20x SSC
(standard saline citrate)
3M NaCI, 300mM trisodium citrate
50x TAE 200mM Tris base, 50mM EDTA (pH8.0), 
bring to pH8.0 with acetic acid
10x TBE 890mM Tris, 10mM EDTA, 890mM boric 
acid
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TE buffer 10mM Tris HCI, 1mM EDTA, pH8.0
Towbin Blotting buffer 25mM Tris base, 192mM glycine, 20% 
(v/v) methanol
Trypsin 0.25% (w/v) trypsin, in Tris-saline 
Containing phenol red, adjusted to pH 7.5 
with NaHCC>3
UV X-Linking binding buffer 60mM KCI, 20mM HEPES pH7.6, 1mM
IVIgCb, 10% glycerol
Versene 0.6mM EDTA in PBS, 0.002% phenol red
Water Sterile distilled water obtained from a 
“Milli-Ro 60 plus” deioniser (Millipore, 
USA) and sterilised by autoclaving
All chemicals and reagents were purchased from BDH Chemicals UK or 
from Sigma Chemical Co. unless otherwise stated in this section or in the 
methods.
Amersham ECL Western blotting reagents,
nitrocellulose membrane, PVDF 
membrane, nylon membrane, Rainbow 
molecular weight markers
Beecham Research Ampicillin sodium B.P. (Penbritin®)
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Bio-Rad
Joseph Mills Ltd. 
Prolabo
Ammonium persulphate, Bradfords 
reagent, Coomassie blue
Ultra pure ethanol, methanol
Butanol, glacial acetic acid, glycerol, 
isopropanol, xylene
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2.2 Methods
2.2.1 Tissue Culture
2.2.1.1 Growth and maintenance of cell lines
HeLa cells were grown in Dulbecco’s Modified Eagles Medium (DMEM), 
supplied by Life Technologies, supplemented with 10% foetal calf serum 
(FCS) and 5% L-glutamine (10mg/ml), also supplied by Life Technologies. 
HaCaT cells were maintained under non-differentiating conditions in calcium- 
free DMEM supplemented with 10% FCS. For the purposes of differentiation, 
HaCaT cells were grown in E medium (see below).
Primary human foreskin keratinocytes were isolated from newborn 
circumcisions, pooled, and supplied by Clonetics, BioWhittaker, UK Ltd. 
Primary cells were maintained in Keratinocyte Growth Medium (KGM) 
supplemented with 50}ig gentamycin sulfate, 50ng amphotericin, 0.1 ng 
human epidermal growth factor, 30pg bovine pituitary extract, 5pg bovine 
insulin, and 0.5pg hydrocortisone, supplied by Clonetics, BioWhittaker, UK 
Ltd.
J2 3T3 cells were maintained in DMEM supplemented with 10% donor calf 
serum (DCS) and 5% L-glutamine (10mg/ml).
HPV-positive cell lines (W12, 20863, 20861, 2W12, CIN 612 9E) were 
maintained in monolayer culture in W12 medium (DMEM supplemented with 
10% FCS, 0.1 nM cholera toxin and 0.4pg/ml hydrocortisone). These human 
epidermal keratinocyte cell lines were cultivated with a feeder layer of J2 3T3 
cells; this method has been shown to support the clonal growth of 
keratinocytes only (Rheinwald and Green, 1975). The 3T3 feeder layer was 
prepared by first treating the feeder cells with mitomycin C (4jj.g/ml) for 2-5 h 
at 37°C to irreversibly inhibit proliferation (Rheinwald and Green, 1975). 
Following treatment, the 3T3 cells were washed 3 times with PBS, 
trypsinized and re-plated in W12 medium. The plating density of the feeder
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cells is dependent on the desired seeding density of the keratinocyte cell 
lines since the optimal ratio is 5:1 of J2 3T3 cells to keratinocytes. Generally, 
cell stocks of the HPV-positive lines were prepared by growing the lines in 
W12 medium, with 0.5ng/ml epidermal growth factor (EGF) added 24h after 
plating. For the purposes of differentiation in monolayer culture and on 
organotypic rafts, cells were cultured in epithelial (E) medium without EGF.
E medium was prepared in 51 vats as follows (Meyers, 1996):
dH20  4.0625I
DMEM with 4500mg/l D-glucose &L-Glutamine, 3.75I
no sodium pyruvate/sodium bicarbonate 
F-12 nutrient mixture with L-Glutamine, 1.251
no sodium bicarbonate
Sodium bicarbonate 15.34g
Adenine 18mM
Insulin 5pg/ml
Transferrin 5pg/ml
3, 3’, 5-Triiodo-L-Thyronine (T3) 2pM
Penicillin 500U
Streptomycin 500pg/ml
Hydrocortisone 2pg/ml
Cholera enterotoxin 10nM
Cone. HCI 1.56ml
The solution was mixed well and the pH adjusted to pH 7.1 with conc. HCI. 
Finally the solution was filter-sterilised using a low protein 0.2pM filter, 
aliquoted into sterilell bottles and stored at 4°C.
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2.2.1.2 Preparation of cell stocks
Following trypinisation, cells were counted and resuspended in the 
appropriate growth medium at 1x106 cells/ml and aliquoted to screw cap 
tubes. Dimethylsulphoxide (DMSO) was added to a final concentration of 
10% (v/v) and the cells were stored under liquid nitrogen.
This procedure was followed for all cell lines grown.
2.2.1.3 Establishment and maintenance of organotypic raft cultures
This method has been adapted from a previously published protocol 
(Meyers, 1996). The dermal equivalent was prepared by mixing non- 
mitocycin C treated J2 3T3 fibroblasts (6.25x105 cells/raft) with a collagen 
mix (2.5ml/raft) composed of 80% type IV collagen (generously provided by 
Dr. Mike Edward, Dept, of Dermatology), 10% 10xDMEM and 10% 
reconstitution buffer (2.2% (w/v) NaHCOs, 4.77% (w/v) HEPES in 0.062N 
NaOH) and 0.024N NaOH. The dermal equivalent was aliquoted to each well 
of a six well dish and incubated at 37°C for 30 min to set. Epithelial cells 
were seeded onto the dermal equivalent at 1.0x106cells/raft. The collagen 
matrixes were incubated overnight at 37°C to allow attachment of the 
epithelial cells to the dermal equivalent and growth to confluence. On the 
following day, the epithelia cells were brought to the air-liquid interface by 
raising the collagen matrixes onto wire grids. The epithelial cells continued to 
be fed by diffusion through the collagen matrix from the surrounding E 
medium for up to 12 days; medium was changed every second day. Once at 
the air-liquid interface, the rafts were treated with 10pM 1,2-dioctanoyl-sn- 
glycerol (C8:0; Sigma) on alternate days to induce differentiation, or 
remained untreated as a negative control for C8:0 treatment.
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2.2.1.4 Preparation of cell extracts
(i) Protein extracts from monolayer culture
Cells were washed twice in cold PBS then harvested in 5ml of PBS by 
scraping. Cells were pelleted by centrifugation at 1000rpm for 5 min at 4°C 
(Sorvall RT 6000B, refrigerated benchtop centrifuge) and resuspended in 
800pl ice cold Buffer E (100mM Tris-HCI pH8.0, 100mM NaCI, 2mM EDTA, 
2mM EGTA, 1% (v/v) NP40, 0.5% (v/v) sodium deoxycholate, 0.5mM PMSF) 
and chilled on ice for 15 min. Following cell lysis, chromosomal DNA was 
sheared by passing the solution through a 23 gauge needle attached to a 
2ml syringe, 5 to 10 times. Cell debris was pelleted by micro-centrifugation at 
12000rpm at 4°C for 15 min (Hettich EBA 12R, refrigerated microcentrifuge). 
The soluble protein extract was removed and stored at -70°C.
(iil Protein extracts from organotypic raft culture
Tissue harvested from organotypic raft culture was washed twice with ice- 
cold PBS and pelleted by centrifugation at 1000rpm for 5 min at 4°C (Sorvall 
RT 6000B, refrigerated benctop centrifuge). The pelleted tissue was 
resuspended in 5 volumes of ice-cold suspension buffer (0.1 M NaCI, 0.01 M 
Tris HCI pH7.6, 0.001 M EDTA pH8.0, 1pg/ml aprotinin, 100pg/ml PMSF. An 
equal volume of 2x SDS gel-loading buffer was added and the samples were 
placed in a boiling water bath for 10 min. The chromosomal DNA was 
sheared by sonication in a soni-bath (Kerry Ultrasonic Bath) for 30-60 sec 
and the cell debris was pelleted by centrifugation at 10,000rpm for 10min 
(Eppendorf Microcentrifuge 5415 C). The soluble protein extract was 
removed and stored at -70°C.
(iii) Nuclear Extracts
Nuclear extracts were prepared from cells grown in monolayer culture by 
resuspending harvested cells in three packed cell volumes of CE buffer 
(10mM HEPES pH7.8, 1mM EDTA, 60mM KCI, 1mM PMSF, 0.1% (v/v)
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NP40, 25% (v/v) glycerol, 4% (v/v) protease inhibitor cocktail) and chilled on 
ice for 4 min. Nuclei were pelleted at 14,000rpm for 10 sec (Eppendorf 5415 
C, microcentrifuge) and resuspended in three packed cell volumes of CW 
buffer (10mM HEPES pH7.8, 1mM EDTA, 60mM KCI, 1mM PMSF) followed 
by 10-20 strokes in a Dounce homogeniser. Nuclei were pelleted again at 
14,000rpm for 60 sec and resuspended in two packed cell volumes of NE 
buffer (20mM Tris HCI pH8.0, 420mM NaCI, 1.5mM MgCh, 0.2mM EDTA,
0.5mM PMSF, 25% (v/v) glycerol, 4% (v/v) protease inhibitor cocktail) and 
chilled on ice for 10 min. The suspension was centrifuged at 14,000rpm for 
10 min at 4°C (Hettich EBA 12R, refrigerated microcentrifuge). The 
supernatant was removed as the nuclear extract and stored at -70°C. This 
method was used in preference to the method of Dignam (as described in 
Wahle et a/., 1994) because it was faster, gave good nuclear / cytoplasmic 
separation and the final salt concentration of the extract was quite high 
(210mM NaCI) which was useful because I wanted to use these extracts to 
identify nuclear proteins that bind the HPV-16 NRE with high affinity.
2.2.1.5 Estimation of protein concentration
10jal of protein sample was diluted in 90pl of TE buffer and mixed with 300pl 
of Bradford’s reagent (BioRad). Following mixing the absorbency of the 
solution was measured at 620nm (Anthos htll plate reader) and converted to 
mg protein by comparison with a standard curve produced using known 
quantities of bovine serum albumin.
2.2.1.6 Transfection of cells
(\) Lipofection with Lipofectamine (Gibco. BRL1
HeLa cells were seeded at 1x105 cells per well of a six well dish and 
incubated overnight at 37°C. On the following day, 2pg of the DNA to be 
transfected was diluted into 10Opil of serum-free medium and 2pl of 
Lipofectamine reagent, per transfection, was added to 10Opil of serum-free
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medium. The two solutions were combined, mixed and allowed to incubate 
at room temperature for 30 min, to allow DNA-liposome complexes to form. 
The cells to be transfected were rinsed with 2ml of serum-free medium and 
800pl of serum-free medium was added to the DNA-Lipofectamine mix 
which was then applied to the pre-rinsed cells. The cells were incubated at 
37°C for 5 h and 1 ml of growth medium with 2x serum was added and 
incubation continued overnight. The medium was replaced the following day 
with fresh, complete medium and the cells were harvested 48 h after the 
start of transfection.
(i0 Electroporation of primary keratinocytes
Primary foreskin keratinocytes were electroporated with linearized HPV-16 
DNA released by digestion with Bam H1 from the pBS vector backbone of 
either plasmid 114K or plasmid 114B (gifts from Matthias Durst, Kirnbauer et 
a/., 1993). For each electroporation, 10pg HPV-16 DNA was mixed with 
4.25pg boiled salmon sperm DNA. Approximately 5x106 primary cells, 
resuspended in 250pl of E media plus 5mM BES pH7.2, were incubated with 
the DNA mixture at room temperature for 10 min. The solution was 
transferred to an electroporation cuvette (0.4cm BIO-RAD Gene Pulser 
Cuvette) and electroporated at 210v/960pFd (BIO-RAD Gene Pulser) 
followed by a 10 min incubation at room temperature. Each electroporation 
sample was layered onto 10ml E media and centrifuged at 1,000rpm for 5 
min (Sorvall RT 6000B refrigerated benchtop centrifuge), the pellet was 
resuspended in 6ml of E media and seeded onto freshly prepared mitomycin 
C treated J2 3T3 fibroblast feeders.
2.2.2 Chloramphenicol acetlytransferase (CAT) assay
Transfected cells were harvested by scraping and pelleted by centrifugation 
at 1000rpm for 5 min (Sorvall RT 6000B refrigerated benchtop centrifuge). 
The cell pellet was resuspended in 1ml of PBS, centrifuged at 14,000rpm for
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25 sec (Eppendorf 5415C microcentrifuge) and the supernatant was 
discarded. The pellet was resuspended in 160jnl of prechilled resuspension 
buffer (0.11M Tris-HCI pH7.8, 1mM EDTA, 1mM DTT) and the cells were 
lysed by freeze thawing three times in a dry ice/ethanol mix and at 37°C. Cell 
debris was pelleted by centrifugation at 14,000rpm for 3 min at 4°C (Hettich 
EBA 12R refrigerated microcentrifuge), the supernatant was retained and 
incubated at 65°C for 6 min to inactivate internal acetylases. Each sample 
was incubated at 37°C for 2 h with 20pl 0.5mM chloramphenicol, 2pl 3H- 
chloramphenicol (58.4mCi/mmol) and 2jul butyryl coenzyme A (25mM). The 
reaction was stopped by adding 400pl xylene, mixed by vortexing and micro­
centrifuged at 14,000rpm for 2 min (Eppendorf 5415C). The upper phase 
was retained and 200jal of xylene extraction buffer (10mM Tris-HCI pH7.5, 
1mM EDTA) added, mixed by vortexing and centrifuged as before, again the 
upper phase was retained and the extraction procedure was repeated three 
further times. Following the final extraction, one tenth of the volume of the 
remaining upper aqueous phase was added to 2ml Ecoscint and counted in 
a liquid scintillation counter (Beckman LS 5000CE).
2.2.3 Manipulation of DNA
2.2.3.1 Preparation and transformation of competent bacterial cells 
(il DH5a cells
A 1ml overnight culture was inoculated into 100ml L-Broth and grown for 
approximately two hours at 37°C with shaking until the ODeoo was 0.6. The 
culture was then chilled on ice for 15 min and the cells pelleted by 
centrifugation at 3,000rpm for 15 min at 4°C in a Sorvall RT 6000B 
refrigerated benchtop centrifuge. The pellet was resuspended in 30ml cold 
TfB I (30mM potassium acetate, 50mM manganese chloride, 100mM 
potassium chloride pH 5.8, 10mM calcium chloride, 15% glycerol) and chilled
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on ice for 1 h. Cells were pelleted as before and resuspended in 8ml of cold 
TfB I! (10mM sodium MOPS pH 7.0, 75mM calcium chloride, 10mM 
potassium chloride, 15% glycerol). Cells were chilled overnight at 4°C prior to 
use or aliquoted and stored at -70°C until required.
(iO XL1 blue cells
Competent XL1 blue cells were prepared as described above for the DH5a 
cells but following centrifugation the cell pellet was resuspended in 20ml of 
sterile cold 100mM CaCb and chilled on ice for 30 min. The suspension was 
centrifuged at 2,500rpm for 5 min at 4°C in a Sorvall RT 6000B refrigerated 
benchtop centrifuge and the pellet was resuspended in 10ml of sterile cold 
100mM CaCb and chilled on ice for 15 min followed by centrifugation as 
before. The pellet was then resuspended in 5ml sterile cold 100mM CaCh 
and chilled overnight at 4°C prior to use or aliquoted and 10% glycerol (v/v) 
added and stored at -70°C until required.
200^il aliquots of bacterial cells were thawed gently on ice prior to 
transformation. Approximately 10ng of DNA (5-10pl) was added to the cells 
and chilled on ice for 30 min, the mix was then heat shocked by incubating at 
42°C for 45 sec and chilled on ice for 2 min. 500jJ of L-Broth was added to 
the cells which were then incubated at 37°C with shaking for 1 h before 
plating onto LB plates containing ampicillin (100pg/ml). Plates were 
incubated overnight at 37°C.
2.2.3.2 Phenol:Chloroform extraction and ethanol precipitation
Generally, the reaction volume was increased to 200pl with TE buffer and an 
equal volume of phenokchloroform was added, mixed by vortexing and 
microcentrifuged for 5 min at maximum speed (Eppendorf 5415C); (phenol 
pH 7.9 for DNA; phenol pH 4.5 for RNA). The upper phase was transferred
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to a clean eppendorf tube, mixed thoroughly with an equal volume of 
chloroform and centrifuged as before. Again the upper phase was 
transferred to a clean tube and 1/10 of the volume of 3M sodium acetate pH
5.2 (DNA) or 7.5M ammonium acetate (RNA) was added together with 2.5 
volumes of ice-cold 100% ethanol. The solution was mixed by inversion and 
chilled on ice for 30 min followed by centrifugation at maximum speed for 10 
min (Eppendorf 5415C microcentrifuge) to pellet the nucleic acid. The pellet 
was washed in 70% ethanol, centrifuged for 5 min, air-dried and 
resuspended in DEPC-treated dH20 (RNA) or TE buffer (DNA).
2.2.3.3 Purification of plasmid DNA
(i) Small scale purification of plasmid DNA: alkaline lysis
1 ml of bacterial culture containing the plasmid DNA was microcentrifuged for 
1 min at maximum speed (Eppendorf 5415C) and the pellet was 
resuspended in 100pl of solution I (0.5M TrisCI pH8.0, 10mM EDTA) and 
mixed by vortexing. The cells were lysed by adding 200pl of freshly prepared 
solution II (1% SDS, 0.2N NaOH), mixed by inversion and incubated on ice 
for 5 min. 150p.l of neutralizing solution III (3M potassium acetate, 11.5% 
acetic acid) was added to the samples and mixed gently by inversion. Cell 
debris was pelleted by centrifugation at 14,000rpm for 10 min (Eppendorf 
5415C microcentrifuge). The supernatant was transferred to a clean 
eppendorf tube and contaminating proteins were removed by 
phenokchloroform extraction. Plasmid DNA was ethanol precipitated, 
pelleted, washed with 70% ethanol and resuspended in TE buffer.
(ii) Large scale caesium chloride purification of plasmid DNA 
500ml of overnight bacterial culture was pelleted by centrifugation at 
6000rpm for 10 min at 4°C (Sorvall GSA rotor, lowspeed centrifuge). The 
pellet was resuspended in 8ml solution I (0.5M TrisCI pH8.0, 10mM EDTA, 
1mg lysozyme) and chilled on ice for 15 min. The cells were lysed by adding
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16ml of fresh solution II (1% SDS, 0.2N NaOH), mixed by inversion and 
incubated on ice for 10 min. The sample was neutralised by the addition of 
12ml of solution III (3M potassium acetate, 11.5% acetic acid), mixed by 
inversion and chilled on ice for 15 min to precipitate the protein complexes. 
Cell debris was pelleted by centrifugation at 13,000rpm for 20 min (Sorvall 
SS34 rotor, lowspeed centrifuge), the supernatant was filtered through 
muslin and the plasmid DNA isopropanol precipitated from the filtrate. The 
DNA pellet was allowed to air dry and was resuspended in 4.5ml of TE buffer 
with 5g CsCI and 200pl ethidium bromide (10mg/ml). This solution was 
transferred to an ultracentrifuge tube and centrifuged at 48,000 rpm for 18h 
at 4°C (Beckman Ti70 rotor, ultracentrifuge). Following centrifugation the 
plasmid DNA band was removed by side-puncturing the tube using a syringe 
and needle and transferred to a 15ml tube. Ethidium bromide was removed 
from the plasmid DNA by repeated extraction with water-saturated butan-2-
ol. The DNA was precipitated with ethanol and finally resuspended in TE 
buffer.
2.2.3.4 Restriction enzyme digestion of DNA
Small scale restriction enzyme digestion of DNA was used to identify 
recombinant plasmids. Digests were generally carried out in 20pl reaction 
volumes using 10 units of restriction enzyme per |ug of DNA and 1x enzyme 
specific buffer. Reactions were incubated at 37°C usually for 1-2 h then 
agarose gel loading buffer was added prior to electrophoresis.
2.2.3.5 DNA Ligation
Vector and DNA fragments were prepared by restriction enzyme digest, gel- 
purified and ligated, usually, at a 1:3 ratio. Reactions were carried out in 20pl 
volumes containing 1 x ligase buffer and 2 units of T4 DNA ligase with 1mM 
ATP and were incubated overnight at 15°C or at room temperature for at
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least 4 h. PCR products were ligated into the pGEM-T vector following the 
manufacturer’s instructions.
2.2.3.6. Gel electrophoresis of DNA and recovery
(i) Agarose gel electrophoresis
DNA fragments produced by restriction enzyme digestion or PCR were 
fractionated by agarose gel electrophoresis. 1 % horizontal slab gels were 
prepared with Agarose LE Analytical grade (Promega) in 1xTBE buffer and 
electrophoresied at 100V. 100bp DNA ladder standard size markers (Gibco, 
BRL) were used where appropriate. Following electrophoresis, gels were 
stained in an ethidium bromide solution (0.5pg/ml) for 10 min. DNA was 
visualised either under short-wave UV light, or under long UV light for 
preparative gels, and photography was carried using an Ultra Violet Products 
Gel Documentation System, Image Store 7500, Version 7.2.
Agarose gel slices containing the appropriate DNA fragments were excised 
from gels under long UV light and the DNA recovered using a Millipore 
Ultrafree-DA kit. The gel slice was placed in the Gel Nebulizer and 
microcentrifuged at 5,000 rpm for 10 min (Eppendorf 5415C) causing the 
resultant gel slurry to be sprayed onto the sample filter cup. The membrane 
retained the gel matrix and the DNA passed through into the filtrate vial.
(ii) Acrvlamide gel electrophoresis
Small DNA fragments produced by PCR were analysed on 6% non­
denaturing acrylamide gels prepared as follows:
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30% acrylamide/ 3ml
bisacrylamide mix
10 x TBE 1.5ml
10% APS 100pl
TEMED 12pl
dH20 10.4ml
Electrophoresis was carried out at 130V for 45 min and gels were stained in 
ethidium bromide (0.5pg/ml) for 10 min, visualised under UV light and 
photographed using an Ultra Violet Products Gel Documentation System. 
Acrylamide gel slices containing the desired DNA fragment were excised 
under long UV light and the DNA was eluted overnight at 4°C in 400pl of 
0.5M NaCI. Eluted DNA was ethanol precipitated, pelleted, washed with 70% 
ethanol and resuspended in TE buffer.
2.2.3.7 Oligonucleotide Synthesis and Purification
Oligonucleotide synthesis was preformed on an automated Cruachem 
PS250 by cyanoethyl phosphoramidite chemisty on controlled pore glass 
(CPG) columns. The first nucleoside of the 3’ end of the oligonucleotide was 
attached to the CPG surface via an ester linkage and the completed 
oligonucleotide was removed by passing 1.5ml of ammonia across the 
matrix, cleaving the ester bond and generating a free 3’OH. The base- 
protecting dimethoxytrityl groups were removed by incubation at 55°C in 
ammonia for 5 h and the DNA was lyophilised under vacuum followed by 
phenol:chloroform extraction. Oligonucleotides were ethanol precipitated and 
resuspended in dH2 0 .
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2.2.3.8 Quantification of DNA. RNA and Oligonucleotides
A spectrophotometer (Eppendorf BioPhotometer) was used to determine the 
concentration of DNA, RNA and oligonucleotides based on the following 
calculations:
In addition, the purity of nucleic acid was determined by comparing readings 
at 260nm and 280nm (A260/A280), assuming a ratio of approximately 1.8 
indicated that the samples were relatively free of protein.
2.2.4 PCR Mediated Site-Directed Mutagenesis
The HPV-16 negative regulatory element (NRE) was divided into fifteen non­
overlapping groups of five nucleotides from the 5’ end through to the 3’end. 
Within each group PCR-mediated site-directed mutagenesis (SDM) was 
used to change purine bases to pyrimidines and vice-versa (Fig. 4.1 B). A 
PCR based protocol (Matthews et al., 1994) was used to generate the site- 
directed mutants (Fig. 2.1). Plasmid pBS PE445, which consists of the 445nt 
Pst I/Eco Rl fragment from the HPV-16 late 3’ untranslated region (Fig 1.10) 
inserted into the multiple cloning site of pBS, was used as the wild-type DNA 
template. Fifteen sets of complimentary primers were designed that 
contained each of the five mismatched bases flanked by 10-17 bp of wild- 
type 5’ sequence and 10-17 bp of wild-type 3’ sequence (Table 2.2). The 
mutagenesis protocol is summarized in Fig 2.1 A and B. In each case, the 
mutant forward primer was used together with a reverse primer encoding the 
baceriophage T3 promoter, designated T3 (Fig. 2.1C), to mutate and amplify 
Sac 1 linearized pBS PE445. Kpn 1 linearized pBS PE445 provided the
Double-stranded DNA 
Single-stranded oligonucleotides
1 A26o = 50pg/ml 
1 A26o = 30pg/ml 
1 A26o -  40pg/mlRNA
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template for a separate PCR reaction involving the complimentary mutant 
reverse primer and a forward primer encoding the bacteriophage T7t
promoter, designated T7 (Fig. 2.1C). The result of these separate PCR 
reactions was two complimentary half molecules containing the desired 
mutations, which could then be annealed, and a further round of fill-in PCR 
using the T3 and T7 primers generated a full-length, double-stranded 
product (Fig. 2.1 B). All PCR products generated in this way were 
subsequently cloned into the pGem-T vector and sequenced to ensure only 
the desired mutations were present.
The following PCR conditions were used:
Stage Temperature Time Cycles
1 95°C 3 min 1
95°C 30 sec
2 55°C 1 min
30
72°C 30 sec
55°C 5 min
3 1
72°C 10 min
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T7 only
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*
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Mutated
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T3
T7: CC AAGCTTCT AAT ACG ACTC ACT AT AGGG AT AT C ATTT AC AAGC AC AT AC AAGC
T3: CAGAGATGCAATTAACCCTCACTAAAGGGAGAATTCCCTCATCTACCTCTACAACT
Fig. 2.1. Site-directed mutagenesis of the NRE. A. Cartoon of pBS PE445 
showing the relevant restriction enzyme sites and positions of the primers used 
to mutate the NRE. B. Two complimentary half molecules, containing the NRE 
mutation, were PCR amplified, melted, annealed and amplified again to 
generate a full-length, double-stranded molecule. C. Sequence of the primers 
designated T7 and T3, bacteriophage RNA polymerase promoter sequences 
are underlined. Sequences of the mutagenesis primers are listed in Table 2.2.
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2.2.5. Southern Blotting
2.2.5.1 Hirt extraction of DNA from monolayers
Monolayer cells were washed in PBS, trypsinized and pelleted at 1 .OOOrprn 
for 5 min (Sorvall RT 6000B, refrigerated benchtop centrifuge). Cell pellets 
were resuspended in 3ml of Hirt extraction buffer (400mM NaCI, 10mM 
TrisCI pH 7.4, 10mM EDTA) and RNase A, Proteinase K, and SDS was 
added to final concentrations of 50pg/ml, 50ng/ml, and 0.2% (v/v), 
respectively. Solutions were incubated at 55°C for 3 h with vortexing every 
hour followed by the addition of 1.25M NaCI and overnight incubation at 4°C. 
The following day, cell debris was pelleted by centrifugation at 17,000rpm for 
1 h at 4°C (Sorvall SS34 rotor, lowspeed centrifuge). The supernatant was 
extracted twice with phenol:chloroform and once with chloroform. The DNA 
was ethanol precipitated from the supernatant, washed with 70% ethanol 
and resuspended in TE buffer. The concentration of DNA was determined by 
spectrophotometry at A260nm.
2.2.5.2 Total DNA extraction from rafts
Rafts were harvested into 15ml polypropylene tubes and washed with PBS. 
3ml of Hirt extraction buffer (400mM NaCI, 10mM TrisCI pH 7.4, 10mm 
EDTA) was added to each tube together with 50pg/ml RNase A and 0.2% 
(v/v) SDS and incubated overnight at 37°C on a rotating wheel. On the 
following day, 50^ig/ml of Proteinase K was added and the solution was 
incubated for 1h at 37°C on a rotating wheel. DNA was sheared by passing 
the solution through an 18-gauge needle 10 times. Contaminants were 
removed from the solution by extraction with phenol:chloroform and the DNA 
was precipitated with ethanol overnight at -20°C. On the following day, the 
DNA was pelleted by centrifugation at 10,OOOrprn for 30 min at 4°C (Sorvall
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SS34 rotor, lowspeed centrifuge), washed with 70% ethanol and 
resuspended in TE buffer. The concentration of DNA was determined by 
spectrophotometry at A260nm.
2.2.5.3 Electrophoresis and transfer
10pg samples of total genomic DNA and Hirt DNA were digested with Bam 
H1 to linearize HPV-16 or Eco Rl to linearize HPV-31 prior to electrophoresis 
on 0.8% agarose gels at 80V for 2 h. Following electrophoresis, the gel was 
photographed and the distance of the DNA markers was measured. The gel 
was then soaked in 100ml of 0.25M HCI with gentle shaking for 15 min until 
the bromophenol blue front turned yellow indicating that the acid treatment 
was complete. After a 5 min wash in dH20 the gel was soaked in 0.4N 
NaOH for 30 min. Meanwhile, a nylon membrane (Hybond-N, Amersham), 
similar in size to the gel, was washed briefly in dH2 0  and then soaked in 
0.4N NaOH for 20 min. Following soaking, a blot was assembled such that 
the DNA side of the gel was in direct contact with the nylon membrane which 
was overlaid with 10 sheets of 3MM paper, a glass plate and a weight; 0.4N 
NaOH was used as transfer buffer. Following an overnight transfer, the blot 
was dissembled, the membrane allowed to air-dry, and the DNA irreversibly 
bound to the membrane by UV cross-linking at 1.25x105 pJoules for 2 min in 
a Stratagene UV Stratalinker.
2.2.5.4 Random priming of dsDNA
A random primer method was used to synthesize radioactively labelled HPV- 
16 and HPV-31 DNA probes. Firstly, DNA templates were generated by 
releasing the HPV-16 genome from the plasmid pBS 114K by digestion with 
Bam H1; The HPV-31b viral genome was freed from the plasmid pBS 
HPV31 by digestion with Eco R1. DNA templates were resuspended in TE 
buffer at 1.25pg/ml and the labelling reactions were set up as follows:
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20ng template DNA 16pl
Rxn (A)* 5pl
BSA 1jal
a [32P] dATP (800Ci/mmol) 2.5pl
Klenow DNA polymerase 0.5pl
*Rxn (A):
Solutions A, B, and C were mixed in the following ratio: 
100:250:150
Solution A = 1ml solutioncp (1.25M TrisCI pH 8.0, 0.125M 
MgCb) + 18jul p-Mercaptoethanol + 5pl of 100mM dCTP, 
dGTP, dTTP
Solution B = 2M HEPES pH 6.6 
Solution C = pN6 (Promega)
Reactions were incubated overnight at room temperature. Unincorporated 
nucleotides were removed using Mini Quick Spin Columns (Roche). The 
sephadex matrix in the column was first resuspended, the lid removed and 
the bottom tip broken off. The column was centrifuged at 6,500rpm for 1 min 
(Eppendorf 5415C, microcentrifuge) and transferred to a clean eppendorf 
tube. The radiolabelled reaction was added drop-wise directly onto the 
matrix and the column was centrifuged at 6,500rpm for 4 min and the eluate 
retained. The activity of the probes was calculated by Cerenkov counting in a 
Beckman liquid scintillation counter.
2.2.5.5 Hybridisation and washing
The nylon membrane was washed briefly in 2 x SSC prior to prehybridisation 
in 10ml of Pall membrane hybridisation buffer (5 x Denhardts solution, 5 x 
SSC, 0.2% SDS (v/v), 0.5pg/ml salmon sperm DNA) for 2 h at 65°C. 
Radioactively labelled DNA probe (5 x 106cpm) was added to the
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hybridisation buffer and hybridisation continued overnight at 65°C. On the 
next day, the membrane was removed from the hybridisation buffer and 
washed with shaking at 65°C for 15 min in each of the following solutions: 
Wash A (2 x SSC, 0.1% SDS), Wash B (0.5 x SSC, 0.1% SDS), Wash C 
(0.1 x SSC, 0.1% SDS) and Wash D (0.1 x SSC, 1% SDS). The membrane 
was allowed to air dry and then exposed to Kodak X-OMAT S film.
2.2.6 SDS-PAGE
Proteins were separated by electrophoresis through polyacrylamide gels with 
SDS using Bio-Rad mini gel electrophoresis tanks (Laemmli, 1970). The gel 
apparatus and glass plates were assembled according to the manufacturer’s 
instructions. Gel mixes were prepared as follows:
12% resolving gel 15% resolving gel Stacking gel 
dH20  3.3ml 2.3ml 2.95ml
30% acrylamide/ 4ml 5ml 650pl
bisacrylamide mix
1.5M Tris pH 8.8 2.5ml 2.5ml
1M Tris pH 6.8 - - 2.5ml
10% SDS 100fxl 100*il 50pl
10% APS 100pl 100*il 50pl
Temed 12jnl 12jil 12pl
The resolving gel was mixed well and poured between the glass plate 
sandwich leaving a 1.5cm space at the top for the stacking gel. The 
resolving gel was overlaid with water to occlude air bubbles while the gel 
polymerised, following polymerisation the water was removed and the 
stacking gel was poured on top of the resolving gel and a comb inserted.
The gel was placed in the electrophoresis apparatus, the comb removed and 
the tank filled with SDS-PAGE running buffer. Samples in protein loading
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buffer were boiled for 5 min prior to loading onto the gel, 2pl Rainbow marker 
was also loaded onto each gel. Gels were run at 130v until the bromophenol 
blue front reached the bottom of the gel. Gels were removed from the glass 
plate sandwich and either stained with Comassie blue stain for 30 min and 
then destained in protein gel destain, or subjected to Silver Staining, or 
transferred electrophoretically to nitrocellulose membrane for Western blot 
analysis.
2.2.6.1 Silver Staining
The Bio-Rad Silver Stain kit was used to stain SDS-PAGE gels to detect 
proteins present at a low concentration. Gels were incubated, with shaking, 
in fixative (40% methanol, 10% acetic acid) for at least 30 min then 
transferred to oxidizer (contains f<2Cr207 and HNO3) for a further 5 min. The 
gel was then washed extensively in large volumes of water with regular 
changes of wash for 15 min. A 0.1% solution of silver reagent was prepared 
by dissolving 0.1g of silver nitrate in 100ml dh^O and the gel was incubated 
in this freshly prepared solution for 20 min. The gel was then washed briefly 
in water for 30sec and transferred to the developer solution (contains 
Na2C03  and paraformaldehyde) for 30 sec then the solution was removed 
and fresh developer added and incubated for 5 min. The developer was 
changed every 5 min until the desired staining intensity was obtained. The 
staining reaction was stopped by incubating the gel in stop solution (5% 
acetic acid) for 15 min.
2.2.6.2 Western Blotting
For Western blot analysis, proteins fractionated on SDS-PAGE gels were 
transferred to nitrocellulose or polyvinylidene fluoride (PVDF) membranes 
(Hybond-C or Hybond-P, Amersham) using a Bio-Rad transblot cell (Towbin 
et al., 1979). A blotting stack was assembled in which the gel was in direct
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contact with the membrane while sandwiched between two sheets of 3MM 
paper, which in turn were sandwiched between sponges (provided by the 
manufacturer). Electroblotting was carried out for 1h at room temperature at 
250mA or overnight at 4°C at 50mA. Membranes (Hybond-C or Hybond-P, 
Amersham) were blocked in PBS with 5% dried milk overnight at 4°C or for 
1h at room temperature with gentle shaking. Following 3 washes of the 
membrane in PBS with 0.05% Tween (PBS-T), the membrane was 
incubated in primary antibody (diluted in PBS-T with 1% dried milk) for 2 h at 
room temperature with shaking. Membranes were washed 3 further times in 
PBS-T then incubated with secondary antibody for 1 h at room temperature 
with shaking. Horseradish peroxidase conjugated anti-mouse IgG or protein 
A was diluted 1:1000 in PBS-T to detect monoclonal and polyclonal primary 
antibodies, respectively. Membranes were washed extensively in PBS-T 
then subjected to enhanced chemiluminescence (ECL) using the Amersham 
ECL system. Reagents 1 and 2 were mixed in equal proportion and the total 
volume poured directly onto the membrane and incubated for 1 min. Excess 
ECL reagent was drained from the membrane, which was then wrapped in 
clingfilm and exposed to Kodak X-OMAT S film for 5 sec to 10 min.
2.2.6.3 Stripping membranes for reprobina
Bound primary and secondary antibodies were removed from membranes by 
incubating the membrane in stripping buffer (0.288mM p-Mercaptoethanol, 
2% v/v SDS, 62.5mM Tris-CI pH 6.7) at 50°C for 30 min with shaking 
followed by 3 x 10 min washes in PBS-T. Membranes could then be blocked 
and reprobed as previously described.
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2.2.7 Immunohistochemistry
Immunohistochemistry was carried out using the Vectastain® ABC Kit 
(Vector Laboratories). 4pm cross sections of paraffin-embedded rafts were 
dewaxed in xylene for 5 min and rehydrated in a graded series of alcohol 
washes (10 dips each in 100%, 100%, 95%, 70%, and 50% ethanol). Slides 
were washed in running tap water for 5 min followed by a 20 min incubation 
in 0.3% hydrogen peroxidase to quench endogenous peroxidase activity. 
Slides were then washed for 5 min in PBS-B (10mM sodium phosphate pH 
7.5, 0.9% saline) and incubated for 20 min in normal blocking serum. Excess 
serum was removed from the sections and the slides were incubated in the 
appropriate dilution of primary antibody for 2 h. Following a 5 min wash in 
PBS the slides were incubated with diluted biotinylated secondary antibody 
for 30 min, then washed again for 5 min in PBS-B buffer. Pre-mixed ABC 
reagent (avidin and biotinylated horseradish peroxidase macromolecular 
complex) was incubated on the sections for 30 min and this was followed by 
a 5 min wash in PBS-B. Diaminobenzidine tetrahydrochloride (DAB) 
chromogen was used to localize peroxidase in the tissue sections by 
incubating the slides in a solution of DAB (with or without nickel chloride) for 
10 min. DAB was removed and the slides were washed thoroughly in 
running tap water prior to counterstaining.
2.2.7.1 Counterstaining
Sections were counterstained in hematoxylin (Gill’s Formula, Vector 
Laboratories) for 5 min, rinsed in tap water, and dipped 10 times in acid rinse 
solution (2% glacial acetic acid) to clear background staining. This was 
followed by a 1 min incubation in Scott’s tap water substitute (0.04M 
NaHC0 3 , 0.16M MgS04) to enhance the development of the hematoxylin 
colour. The slides were then washed in tap water and dehydrated in a 
graded series of alcohol washes (10 dips each in 50%, 70%, 95%, 100%
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and 100% ethanol) and incubated in xylene prior to mounting with Pertex 
(Vector Laboratories).
2.2.8 RNA Binding Assay
2.2.8.1 Large-Scale In Vitro Transcription of RNA
Reactions were assembled at room temperature in the following order:
10x transcription buffer 20pl
100mM ATP, CTP, GTP, UTP 20pl
100uM DTT 10pl
RNasin (40U) 1pl
DNA template (=500pmol RNA *) XU1
T3 RNA polymerase (200U) 4|al
Diethyl pyrocarbonate (DEPC) dH20 to 200pl
* 309 x length of template (nt) = molecular weight of template 
Concentration of template (pmol/ pi) = conc. of template (pg/ml)
/molecular weight of template
Reactions were incubated at 37°C for 2 h followed by acid phenol:chloroform 
extraction and ethanol precipitation.
2.2.8.2 Linking RNA to Agarose Beads
In vitro transcribed RNA was covalently linked to adipic acid dihydrazide 
agarose beads by first incubating 500pmol of substrate RNA with 100mM 
sodium acetate (pH 5.0) and 5mM sodium periodate in the dark at room 
temperature for 1 h. The oxidised RNA was ethanol precipitated and 
resuspended in 500pl of 0.1 M sodium acetate pH5.0. A 400pl aliquot of
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adipic acid dihydrazide agarose bead 50% slurry (Sigma) was washed four 
times in 10ml of 0.1 M sodium acetate pH5.0 and pelleted after each wash at 
300rpm for 3 min (Heraeus Multifuge 3, refrigerated benchtop centrifuge). 
The washed beads were resuspended in 300jliI of 0.1 M sodium acetate 
pH5.0 and the periodate-treated RNA was added to the slurry and incubated 
for 12 h at 4°C on a rotating wheel. The RNA bound beads were pelleted at 
300 rpm for 3 min as before and then washed three times in 1 ml of 2M NaCI 
and a further 3 times in 1ml of buffer D (20mM HEPES-KOH pH7.6, 5% 
glycerol, 0.1M KCI, 0.2mM EDTA, 0.5mM DTT) with centrifugation after each 
wash at 300rpm for 3 min. A 400pl aliquot of Ag Poly(U) Type 6 linked beads 
(Pharmacia Biotech) were washed in 2M NaCI and buffer D as described 
above.
2.2.8.3 RNA Binding Reaction
The beads with the bound RNA and the Poly(U) beads were incubated 
separately in 650pl binding reactions containing 250pl of HeLa nuclear 
extract for 20 min at 30°C. The beads were pelleted by centrifugation at 
1,OOOrprn for 3 min (Hettich EBA 12R, refrigerated microcentrifuge) and 
unbound proteins were removed by washing the beads four times in 1ml of 
buffer D with 4mM MgC^ and spinning at 1,OOOrprn for 3 min after each 
wash. Proteins bound to the RNA were eluted into 60pl of protein loading 
buffer by heating the beads to 90°C for 5 min. Eluted proteins were then 
fractionated by SDS-PAGE.
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2.2.9 UV Cross-Linking
2.2.9.1 In Vitro Transcription of Radiolabelled RNA
An in vitro transcription kit (Stratagene) was used to generate radiolabelled 
RNA transcripts. Reactions were assembled in the following order at room 
temperature:
Reactions were incubated at 37°C for 2 h. Unincoporated NTPs were 
removed from the transcription reaction by passing the reaction through an 
RNA mini quick spin column (Roche Diagnostics). The specific activity of the 
radiolabelled RNA was measured by Cerenkov counting in a Beckman liquid 
scintillation counter.
5x transcription buffer 
2.5mM ATP, CTP, GTP 
100uM UTP 
100mM DTT 
RNasin
linearized DNA template (150ng) 
T7 RNA polymerase 
a [32P]-UTP (800 mCi/mmol)
2pl
2pl
1.2pl
1pl
0.5pl
1pl
0.5pl
2.5pl
Final volume 10.2pl
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2.2.9.2 Cross-linking binding reaction
Radiolabelled RNA probes were incubated with HeLa nuclear extracts in 96 
well dishes at room temperature in the following order:
Diethyl pyrocarbonate (DEPC) treated dh^O to 20pl
Reactions were incubated at room temperature for 20 min. UV cross-linking 
was performed using a Stratagene UV Stratalinker at a setting of 2.5x105 
pJoules. Unbound RNA was digested by the addition of 1 pi RNase A 
(10pg/ml) and incubation at 37°C for 15 min. Proteins with bound RNA were 
eluted into protein loading buffer and separated by SDS-PAGE. Gels were 
exposed overnight using Kodak X-OMAT S film and for some experiments 
the separated proteins were transferred to a nitrocellulose membrane and 
Western blotted as previously described.
2.2.10 RNase Protection Assay (RPA)
2.2.10.1 Extraction of sample RNA
Total RNA was extracted from monolayer cells and raft tissue using TRIzol™ 
reagent (Gibco BRL) based on a modification of a previously published 
protocol (Ozbun et al., 1997). Raft tissue was homogenized in 2ml of TRIzol 
using a Dounce homogenizer. For monolayer cells 2ml of TRIzol was added 
to a 100mm dish and the lysate passed several times through a 5ml pipette.
2x UV X-linking binding buffer 
(60mM KCI, 20mM HEPES pH7.6, 
1mM MgCb, 10% glycerol)
Baker’s yeast tRNA (10mg/ml)
32P labelled RNA probe (5x10ecpm) 
Hela nuclear extract
10pl
2pl
xpi
2pl
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Following extraction in TRIzol, the homogenized samples were incubated at 
room temperature for 5 min and 0.2 volumes of chloroform were added. The 
samples were mixed vigorously for 15 sec by shaking and incubated at room 
temperature for 3 min. The phases were separated by centrifugation at 
3,500rpm for 15 min at 4°C (Sorvall RT 6000B, refrigerated benchtop 
centrifuge) and the upper aqueous phase was transferred to a clean tube. 
The RNA was precipitated by the addition of 0.833 volumes of isopropanol 
followed by a 10 min incubation at room temperature. The samples were 
centrifuged at 9,500rpm (Sorvall SS34 Rotor, lowspeed centrifuge) for 10 
min at 4°C to pellet the RNA. The pellet was then washed with 1 ml of 70% 
ethanol, mixed by vortexing and centrifuged again at 8000rpm at 4°C for 15 
min and finally resuspended in dhhO. The quality of the RNA was checked 
by agarose gel electrophoresis to verify the presence of undegraded 28s 
and 18s ribosomal RNA.
2.2.10.2 Preparation of Riboprobe Template
Digesting 10pg of the plasmid pHPV16-RL1 with Sspl generated a antisense 
HPV-16 L1 riboprobe template; map in appendix 1. Digesting the plasmid 
pGOZ31-L1 with Hind III generated a antisense HPV-31 L1 template, map in 
appendix 1. The linearized plasmids were incubated with 150pg/ml of 
Proteinase K for 30 min at 50°C followed by phenolichloroform extraction 
and ethanol preciptation.
2.2.10.3 In vitro transcription of a Radiolabelled Riboprobe
An in vitro transcription kit (Stratagene) and Ambion RPA II kit were used to 
generate radiolabelled RNA riboprobes by mixing the following components, 
in order, at room temperature:
Materials and Methods
10x Transcription Buffer 1pl
200mM DTT 0.5jul
10mM ATP, CTP, GTP 1.5pl
RNasin (12.5U) 0.5pl
DNA Riboprobe Template (500ng) 1 JLil
a [32P] UTP 2.5pl
T7 RNA polymerase (10U) 0.5|_il
Diethyl pyrocarbonate (DEPC) dh^O to 20 pi
Reactions were incubated at 37°C for 60 min and for a further 15 min 
following the addition of 1 jlxI of RNase-free DNase I (2U/pl). The reaction was 
stopped by adding an equal volume of gel loading buffer (80% v/v 
formamide, 2mM EDTA, 0.1% bromophenol blue, 0.1% xylene cyanol) and 
heating the sample at 90°C for 3 min. The full-length riboprobe was excised 
from a denaturing 5% acrylamide/8M urea gel (see below) following 
electrophoresis at 200v for 40 min and eluted overnight at room temperature 
in 350pl of elution buffer (0.5M NhUOAc, 1mM EDTA, 0.1% SDS). The 
activity of the riboprobe was determined by Cerenkov counting in a liquid 
scintillation counter (Beckman LS 5000 CE).
5% acrylamide/8M urea gels (60ml) were prepared as follows:
Urea 28.8g
10xTBE 6ml
40% acrylamide 7.6ml
dH20  11.6ml
10% APS 480pl
TEMED 50pl
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The solution was mixed thoroughly and incubated at 37°C to allow the urea 
to dissolve prior to the addition of APS and TEMED.
2.2.10.4 Hybridization of the riboprobe and sample RNA
For each sample, 8x104cpm of 32P labelled probe was mixed with 10pig of 
RNA. Control reactions consisted of the riboprobe mixed with 10pig of torulla 
yeast RNA (Ambion). Each mixture was ethanol precipitated and the pellet 
resuspended in 20ptl of Hybridization buffer (80% v/v formamide, 0.1M 
CeHsNasO/ pH6.4, 0.3M NaOAc pH6.4, 1mM EDTA) and incubated for 16 h 
at 45C.
2.2.10.5 RNase digestion of hybridised probe and sample RNA
200|il of RNase solution (1:100 dilution of RNase mix (250U/ml RNase A; 
10,000U/ml RNase T1) in RNase digestion buffer (proprietary) was added to 
each sample including one yeast RNA control reaction, designated Y1, the 
other yeast RNA control reaction, designated Y2, received only RNase 
digestion buffer. Samples were incubated at 37°C for 30 min and the reaction 
stopped by adding 300pil Solution Dx (RNase inactivation/precipitation 
solution; proprietary) to each tube. Protected fragments were precipitated by 
freezing at -20°C for 15 min and pelleted by centrifugation at maximum 
speed for 15 min at 4°C (Hettich EBA 12R, refrigerated microcentrifuge). 
Pellets were resuspended in 8pil of gel loading buffer, heated at 90°C for 3 
min, and electrophoresied through a denaturing 5% polyacrylamide / 8M 
urea at 200v for 2 h. Gels were exposed overnight to Kodak X-OMAT S film 
to detect the protected fragments.
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CHAPTER 3 -  Characterisation of HPV-16 positive epithelial cell lines
All HPVs have a strict tissue tropism and are absolutely dependent on 
terminally differentiating keratinocytes for viral late protein expression, such 
that, only basal keratinocytes capable of undergoing terminal differentiation 
can support the complete viral life cycle (Meyers et a/., 1994a). Early 
attempts at establishing HPV-positive lines using clinical material 
consistently resulted in the production of cell lines with integrated viral DNA, 
which could not complete the viral life cycle (Friedl et a/., 1970, Pattillo et al., 
1976, Durst et al., 1986, Pirisi et al., 1987). Therefore, the establishment of 
the W12 cell line was a very important development in the study of HPV-16 
gene expression. This cell line was derived from a HPV-16 positive, low- 
grade cervical lesion and is an immortalised but not fully transformed line 
(Stanley et al., 1989). Approximately 100 copies of the HPV-16 genome are 
stably maintained in an episomal form in these cells, although, with 
continued growth in vitro, the cells have developed an aneupolid karyotype 
(Stanley et al., 1989). However, while the W12 cells have acquired an 
extended life span they remain responsive to cholera toxin and epidermal 
growth factor (EGF) similar to normal cervical keratinocytes cultured in vitro, 
indicating that the W12 cell line is operationally equivalent to a basal 
epithelial cell latently infected with HPV-16 (Sterling et al., 1990). In 
monolayer culture, W12 cells exhibit typical basal keratinocyte morphology, 
undergo limited stratification and express basal cell specific keratins but not 
markers of terminal differentiation (Greenfield and Stanley, unpublished 
data; Chapter 3). However, when these cells are transplanted into the flank 
of the athymic mouse, an epithelial lesion develops with many histological 
features in common with the lesion from which the line was derived. 
Numerous cells in the granular layer are positive for the late viral proteins L1 
and E1AE4, and HPV-16 viral particles are observed in the degenerating 
nuclei in the uppermost layers of the graft (Sterling etal., 1990, Sterling et 
al., 1993). This implies that, under appropriate conditions, this cell line can
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undergo a productive HPV-16 life cycle and therefore represents an 
invaluable tool in the study of HPV-16 late gene expression in response to 
epithelial differentiation.
Following the derivation of the W12 line, another group found that, in their 
hands, the HPV-16 genome was unstable in this line and rapidly became 
integrated with continued in vitro growth (Jeon et at., 1995a). To overcome 
this, clonal populations of the W12 line were derived which harboured 
multiple copies of extrachromosomal viral DNA which appeared less inclined 
to integrate; this clonal derivative was called the 20863 line (Jeon et ai., 
1995a). The 20863 line has also been shown to grow well both in monolayer 
culture and when applied to the organotypic raft system. The L1 capsid 
protein is readily detectable in the granular layers of these rafts, although the 
pattern of epidermal differentiation appears slightly perturbed (Flores et al., 
1999). The 20863 line was further sub-cloned by another group to yield a 
line called 2W12 which, like the parental line, maintains the HPV-16 genome 
episomally, however, little is known about this line and it will discussed only 
briefly in this chapter (Ozbun and Meyers, unpublished data).
The aim of the work presented here was to study the regulation of HPV-16 
late gene expression during epithelial cell differentiation and therefore, we 
wished to use the W12 and 20863 cell lines as a model system of a 
productive HPV-16 infection since these cells are considered to be 
representative of the situation in a pre-invasive lesion and seem to be 
capable of completing the viral life cycle when transplanted onto nude mice 
or applied to the organotypic raft culture system. However, neither of these 
lines has been particularly well characterised and so we set about 
characterising the growth of these lines both in monolayer culture and on 
organotypic rafts whilst paying particular attention to the pattern of late gene 
expression.
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3.1. The HPV-16 genome is episomal
Total genomic and/or Hirt DNA extracts were routinely prepared from 
monolayer and organotypic raft cultures of W12 and 20863 cells and 
analysed by Southern blotting to verify the state of the viral DNA in the cell 
lines. Figure 3.1 shows a typical blot of episomal viral DNA probed with a 
full-length HPV-16 DNA probe. Bands representing open circular and 
supercoiled viral DNA, and full-length linearized HPV-16 DNA, are indicated 
in Fig. 3.1A and B, lanes 2 and 4, and lanes 3 and 5 respectively.
This experiment was repeated regularly throughout the course of this work to 
ensure the HPV-16 genome remained episomal in the cell lines used (data 
not shown). Contrary to the report by Jeon et al., (1995a) we found that the 
HPV-16 genome was stably maintained as episomes in the W12 line, at 
least to passage number 19.
3.2.1. Protein expression in W12 monolayer cultures
An earlier key study characterising the growth of the biopsy-derived HPV-31 
cell line CIN 612, described the use of phorbol esters to facilitate the 
completion of the HPV-31 life cycle and production of infectious virions in 
organotypic raft culture (Meyers et al., 1992). Phorbol esters, such as PMA 
and C8:0, are thought to bring about a more complete differentiation 
programme through the activation of the PKC pathway. Although the exact 
mechanism of action remains unclear, enhanced expression of the 
differentiation markers K10 and filaggrin has been reported (Meyers et al., 
1992). Phorbol ester treatment of W12 monolayer cultures has been shown 
to relieve the inhibitory effects of a negative regulatory element located 
within the 3’UTR of HPV-16 (Dietrich-Goetz et al., 1997). Also, PMA- 
treatment appears to affect the level of expression and distribution of a 
number of RNA processing factors known to interact with this element 
(Dietrich-Goetz et al., 1997, Koffa et al., 2000). Initially, I wished to establish
93
Chapter 3 - Results
the effects, if any, of prolonged growth in monolayer culture on viral late 
protein expression in the absence of phorbol esters. This had not previously 
been addressed, although an earlier studying using C8:0-treated monolayer 
cultures of CIN 612 cells reported no detectable HPV-31 late protein 
expression (Hummel et al., 1995). Protein extracts prepared on consecutive 
days from W12 and 20863 cells grown for 5 to 10 days were analysed by 
Coomassie blue staining, on the basis of total protein in pig (as calculated by 
Bradford assay) (Fig. 3.2A), or as equivalent numbers of cells (Fig. 3.2B). 
Comparing figures 3.2A and B, it is clear that analysing protein extracts in 
terms of total protein allows a more accurate comparison than that resulting 
from analysis based on similar cell counts. While the extracts analysed in 
Fig. 3.2B have been prepared from similar numbers of cells, the amount of 
protein appears to decrease steadily from day 5 to day 10; a possible 
explanation for this might be that the level of expression of non-essential 
cellular proteins is downregulated with differentiation. This experiment was 
repeated at least three times using different protein extracts and similar 
results were obtained each time (data not shown).
3.2.2. L1 expression in monolayer cultures
Total protein extracts were prepared from 20863 and W12 cells grown for 5 
to 10 days in monolayer culture and, based on the results shown in Fig. 3.2, 
we chose to analyse 10pig of each extract for HPV-16 L1 protein expression. 
Surprisingly, Western blotting with the CamVir 1 antibody (anti-HPV-16 L1) 
identified a specific band of approximately 59kDa in each extract (Fig. 3.3A, 
lanes 1 to 6). However, the intensity of the band appeared to increase from 
day 5 to day 7 and this intensity was maintained until day 10. Although the 
quality of this blot could be better, if the level of L1 expression is compared 
between days 5 and 10 only, lanes 1 and 6, it is clear that while there is 
some L1 protein in day 5 monolayer cultures of 20863 cells, the level of 
expression of this viral protein increases substantially in cells cultured for 10
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days. One shortcoming of this experiment, however, is that the cells used 
had previously been grown to sub-confluence, for approximately 5 to 7 days, 
prior to use in this experiment. It is not yet known if the differentiation 
programme in W12 or 20863 cells is reset when these lines are serially 
passaged. If this is not the case, then the extracts used in Fig. 3.3A are 
further along the differentiation pathway than if the cells were freshly 
recovered from frozen specifically for the purposes of this experiment. This 
might help explain why L1 expression is detected even after only 5 days in 
monolayer culture (lane 1) and the level of late protein expression does not 
appear to increase from day 7 to day 10 (lanes 3 to 6). To test this, W12 
cells were recovered from liquid nitrogen and the time course begun 
immediately. Protein extracts were prepared following 5 days and 10 days 
growth and analysed again for L1 expression; J2 3T3 extract was included 
as a negative control. It appears that under these experimental conditions 
only W12 cells cultured for 10 days express detectable levels of L1 protein 
(Fig. 3.3B, lane 2). This experiment was repeated using freshly prepared 
extracts on at least three occasions and the results were very similar (data 
not shown). This observation suggests that W12 or 20863 cells harvested 
after only 5 days growth in monolayer culture are predominantly 
undifferentiated whereas growing these cells for 10 days, even in the 
absence of phorbol esters, results in the initiation of differentiation, as 
indicated by an increase in the level of expression of the capsid protein, L1.
The protein profile of W12 day 5 and day 10 extracts was compared 
following Coomassie blue staining (Fig. 3.4A) and appears to be very similar, 
at least at this level of sensitivity. One might argue that the apparent 
expression of L1 protein in monolayer culture is an artefact of the HPV-16 
cell lines, or the culturing methods used in our laboratory. I therefore 
attempted to ascertain if these epithelial cells were undergoing 
differentiation, since the tight linkage between viral late protein expression 
and keratinocyte differentiation has been well documented. The level of
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expression of involucrin, a known marker of differentiation that is generally 
expressed in the spinous and granular layers of the epithelium, was 
compared between day 5 and day 10 extracts by Western blotting with SY5, 
an anti-involucrin antibody. Involucrin synthesis is a specific marker of 
squamous differentiation in keratinocytes, since no other cell types produce 
this protein, at least in any significant quantity (Fuchs et al., 1994). The level 
of this protein is dramatically increased in day 10 extracts compared to day 
5, supporting the hypothesis that while day 5 cells are relatively 
undifferentiated, day 10 cells are indeed differentiating (Fig. 3.4B). Western 
blotting the W12 day 5 and day 10 extracts with the 6CS antibody (anti- 
GAPDH) indicates that similar amounts of protein were loaded in each lane 
(Fig. 3.4C lanes 1 and 2).
Taken together these results suggest that W12 and 20863 cells begin to 
differentiate following prolonged growth in monolayer culture even in the 
absence of phorbol ester treatment. This observation contrasts with several 
previous reports and also raises the possibility that previous studies 
involving a comparison of “undifferentiated” and differentiated cell 
populations following phorbol ester treatment were perhaps comparing 
differentiating samples and slightly more differentiated samples instead 
(Hummel et al., 1995, Ozbun et al., 1997, Koffa etal., 2000).
3.2.3. Protein expression in monolayer cultures of HaCaT cells
In the previous experiment the J2 3T3 line was used as a negative control, 
however, this murine fibroblast line cannot be induced to differentiate and is 
therefore not the most suitable control for this type of experiment. Attention 
therefore was directed to the HaCaT cell line for use as a potential control for 
the differentiation of epithelial cells, since although this line is immortalised, it 
has retained the ability to differentiate (Boukamp et al., 1988, Schoop et al., 
1999). HaCaT cells were grown in monolayer culture in a similar manner to 
that used for W12 and 20863 cells and protein extracts were prepared from
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cells harvested following 5 days and 10 days in culture. Coomassie blue 
staining was used to compare the protein profile of these extracts, however, 
there appeared to be no significant differences between these extracts (Fig. 
3.5A). Immunoblotting day 5 and day 10 HaCaT extracts with an anti- 
involucrin antibody, SY5, revealed that, similar to the situation in W12 cells, 
the level of expression of this differentiation marker is significantly increased 
between days 5 and 10 (Fig. 3.5B). Western blotting with 6CS, the anti- 
GAPDH antibody, confirmed that similar amounts of protein had been loaded 
for each sample (Fig. 3.5C). This result indicates that epithelial cells, which 
lack HPV-16, can also be induced to differentiate through prolonged growth 
in monolayer culture. Differentiating day 10 HaCaT cells are therefore, I 
believe, a more suitable negative control in experiments designed to analyse 
the differential expression of viral late proteins.
3.2.4. Viral late protein expression in monolayer cultures of epithelial 
cells
Protein extracts prepared from day 5 and day 10 W12 cells and day 10 
HaCaT cells were Western blotted with CamVir 1, an antibody directed 
against HPV-16 L1, to ensure that the previous result (Fig. 3.3B) could be 
repeated in the presence of a more suitable control. From the blot shown in 
Fig. 3.6A, it appears that, as expected, HaCaT cells do not express HPV-16 
L1. However, as shown previously, day 5 W12 cells express a small amount 
of L1 protein, while the level of expression of this late viral protein is 
increased in day 10 W12 cells (Fig. 3.6A). This experiment was repeated at 
least three times with fresh extracts and similar results were recorded each 
time. In order to ensure that similar amounts of protein had been analysed 
for each sample, this blot was stripped and reprobed with an antibody 
directed against GAPDH, 6CS (Fig. 3.6B) and it appears that each sample 
on this blot contains a similar amount of protein.
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Extracts similar to those used in the above experiments were immunoblotted 
using an antibody directed against HPV-16 E1AE4, TVG 402.1 found that 
when 10jig of each extract were analysed, only a very faint band could be 
detected in W12 day 10 samples following a long exposure (data not 
shown). The amount of extract was then increased to 20pg in order to 
improve the detection of E1AE4. As shown in Fig. 3.6C lane 3, a band of 
approximately 10kDa could be readily detected in W12 day 10 extracts, but 
day 5 W12 extracts appeared to express only a low level of this viral protein 
(Fig. 3.16C lane 2). Day 10 HaCaT cells did not express HPV-16 E1AE4 (Fig. 
3.6B lane 3). When this blot was stripped and reprobed with the 6CS 
antibody each lane appeared to contain a comparable amount of protein as 
indicated by the level of expression of GAPDH (Fig. 3.6D). The apparent 
absence of expression of the late viral proteins, L1 and E1AE4, in day 5 W12 
extracts further supports the hypothesis that these cells are relatively 
undifferentiated, while day 10 W12 cells appear to be differentiating, as 
indicated by the enhanced expression of involucrin and the presence of late 
viral proteins.
3.2.5. Protein expression in untreated and phorbol ester-treated 
monolayer cultures
Having established that W12 and 20863 cells begin to differentiate if grown 
in monolayer cultures for extended periods of time, I next wanted to compare 
extracts prepared from 20863 and W12 cells grown for 5 and 10 days in the 
presence and absence of the phorbol ester, C8:0. A Coomassie stain of 
these extracts did not suggest that there were any significant differences 
between the protein profiles of C8:0 treated and untreated cells (Fig. 3.7A). 
The extracts were then analysed by Western blotting with the SY5 antibody, 
directed against involucrin (Fig. 3.7B). As before, the level of expression of 
this cellular protein increased between day 5 and day 10 cells, however,
C8:0 treatment did not appear to have any significant effect on the
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expression of involucin (Fig. 3.7B, lanes 3 and 4). When the same samples 
were immunoblotted with the CamVir 1, ab anti-HPV-16 L1 antibody, a small, 
but similar, amount of L1 protein was detected in treated and untreated day 
5 extracts (Fig. 3.7C, lanes 1 and 2). However, C8-treated day 10 samples 
appeared to express slightly more L1 protein than the corresponding 
untreated sample (Fig. 3.7C, lanes 3 and 4). These observations tend to 
suggest that while phorbol-ester treatment of W12 and 20863 monolayer 
cultures does not affect the level of expression of the differentiation marker, 
involucrin, C8:0 treatment may have a positive effect on the expression of 
the late viral protein, L1.
3.3.1. Organotypic raft cultures of HPV-16 epithelial cell lines
The organotypic raft culture system is a very useful in vitro system for the 
propagation of HPV since it is capable of reproducing the keratinocyte 
differentiation programme seen in vivo, and allows viral late protein 
expression (Meyers et al., 1994a, b). Keratinocyte lines transformed by HPV- 
16 or HPV-18 appear to undergo abnormal differentiation, comparable to the 
in vivo situation, when cultivated on rafts (McCance et al., 1988, Rader et al., 
1990, Merrick et al., 1992). However, when cell lines containing episomal 
viral genomes are applied to the raft culture system they stratify, differentiate 
and express viral late proteins in the upper layers of the epithelium (Rader et 
al., 1990, Bedell e ta i, 1991, Meyers etal., 1992, Frattini etal., 1997,
Meyers et al., 1997). In addition, treatment of raft cultures of the HPV-31 cell 
line, CIN 612, with an activator of the protein kinase C (PKC) pathway was 
found to result in production of mature infectious virions (Meyers et al.,
1992). However, more recent reports using HPV-11, -18 and -31 cell lines, 
established from cloned viral DNA, present evidence of the complete viral life 
cycle in the absence of phorbol ester treatment (Frattini et al., 1996, 1997, 
Meyers et al., 1997, Thomas et al., 2001). It has previously been reported 
that phorbol ester-treatment of W12 raft cultures leads to a strong induction
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of the capsid proteins, L1 and L2 (Higgins and Stanley, unpublished data). 
However, although mature HPV-16 virions are produced from these raft 
tissues they do not appear to be infectious (Meyers and Ozbun, personal 
communication). The reason for this is not yet understood, although it may 
be an artefact of the W12 line. Nevertheless, organotypic raft cultures of the 
W12 and 20863 lines are invaluable tools in studying the differential control 
of HPV-16 late protein expression and so we have used this system to 
cultivate the W12, 20863 and 2W12 lines as well as the HPV-31 cell line,
CIN 612 9E, in our laboratory. Rafts were harvested following 12 days at the 
air-liquid interface and histochemically stained using hematoxylin and eosin 
(H&E). Figure 3.8 shows typical H&E stains of C8-treated W12 and 2W12 
raft tissues; variations in colour are due to differences in the depth of 
counterstaining. Although I have not shown the H&E stains of the 20863 and 
CIN 612 raft sections, each line tested appeared to form stratified layers and 
closely resembled tissue from a CIN I lesion. Although the thickness of the 
stratified epithelium differed between the lines, in general, the lower third of 
the epithelium contained basal-like cells, whereas differentiation occurred in 
the upper epithelium. Overall, I generally observed that the basal layers 
appeared as an organised arrangement of cuboidal cells with large nuclei 
and little cytoplasm. Moving upwards, the cell shape changes gradually to 
flattened, enucleated squames in the uppermost epithelial layers as a result 
of differentiation and stratification (Fig. 3.8A and B). Unlike normal cervical 
tissue, these HPV-positive lines form cornified layers as indicated in Fig. 3.8. 
In addition, some abnormal mitotic figures were observed in cells beyond the 
basal layer (Fig. 3.8 A and B). There appeared to be little morphological 
difference between untreated and C8-treated organotypic rafts cultivated 
using each of the cell lines tested (data not shown). This is unsurprising 
because although phorbol-ester treatment is believed to result in a more 
complete differentiation programme it is unlikely that these subtle differences 
would be visible using this staining technique (Meyers et al., 1992). The 
cornified layer of C8-treated 2W12 organotypic rafts appears to be thinner
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than that of the C8-reated W12 samples and also seems ruptured in places 
perhaps suggesting that virus-containing cells have been shed from this 
superficial layer. However, this might also be an artefact of the procedure 
used to prepare the section for staining. However, as with the W12 line, 
while this 2W12 line produces mature virions on organotypic rafts they are 
not believed to be infectious (Ozbun and Meyers, personal communication.). 
The 2W12 line was sub-cloned from the 20863 line which in turn was derived 
from the parental W12 line. It is possible therefore that the selective 
pressures used to isolate this line have led to the outgrowth of cells 
harbouring episomal HPV and a high proportion of integrated viral DNA and 
thus bare more resemblance to a CIN II lesion. Due to time constraints this 
line was not characterised any further.
3.3.2. Protein expression in HPV-16 raft tissue
Protein extracts were prepared from C8-treated or untreated W12 or 20863 
organotypic raft cultures and compared following Coomassie blue staining 
(Fig. 3.9A). Not surprisingly the protein profile of both samples was very 
similar, although the band at approximately 60kDa appears stronger in the 
C8:0-treated sample compared to the untreated sample. The overall protein 
profile from the raft material was comparable to the profile generated from 
monolayer cultures, although the intensity of some bands, possibly keratins, 
is stronger. The raft extracts were analysed for terminal differentiation by 
Western blotting with SY5, the anti-involucrin antibody and both samples 
contained a large amount of involucrin protein and it was difficult to establish 
if there was any difference between untreated and C8-treated samples (Fig. 
3.9B lanes 1 and 2). This result is not unexpected given the fact that the 
organotypic raft system is capable of accurately recreating the epithelial 
differentiation programme. The raft extracts were then immunoblotted with 
the anti-GAPDH antibody 6CS (Fig. 3.9C), which indicated that each sample 
contained a similar amount of protein.
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Immunohistochemical staining of harvested raft tissue was performed using 
antibodies directed against the epidermal differentiation markers keratin type 
10 (K10) and involucrin. In normal epithelia, K10 is expressed in the 
suprabasal layers beginning in the spinous layer, while involucrin is found 
only in the upper spinous and granular layers of human epidermis (Fuchs et 
al., 1994). This experiment was repeated several times for each line and a 
representative result is shown of the C8-treated W12 line (Fig. 3.10A). Cells 
positive for K10 expression are stained brown and while some basal layer 
cells appear stained, the majority of positive cells are in the suprabasal 
layers. A similar result was observed for each of the HPV-lines tested and 
also the HaCaT cell line, which was included as a control for epidermal 
differentiation (data not shown). In agreement with previous studies the 
HaCaT rafts that I generated did not appear to form a cornified layer and this 
would tend to suggest that HaCaT rafts are unable to complete the full 
terminal differentiation programme (Boelsma et al., 1999, Schoop et al., 
1999). In Fig. 3.1 OB, C8-treated W12 cells expressing involucrin are stained 
brown and it is clear that these cells are found predominantly in the upper 
spinous and granular layers, in agreement with the pattern of involucrin 
expression in normal differentiated epidermis. Each of the HPV-positive lines 
and the HaCaT cell line yielded similar results (data not shown).
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3.3.3. Viral late protein expression in organotypic raft cultures
Since it appeared that the epithelial differentiation programme had been 
recreated using HPV-16 cell lines on the raft system, I next attempted to 
establish if the viral late proteins, L1 and E1AE4, were expressed and 
determine the effects, if any, of C8:0 treatment on the level of expression of 
these proteins. Protein extracts prepared from untreated and C8-treated 
W12 raft tissue were Western blotted with CamVir 1, an anti-HPV-16 L1 
antibody, and it appeared that C8-treated rafts expressed slightly more L1 
protein than untreated rafts (Fig. 3.11 A, lanes 1 and 2). This observation is in 
agreement with the result generated using untreated and C8:0-treated W12 
day 10 monolayer samples (Fig. 3.7C, lanes 3 and 4). This blot was stripped 
and reprobed with the anti-GAPDH antibody, 6CS, and the level of GAPDH 
protein in both samples appears very similar (Fig. 3.11A, lanes 3 and 4).
The raft samples were also Western blotted with the TVG 402 antibody, 
directed against HPV-16 E1AE4. Similar to the situation with L1, the level of 
expression of E1AE4 appeared to be slightly upregulated in C8-treated rafts 
compared to untreated samples (Fig. 3.11B, lanes 1 and 2). As before, this 
blot was stripped and reprobed with 6CS and the result indicates that 
comparable amounts of protein had been loaded for each sample (Fig.
3.11B). These experiments were repeated at least three times with different 
extracts and the results were consistently similar. These results suggest that 
while both untreated and C8:0-treated W12 rafts produce a readily 
detectable amount of HPV-16 late proteins, treatment with phorbol ester 
increases the level of expression of the viral proteins L1 and E1AE4.
The rafts were further analysed for viral late protein expression by carrying 
out immunohistochemical staining using antibodies raised against the HPV- 
16 late proteins E1AE4 and L1. Previous studies detected the non-structural 
E1AE4 protein in the upper layers of the epidermis, and experiments using 
the TVG 402 antibody indicated that this viral protein is localized to the
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expression due to the presence of background staining. In addition, it 
appears that the anti HPV-16 E1AE4 antibody, TVG 402, that I used in this 
experiment does not work well on paraffin-embedded material, and since the 
sections that I used originated from paraffin-embedded raft tissue, it is 
possible that this may have affected the efficiency of epitope recognition. An 
additional HPV-16 E1AE4 antibody, TVG 405, generated by the same group 
is reported to be more suitable for paraffin-embedded tissue (Doorbar et al., 
1997), unfortunately due to a lack of time this experiment could not be 
repeated using this antibody. The anti-HPV-16 L1 antibody, CamVir 1, has 
previously been used to examine HPV-16 positive clinical material and nude 
mouse grafts of the W12 line; in each case, L1 protein expression was 
confined to the upper granular layers of the epithelium (McClean et al., 1990, 
Sterling et al., 1990, Sterling etal., 1993). Cells staining positively for L1 
expression following immunohistochemistry of W12 raft sections are 
blue/black in colour, as shown in the representative section in Fig. 3.12A.
A number of L1 -positive cells are present in the granular layer of this section 
but no such expression was apparent in the HaCaT control (data not shown). 
While there appears to be a distinct patch of positively-stained cells in the 
W12 raft section shown, there also appears to be some diffuse staining in 
the upper granular layer, particularly to the right of the positively stained 
patch, and this observation is similar to previous reports utilising rafts 
containing cells harbouring HPV-16, HPV-18 and HPV-31 (Frattini et al., 
1996, Frattini et al., 1997, Flores et al., 1999). Cells in the granular layer are 
undergoing nuclear breakdown and this might help to explain this staining 
pattern.
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3.3.4. L1 mRNA expression in organotypic rafts
Since C8-treatment appears to have a slight positive effect on the level of 
expression of the L1 protein, I next attempted to determine the effect of C8:0 
treatment on the level of HPV-16 and HPV-31 L1 mRNAs using RNase 
protection assays (RPAs). Late viral transcripts have previously been 
detected in undifferentiated HPV-positive cells, and C8:0 treatment of rafts of 
the HPV-31 cell line. CIN 612, results in an increase in expression of both L1 
and L2 mRNAs (Hummel etal., 1995, Ozbun etal., 1997). However, the 
effect of C8 treatment on HPV-16 L1 mRNA expression has not yet been 
examined. The level of HPV-31 L1 mRNAs appears to increase with C8:0 
treatment of CIN 612 organotypic rafts, in agreement with previous reports 
(Fig. 3.13A). When HPV-16 L1 mRNA levels were compared between 
treated and untreated rafts it also appeared that C8:0 treatment resulted in a 
slight increase in HPV-16 L1 mRNA expression, although, the difference 
between untreated and treated mRNA samples was not as pronounced as 
previously observed for HPV-31. Nonetheless, this experiment was repeated 
with fresh extracts on a number of occasions and similar results were 
obtained.
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3.3.5. Viral DNA amplification in organotypic rafts
To further investigate the extent of the effect of phorbol-ester treatment on 
rafts containing episomal HPV genomes, the level of viral DNA amplification 
was compared, by Southern blot analysis, using DNA prepared from 
untreated and C8-treated W12 and 20863 raft tissue containing HPV-16 
genomes and CIN 612 raft tissue containing HPV-31 genomes (Fig. 3.14). In 
the uncut samples, bands representing open-circular and supercoiled viral 
DNA are arrowed, while in the restriction enzyme digested samples, 
linearised viral DNA is shown, running at approximately 8kb, thus confirming 
that these rafts contain episomal viral DNA. For both HPV-16 and HPV-31 
there appears to be little difference in the amount of open circular and 
supercoiled viral DNA between untreated and C8-treated samples (Fig. 3.14 
A and B, lanes 1 and 3). However, when the amount of linearized viral DNA 
is compared between treated and untreated samples it is obvious that C8- 
treatment of both W12, HPV-16, and CIN 612, HPV-31, containing rafts, 
results in a upregulation of viral DNA amplification (Fig. 3.14 A and B, lanes 
2 and 4). While this C8:0-dependent increase in HPV-31 viral DNA 
amplification in the CIN 612 line has been previously reported (Meyers et al., 
1992, Ozbun et al., 1998b), this is the first time, to our knowledge, that a 
similar effect has been reported using raft tissue containing episomal HPV- 
16 genomes.
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3.4. Discussion
The study of the HPV life cycle in tissue culture has been hampered by the 
lack of a cell-culture system that stably maintains HPV DNA episomally and 
the difficulty in recreating the three dimensional structure of the epithelium to 
induce the full HPV life cycle. However, the derivation of non-malignant cell 
lines, which maintain HPV genomes episomally, and the cultivation of these 
keratinocyte lines on the organotypic raft culture system has opened the way 
for a fuller understanding of the HPV life cycle.
The central aim of this thesis was to study the regulation of HPV-16 late 
gene expression during epithelial cell differentiation. Initially, I set about 
characterising the growth of the W12 and 20863 cell lines. Both these lines 
contain extrachromosomal copies of the HPV-16 genome and, under 
differentiating conditions, the virus is capable of completing a productive life 
cycle, although the mature virions are not infectious (Sterling et al., 1990, 
Sterling et al., 1993, Flores et al., 1999). In monolayer culture it appears that 
prolonged growth of these cell lines results in an induction of differentiation, 
even in the absence of phorbol ester treatment. W12 or 20863 cells 
harvested following 10 days in monolayer culture, express a high level of the 
differentiation marker involucrin. In vivo, the level of involucrin expression is 
directly related to the degree of cervical keratinocyte differentiation (Fuchs, 
1990). Day 10 W12 or 20863 cells also express detectable levels of the 
HPV-16 late proteins E1AE4 and L1. Previous studies have reported the 
presence of late protein transcripts in monolayer cultures (Stoler et al., 1989, 
Doorbar etal., 1990, Hummel ef al., 1992, Pray efal., 1995, Ozbun etal., 
1997, Koffa et al., 2000); however, to our knowledge, this is the first report of 
the detection of HPV-16 late viral proteins in monolayer culture, although 
Ozbun etal., (1997) suggested that late proteins may be synthesized in 
monolayer cultures but that they are present at levels below the sensitivity of 
currently used techniques. One major implication of our results is that it 
raises the possibility that previous experiments comparing phorbol ester-
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treated and untreated cell samples as differentiated and undifferentiated 
populations were effectively comparing two differentiating samples, since it 
appears that phorbol ester treatment, at least of the W12 and 20863 lines, is 
not necessary for the induction of differentiation. Conversely, analysis of 
W12 and 20863 cells following 5 days in monolayer culture reveals a low 
level of expression of involucrin and little or no late viral protein expression. 
This is an important observation, particularly in light of the results obtained 
with day 10 cells, since it means that we now have a reliable source of 
undifferentiated cells at our disposal, which are capable of mimicking the 
non-productive stage of the viral life cycle. When monolayer cultures of W12 
and 20863 cells were treated with the phorbol ester C8.0, it emerged that 
C8-treatment enhanced the level of expression of HPV-16 L1 but did not 
appear to effect the expression of involucrin, following 10 days in monolayer 
culture. Taken together, these results suggest that while non-treated W12 or 
20863 cells grown in monolayer culture for 5 days are undifferentiated, after 
10 days these epithelial cells have begun to differentiate and C8:0-treatment 
generates slightly more differentiated cells. Therefore, both untreated and 
phorbol-ester treated monolayer cultures of W12 and 20863 cells are a 
valuable resource in the study of differentiation-dependent viral late gene 
expression.
However, while monolayer cultures are useful, their use is somewhat limited 
by the fact that they are unable to support complete terminal differentiation. 
To this end, the organotypic raft culture system is an invaluable technique 
since it can mimic the epithelial differentiation programme similar to that 
found in intact tissue. I have established this tissue culture system in our 
laboratory and have successfully grown a number of HPV-positive cell lines 
on organotypic raft cultures. Histological staining indicates that the rafts 
resemble low-grade cervical lesions and immunohistochemical analysis 
using antibodies against the cellular differentiation markers K10 and 
involucrin indicates that differentiation is proceeding as expected. Protein 
extracts prepared from raft cultures following 12 days at the air-liquid
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interface expressed readily detectable levels of the late viral proteins E1AE4 
and L1 in untreated rafts, and in agreement with the situation in monolayer 
cultures, C8:0 treatment moderately increases the expression of these 
proteins. Immunohistochemical staining using antibodies directed against 
these viral proteins revealed that they are expressed exclusively in the upper 
granular layers of the epithelium, similar to the situation in clinical material. 
Moreover, analysis of HPV-16 and HPV-31 L1 mRNA transcripts in total 
RNA samples prepared from harvested raft cultures indicated that, in 
agreement with previously published results using the CIN 612 HPV-31 line, 
C8:0 treatment results in enhanced transcription of this late message both in 
HPV-31 and HPV-16 rafts. Furthermore, C8:0 treatment also increases the 
rate of amplification of episomal viral DNA in both HPV-16 and HPV-31 
containing raft cultures. It has been well documented that phorbol ester 
treatment of organotypic raft cultures of the CIN 612 line brings about a more 
complete differentiation programme, and is necessary for the productive 
stage of the HPV-31 life cycle (Meyers et al., 1992, Ozbun et al., 1997, 
1998a, 1998b). However, to our knowledge, this is the first comprehensive 
analysis of the effects of C8:0 treatment on HPV-16 containing monolayer 
cultures and organotypic rafts. It has previously been proposed that HPV-31 
late gene expression is controlled, to some extent, by post-transcriptional 
mechanisms dependent on C8:0 activation of the protein kinase C (PKC) 
pathway (Hummel et al., 1995). However, it appears that this proposition 
does not extend to all HPVs. I have shown that while C8:0 treatment 
enhances the level of HPV-16 late protein expression, it is not necessary, 
since late viral proteins were detectable both in untreated monolayer cultures 
and organotypic rafts of the biopsy-derived HPV-16 positive lines, W12 and 
20863. In addition, infectious HPV-18 virions have recently been produced 
using the organotypic raft culture system in the absence of C8:0 treatment 
(Meyers etal., 1997), and an HPV-11 cell line, recently established using 
cloned viral DNA, was also reported to undergo a productive life cycle in 
semisolid media, in the absence of phorbol esters (Thomas et al., 2001).
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It appears that HPV-31 positive cell lines that maintain transfected viral DNA 
episomally can also complete a productive life cycle when grown on 
untreated rafts (Frattini et al., 1996, 1997). These observations tend to 
suggest that the requirement for PKC-induced differentiation changes to 
facilitate virion synthesis is a particular property of the biopsy-derived HPV- 
31 cell line, CIN 612.
Previously published reports have included images of histological sections of 
nude mice grafts of the W12 line (Sterling et al., 1990, Sterling et al., 1993). 
Pictures of the W12 line cultivated on the organotypic raft culture system 
have, until now, not been published. As well as generating a large amount of 
useful information regarding the growth, differentiation and pattern of gene 
expression in HPV-16 infected cells, this extensive characterisation of the 
W12 and 20863 lines has also provided us with a wide range of material 
from undifferentiated monolayer cultures through to terminally differentiated 
raft tissue for use in the study of HPV-16 late gene expression in response to 
epithelial differentiation.
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Fig. 3.1. Southern blot analysis of HPV-16 DNA. The blot was 
hybridized with a full-length HPV-16 DNA probe, prepared from the 
insert of pBS 114K. A. Lane 1 is a copy number control showing 100 
copies of Bam H1 linearized, full-length, HPV-16 DNA. Total genomic 
DNA (lanes 2 and 3), and Hirt DNA (lanes 4 and 5) was extracted from 
20863 cells grown to subconfluence in monolayer culture. Undigested 
(U) DNA (lanes 2 and 4) contains open circular (OC) and supercoiled 
(SC) HPV-16 DNA. The extracted DNA was linearized (L) by digestion 
with Bam H1 (B), (lanes 3 and 5). B. Shorter exposure of lanes 4 and 5 
with open circular, supercoiled and linearized HPV-16 DNA indicated.
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Fig. 3.2. Analysis of protein extracts from W12 cells grown in 
monolayer culture. Protein extracts were prepared from cells grown 
for 5, 6, 7, 8, 9 and 10 days in monolayer culture (lanes 1-6 
respectively). A. 10pg of each protein stained with Coomassie blue. B. 
Protein extracts from each sample, equivalent to 2x104 cells, stained 
with Coomassie blue.
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Fig. 3.3. Western blot analysis of HPV-16 L1 expression. A. 10pg of 
protein extracts prepared from 20863/P16 cells grown in monolayer 
culture for 5, 6, 7, 8, 9, and 10 days (lanes 1-6 respectively) Western 
blotted with the CamVir 1 antibody, directed against HPV-16 L1. B. 
10pg of protein extract prepared from 20863/P16 cells grown for 5 
(lane 1) and 10 days in monolayer culture (lane 2), together with 10pg 
of J2 3T3 extract (lane 3), immunoblotted with CamVir 1.
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Fig. 3.4. Analysis o f protein extracts from monolayer cultures of 
W12 cells. 10pg of protein extracts prepared from W12/P17 cells 
grown in monolayer culture for 5 days, (lane 2), or 10 days (lane 3), 
and rainbow marker (lane 1). A. Staining with Coomassie blue. B. 
Immunoblotting with an anti-involucrin antibody, SY5. C. Western 
blotting with 6CS, an anti-GAPDH antibody.
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Fig. 3.5. Analysis o f protein extracts from monolayer cultures of 
HaCaT cells. 10jag of protein extract prepared from HaCaT cells 
grown in monolayer culture for 5 days, (lane 2), or 10 days (lane 3), 
and rainbow marker (lane 1). A. Staining with Coomassie blue. B. 
Immunoblotting with SY5, an anti-involucrin antibody. C. Western 
blotting with 6CS, an anti-GAPDH antibody.
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Fig. 3.6. Western blot analysis of viral late protein expression in 
monolayer cultured cells. Protein extracts were prepared from 
W12/P17 cells grown for 5 days (D5) and 10 days (D10) in monolayer 
culture (lanes 2 and 3), and HaCaT cells grown in monolayer culture for 
10 days (lane 1). A. 10pg of each protein extract Western blottted with 
CamVir 1,an antibody directed against HPV-16 L1. B. 10pg of each 
extract was Western blotted with 6CS, an anti-GAPDH antibody. C. 20pg 
of each protein extract was Western blotted with TVG 402, an anti HPV- 
16 E1AE4 antibody. D. 20ptg of each extract was Western blotted with 
6CS, an anti-GAPDH antibody.
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Fig. 3.7. Comparison of untreated and C8-treated monolayer 
cultured cells. 10jag of protein extract prepared from W12/P18 cells 
grown in monolayer culture for 5 days (lanes 1, 2), or 10 days (lanes 3, 
4). Cells were untreated (U), (lanes 1, 3), or were treated with C8:0 
(C8), (lanes 2, 4), on alternate days. A. Staining with Coomassie blue. 
B. Western blotting with an anti-involucrin antibody, SY5. C. 
Immunoblotting with the anti-HPV-16 L1 antibody, CamVir 1.
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Fig. 3.9. Analysis of protein extracts prepared from organotypic 
raft tissue. 10pl of protein extracts prepared from untreated (U), (lane 
1), or C8:0 treated (C8), (lane 2), W12/P17 organotypic raft cultures. 
A. Staining with Coomassie blue. B. Immunoblotting with SY5, an 
antibody against involucrin. C. Immunoblotting with 6CS, an antibody 
directed against GAPDH.
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Fig. 3.12. Localisation of HPV-16 L1 protein. A. W12 rafts grown at the 
air-liquid interface for 12 days and stained for HPV-16 L1 expression.
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Fig. 3.13. Ribonuclease protection assays (RPA) assessing the 
levels o f L1 transcripts. CIN-612 9E cells and 20863 cells were 
cultured on organotypic rafts, either untreated (U), or treated with 10pM 
C8:0 (C8), for 12 days at the air-liquid interface. 10pg samples of total 
RNA or yeast RNA (Y) were hybridised with the appropriate L1 
riboprobe. Two yeast RNA samples were included as controls: Y1 was 
RNase digested to show probe specificity, Y2 was not treated with 
RNase to indicate the size of the input probe. A. Hybridisation with a 
riboprobe specific to the 3’ internal L1 ORF of HPV-31 followed by 
RNase digestion. B. Hybridisation with a riboprobe specific to the 3’ L1 
ORF of HPV-16 followed by RNase digestion.
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Fig. 3.14. Southern blot analysis of HPV DNA from raft tissue.
Total genomic DNA was prepared from 20863 cells (A), and CIN 612 
9E cells (B), cultured on organotypic rafts which were either untreated 
(lanes 1, 2), or treated with C8:0, (lanes 3, 4). A. The blot was 
hybridised with a full-length HPV-16 DNA probe, prepared from the 
insert of pBS 114K. Undigested DNA (U), contains open circular (OC), 
and supercoiled (SC), HPV-16 DNA. Extracted DNA was linearised (L) 
with Bam H1 (B). B. The blot was hybridisied with a full-length HPV- 
31b DNA probe, prepared from the insert of pBS HPV31. Undigested 
DNA (U), contains open circular (OC), and supercoiled (SC), HPV-16 
DNA. Extracted DNA was linearised (L) with Hind III (H).
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CHAPTER 4 -  Site-directed mutagenesis of the HPV-16 NRE
Previous studies on the regulation of papillomavirus late gene expression 
have suggested that viral late protein expression is most likely controlled 
through interactions between cellular factors and viral cis-acting inhibitory 
elements (reviewed in Schwartz, 1998). In this scenario, the inhibitory effects 
of these cis-acting elements could be overcome through differentiation- 
dependent changes in the level of expression, activity or sub-cellular 
distribution of the factors with which they interact. Negative factors mediating 
the inhibitory activity may be downregulated with differentiation, or positive 
factors might be upregulated upon differentiation (Tan et al., 1995b). In 
support of this, a number of c/'s-acting negative regulatory elements have 
been identified within the coding region of viral late proteins and also in the 
viral late 3’ untranslated regions (UTR) (reviewed in Schwartz et al., 1999). 
Inhibitory elements within the HPV-16 L1 and L2 open reading frames 
contain features of mRNA instability elements and are believed to control the 
levels of late mRNAs in the nucleus and cytoplasm, and may also affect the 
efficiency of translation of these messages (Tan et al., 1995a, Collier et al., 
1998, Sokolowski et al., 1998). Conversely, an inhibitory element within the 
L2 ORF of HPV-31 is thought to regulate genome replication and stability 
(Terhune et al., 2001).
Negative regulatory elements within viral late 3’ UTRs have been identified in 
BPV-1, HPV-1, HPV-16, and recently, HPV-31 (Furth etal., 1991, Kennedy 
et al., 1990, Tan et al., 1995a, Cumming et al., 2002a). While these 
elements have some sequence similarities, they appear to exert their 
negative effects via distinctly different mechanisms. Each element acts in a 
position and orientation-dependent manner to reduce the levels of 
polyadenylated late mRNAs in the nucleus and cytoplasm in undifferentiated 
cells.
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The HPV-16 negative regulatory element (NRE) is located upstream of the 
late polyadenylation signal in the 3’ UTR. This element reduced the 
expression of a chloramphenicol acetytransferase (CAT) reporter gene by 
99%, following transient transfection in basal epithelial cells (Kennedy et al., 
1990, Dietrich-Goetz e ta i, 1997). Using a series of deletion mutants, the 
minimal NRE was mapped to a 79-nucleotide (nt) region from nt 7128 to 
7206 (Kennedy et al., 1991). This element can be roughly divided in two 
parts and comprises a putative stem loop structure and four weak 5’ splice 
sites in the 5’ portion and a GU-rich region in the 3’portion. Studies to date 
have found no role for the putative stem loop structure in NRE inhibitory 
activity (Clements, unpublished data, Cumming et al., 2002b), however, the 
functional importance of the weak 5’ splice sites and the GU-rich region has 
been the subject of two contradictory reports. Dietrich-Goetz et al., (1997) 
used the full-length 79nt NRE to demonstrate that the GU-rich 3’ region was 
the major determinant of NRE function, and deletion of the first and second 
of the four weak splice sites accounted for only 13% of the NRE-mediated 
while further deletion of the remaining two splice sites, including 2 nt of the 
GU-rich region, resulted in a 50% reduction in CAT activity. In contrast, 
deletion studies carried out by Furth et al., (1994) mapped the HPV-16 NRE 
to a 51 nt region (nt 7128-7178). This shorter element lacks most of the GU- 
rich region of the 79nt NRE. When this 51 nt NRE was tested in an SV40- 
based CAT reporter gene vector it resulted in a 6-fold inhibition of CAT 
activity and the second of the four splice sites was found to be critical for this 
inhibitory activity (Furth et al., 1994). However, it should be noted that the 
constructs used by Dietrich-Goetz et al., contained the endogenous HPV-16 
late polyadenylation signals whereas Furth et al., used constructs containing 
the SV40 early polyadenylation site. It is possible that the HPV-16 NRE 
exerts its inhibitory activity through interactions with the late polyadenylation 
signal, therefore, the use of a heterologous poly(A) site may disrupt this 
cross-talk and indirectly reduce the activity of the NRE. These differences 
have recently been resolved in our laboratory following extensive
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mutagenesis studies (Cumming et al., 2002b). Using a CAT reporter gene 
vector similar to that used by Dietrich-Goetz et al., and a series of deletion 
mutants of the 79nt NRE, in the context of the HPV-16 late polyadenylation 
region, it has been shown that the four weak 5’ splice sites act together to 
mediate the full inhibitory activity of the 5’ portion of the NRE and, while the 
3’ GU-rich region also has independent inhibitory activity, the full 79nt NRE 
is required for maximal inhibition (Cumming et al., 2002b).
UV cross-linking analysis using the minimal 79nt NRE as the target RNA has 
revealed that this element can bind a range of cellular proteins, the most 
prominent of which is a 65kDa nuclear protein band, possibility representing 
more than one protein, and a less prominent 40kDa protein band (Dietrich- 
Goetz et al., 1997, Koffa et al., 2000). Work to date has identified three of 
the cellular factors with which the NRE interacts and these are the auxiliary 
splicing factor U2AF65, the cleavage-stimulating factor CstF-64 and the 
shuttling protein HuR (Koffa et al., 2000). Moreover, the level of expression 
and distribution of these cellular factors was shown to alter following 
epithelial differentiation, U2AF65 being downregulated, CstF-64 upregulated 
and HuR redistributing from the nucleus to the cytoplasm (Koffa et al., 2000).
The aim of the work presented here was two-fold; firstly, I wanted to 
determine which specific short segments of the 79nt NRE are functionally 
important for the inhibitory activity of this element. Secondly, I wished to map 
the NRE sequences that bind cellular proteins, since subsequent mutations 
of sequence motifs with which NRE-binding proteins interact could reveal 
clues as to the RNA-based mechanisms by which the NRE functions.
113
Chapter 4 - Results
4.1.1. Saturating site-directed mutagenesis of the NRE
I attempted to identify important NRE sequences by introducing point 
mutations throughout the element using an approach similar to that used to 
abolish the inhibitory activity of the HPV-1 AU-rich element (Sokolowski et 
al., 1997), and to map the 53nt inhibitory element of BPV-1 (Furth et al., 
1994). A 445nt fragment (nt 7008 to 7453) of the HPV-16 late 3’ UTR that 
encompasses the NRE was used as a template for PCR (Fig. 1.10). The 
NRE was divided into fifteen non-overlapping groups of five nucleotides from 
the 5’ end through to the 3’ end of the element, M1 to M15, as shown in Fig. 
4.1 B. Within each group PCR mediated site-directed mutagenesis was used 
to change purines to pyrimidines and vice versa (Fig. 4.1 B). Each of the 
fifteen mutants was cloned into the pGem-T vector and sequenced (either 
manually or using automated sequencing) to ensure only the desired 
mutations were present. Each of the weak 5’ splice sites were disrupted 
individually with random point mutations and differed significantly from the 
consensus 5’ splice site (AAG/GUAAGU) as indicated in Fig. 4.1 B, M3 
(AAG/TACTGC), M4 (TAG/CAAAGU), M6 (AGA/UGCUGU) and M7 
(UAG/UACGGU).
The putative stem loop structure was not mutated in this study since this 
motif was the subject of another mutagenesis study in the laboratory 
designed to specifically disrupt the secondary structure of this feature. 
Previous extensive work in the laboratory of Barklie Clements, using point 
mutations to disrupt the loops and bulges of the structure, had failed to 
establish a role for this predicted stem loop (Clements, unpublished data).
4.1.2. Mutagenesis does not affect the inhibitory activity of the NRE
Following sequencing, the mutants were cloned immediately downstream of 
the chloramphenicol acetyltransferase (CAT) reporter gene, between the Pst 
\/Hind III sites, in the expression vector, pLW1 (Fig. 4.2). The CAT gene is
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under the control of the HSV-2 immediate early promoter and the plasmid 
lacks poly(A) signals (Fig. 4.2). However, the NRE mutants were constructed 
in the context of the Pst IlEco Rl 445nt fragment from the 3’ UTR of HPV-16 
and so they contain the HPV-16 late polyadenylation sites (Fig. 4.1 A). Each 
mutant NRE plasmid construct was transiently transfected into HeLa cells, 
used as a model for basal epithelial cells, and reporter gene activity was 
assayed. Transfections were carried out in duplicate on at least three 
occasions for each mutant. Results, in counts per minute (cpm), were 
averaged and the standard deviation calculated (Fig. 4.3). The total number 
of counts differed between experiments, although the pattern of CAT activity 
was consistent, and so in order to allow a useful comparison of the results, 
the average CAT activity of each mutant was calculated as a percentage of 
the activity (in cpm) of the positive control plasmid 11, which lacks the region 
containing the NRE between the Pst I and Ssp I sites (Fig. 1.10) and was 
therefore assigned 100% CAT activity in each experiment. Plasmid F11 
contains the full-length, wild type NRE and was included as a negative 
control. From the graph it is clear that none of the mutated forms of the NRE, 
including the splice site mutants M3, M4, M6 and M7, were capable of 
significantly relieving the inhibitory activity of this element, as compared to 
the wild type control F11 (Fig. 4.3).
4.1.3. Mutagenesis does not affect protein binding to the NRE
Radiolabelled riboprobes corresponding to each of the fifteen NRE mutants 
were synthesised by in vitro transcription. The affect of the NRE mutations 
on the ability of the element to interact with nuclear proteins was assayed by 
UV cross-linking analysis and compared to the protein binding profile 
generated using a wild type NRE riboprobe. Initially, UV cross-linking was 
carried out in 60mM KCI and as indicated in Fig. 4.4, none of the mutations 
introduced into the NRE appeared to affect the ability of this element to 
interact with HeLa nuclear proteins; the band intensity and overall profile was
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very similar between mutants and the wild type control. As shown in Figs.
4.4, 4.5 and 4.6, the NRE can bind a number of nuclear proteins of various 
sizes, the most prominent of which is approximately 65kDa, although a 
40kDa protein also binds the element quite strongly. The UV cross-linking 
experiment was repeated and this time the salt concentration was increased 
to 125mM in an attempt to determine if minor differences exist between the 
mutant probes under more stringent conditions, i.e. higher salt. Again, there 
appeared to be no significant differences between the series of NRE mutants 
and the wild type control (Fig. 4.5). The concentration of salt was further 
raised to 250mM and UV cross-linking was repeated. At this increased salt 
concentration the protein binding profiles showed some minor differences, 
(Fig. 4.6). The intensity of the 40kDa band and some smaller bands, which 
might possibly represent serine-arginine (SR) proteins on the basis of size, 
appeared to decrease slightly, particularly in mutants clustered at the end of 
the element (M13, M14, M15) and also in mutants 7 and 8. Each of these 
mutants contains fewer GU residues than in the respective wild type 
sequences, suggesting that efficient binding of the 40kDa and smaller 
proteins require GU-rich sequences. In this experiment the M12 riboprobe 
appears to have degraded slightly as indicated by the decrease in intensity 
of the 65 and 40kDa bands and the increase in smaller protein bands. 
However, when this experiment was repeated the M12 protein profile was 
similar to that of the other mutants and the wild type control, as indicated in 
the additional panel in Fig. 4.6. Nevertheless, even at this relatively high salt 
concentration the overall protein binding profile of each mutant was similar to 
that of the wild type control and also to the profiles generated at 60mM KCI 
and 125mM KCI, suggesting that the majority of nuclear proteins that bind to 
the NRE do so with high affinity, at least in vitro. However, in order to 
establish this conclusively I would have had to carry out UV cross-linking at 
higher salt concentrations, for example 500mM and 1M KCI, as nucleic acid 
binding proteins, e.g.TATA-binding protein (TBP), are generally highly 
charged basic proteins which bind tightly to their target sequences even in
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high salt (Pugh, 2000); unfortunately, due to time constraints, this was not 
attempted. UV cross-linking was repeated at least three times for each NRE 
mutant at increasing salt concentrations and any minor differences in the 
protein binding profiles of mutants were consistent.
4.2. Deletion of the NRE in the context of the viral genome
Since the mutations introduced into the NRE did not appear to affect the 
inhibitory activity of this element, or its ability to bind nuclear proteins, I next 
attempted to delete the NRE in the context of the whole viral genome. I 
planned to establish a cell line in which the NRE-null viral genome was 
maintained episomally by transfecting normal human foreskin keratinocytes 
(NHFK) with the mutant virus construct. At the same time, I also wanted to 
establish a wild type HPV-16 line using viral DNA, known as 114/K, derived 
from a low-grade cervical lesion (Kirnbauer et al., 1993). This is a relatively 
new technique and has been used in recent years to establish stable cell 
lines expressing a number of HPV DNAs extracted from cervical samples 
(Frattini et al., 1996, Frattini etal., 1997, Meyers etal., 1997, Thomas eta!., 
2001). The advantage of this approach is that it permits molecular 
manipulation of the cloned viral DNA prior to transfection. If an NRE-deletion 
mutant were viable then characterisation of the growth of this mutant virus 
both in monolayers and on the organotypic raft culture would provide 
valuable information on the role(s) of this element in the virus life cycle. I was 
particularly interested in studying the possible changes in the timing of viral 
late gene expression in this line, given the proposed central role of the NRE 
in the post-transcriptional control of late gene expression. The NRE deletion 
mutant was constructed using a PCR-based mutagenesis protocol similar to 
that used to generate the NRE site-directed mutants. Since the NRE 
straddles the L1 stop codon I decided to delete only the portion of the NRE 
lying immediately downstream of this site and therefore maintain the integrity 
of the L1 coding region in the mutant virus. Forward and reverse primers
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were designed that lacked 52nt of the NRE immediately downstream of the 
L1 stop codon from position 7155 to 7207, flanked on either side by 12-15 bp 
of wild type sequence, and were designated A52F and A52R. Wild type viral- 
specific forward and reverse primers were designed; 6818F anneals 
upstream of the Eco A/I site and 7440R anneals downstream of the Pml I 
site, as shown in Fig. 4.7. Two complimentary half molecules were 
generated by PCR-amplifying Pml I linearized pBS 114K with A52R and 
6818F and Eco A/I linearized pBS 114K with A52F and 7440R (Fig. 4.8A and 
B). These half molecules were annealed and a further round of fill-in PCR 
using the 6818F and 7440R primers generated a full-length, double stranded 
product (Fig. 4.8C), which lacked the NRE. From the agarose gels shown in 
Fig. 4.8 it appears that the sizes of the PCR products differ slightly from the 
predicted sizes, however, subsequent sequencing of the NRE-deletion 
mutant gave the expected sequence (see below). The filled-in PCR product, 
lacking the NRE, was cloned into the pGem-T vector and clones were 
subsequently digested with Eco Rl and Ssp I to verify the presence of the 
mutated PCR product (data not shown). A number of positive clones were 
checked by automated sequencing to ensure the NRE had been deleted and 
no random mutations had been introduced; at least two of the sequenced 
clones were correct and were designated pGem A52 [3] and pGem A52 [6]. I 
then attempted to sub-clone the Pml 11 Eco Nl digested PCR product from 
these pGem constructs into pBS 114K from which the wild type Pml 11 Eco Nl 
fragment had been removed (Fig. 4.9B). However, despite numerous 
attempts including varying the vector to insert ratio and using 100x T4 DNA 
ligase, as recommended for Eco Nl ligations (New England Biolabs), I was 
unable to ligate the wild type vector and mutant insert and the reason for this 
remains unknown.
As an alternative approach I digested pBS 114K with Bam HI to release the 
viral genome from the vector backbone. The HPV-16 genome was 
recircularised and digested with Eco Rl, which cuts at positions 6819 and
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7453, to remove a 634nt fragment that includes the wild type NRE. The 
pGem A52 mutants, 3 and 6, were also digested with Eco Rl to generate a 
583nt NRE-null insert, which was subsequently ligated with the Eco Rl 
digested viral genome (Fig. 4.9C). Following ligation, 114K A52, 3 and 6, 
were recloned into the Bam HI site of pBS. The ligation of pBS and 114K 
A52 [6] was repeatedly less efficient than pBS and 114K A52 [3] and so 
clones from this ligated product only were digested with Bam HI and Ssp I to 
check the presence and orientation of the insert; if the A52 fragment was 
ligated in the correct orientation into the 114K backbone then this digest 
would produce a number of fragments including one at 1076nt. 
Approximately fifty clones were analysed in this way and only one appeared 
to contain the insert in the correct orientation (Fig. 4.1 OA, lane 4). However, 
routine digests of this plasmid pBS 114K A52 [3-4], following caesium 
chloride preparation, gave unexpected results when compared to the wild 
type control pBS 114K (Fig. 4.1 OB). Undigested pBS 114K (Fig. 4.1 OB lane 
1) runs as a large single band at the top of the gel. In addition to a similar 
large band, undigested pBS 114K A52 [3-4], (Fig. 4.10B lane 4), contains a 
number of bands, the most predominant of which is approximately 3kb in 
size. Digestion of pBS 114K with Eco Rl (Fig. 4.1 OB, lane 2) and Bam HI 
(Fig. 4.1 OB, lane 3) gave the predicted number and size of products based 
on the published HPV-16 sequence (Seedorf et al., 1985). However, when 
pBS 114K A52 [3-4] was similarly digested with Eco Rl (Fig. 4.1 OB, lane 5) 
and Bam HI (Fig. 4.1 OB, lane 6) the only product was a band of 
approximately 3kb similar to that observed in undigested pBS 114K A52 [3-4] 
(Fig. 4.1 OB, lane 4). On the basis of size I suspect this band may be pBS, 
although I did not attempt to identify the DNA, but if this were correct then it 
might suggest that the ligation of pBS and 114K A52 resulted in an 
unfavourable recombination event that led to the loss of 114K A52. In an 
attempt to overcome this problem, DNA from the mini-prep shown in lane 4 
Fig. 4.10A, pBS 114K A52 [3-4], was introduced into a number of strains of
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competent bacteria, including in-house preparations of DH5a and XL1 Blue 
cells and commercial preparations of XL10-Gold ultracompetent cells 
(Stratagene). Unfortunately, this did not solve the recombination problems 
and due to time constraints I was unable to pursue this work any further. 
Further to this, a number of alternative approaches are currently being 
pursued in the laboratory in an attempt to successfully clone an NRE-null 
HPV-16 virus genome.
Fortunately, the establishment of a wild type HPV-16 line was rather more 
straightforward. Following electroporation of the 114/K DNA into freshly 
established monolayer cultures of normal human foreskin keratinocytes, the 
transfected cells were grown for a number of passages then cyroperserved 
prior to characterisation. Preliminary Southern blot analysis of DNA extracted 
from transfected cells at the first passage indicated that the cells contained 
episomal viral DNA, although since the cells were at such a low passage 
they contained very little viral DNA (data not shown). However, as a result of 
the problems encountered with the establishment of the NRE-deletion 
mutant line, this wild type line was not used in this study and was not 
characterised any further.
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4.3. Discussion
The differentiation-dependent control of HPV late protein expression is 
regulated at both transcriptional and post-transcriptional levels. The 
identification of negative regulatory RNA sequences both in HPV-16 and in a 
number of other papillomavirus late 3’ UTRs suggests that these sequences, 
and the cellular factors with which they interact, play an important role in 
controlling the pattern of late protein expression. For example, an AU-rich 
inhibitory element has been mapped to a 57-nt sequence located 
immediately downstream of the L1 stop codon in HPV-1 (Sokolowski etal., 
1997). Multiple nuclear and cytoplasmic HeLa cell proteins interact with the 
HPV-1 AU-rich inhibitory sequence, and of particular functional importance 
are the shuttling proteins hnRNP C1 and C2 and the elav-like HuR protein 
(Sokolowski et al., 1997, Sokolowski et al., 1999). It has been suggested that 
binding of hnRNP C1 and C2 to sequences in HPV-1 late mRNAs may result 
in premature degradation of late messages in undifferentiated cells but 
binding of HuR to these elements in differentiated cells bypasses the 
degradation pathway (Schwartz et al., 1999). Also, a 53-nt sequence located 
immediately upstream of the poly(A) signal in the bovine papillomavirus type 
1 (BPV-1) late 3’UTR has been shown to reduce the efficiency of late 
mRNAs polyadenylation in undifferentiated cells (Furth et al., 1994). The 
inhibitory activity of this sequence has been attributed to a 5’ splice site 
within the element which has been shown to interact with U1 snRNP; 
polyadenylation of late messages is inhibited as a result of the direct 
interaction of the U1 snRNP subunit, U1 70K, and poly (A) polymerase 
(Furth et al., 1994, Gunderson et al., 1998).
The subject of the work presented in this chapter is the 79nt negative 
regulatory element of HPV-16, which straddles the L1 stop codon and 
extends into the late 3’UTR (Kennedy et al., 1991). This element comprises 
a number of interesting features: The 5’ portion contains a putative stem loop
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structure and four weak 5’ splice sites, while the 3’ portion contains a GU- 
rich region (Kennedy etal., 1991). Following the identification of this 
element, it has been shown to interact with a range of cellular proteins, 
including possibly a number of 65kDa nuclear proteins, two of which have 
previously been identified as U2AF65 and CstF-64, and a less prominent 
40kDa protein, believed to be HuR (Dietrich-Goetz et al., 1997, Koffa et al., 
2000). This element has also been implicated in a number of RNA 
processing events including mRNA splicing, polyadenylation, nuclear export 
and cytoplasmic mRNA stability and the NRE is thought to be responsible for 
controlling expression of late viral proteins through its involvement in one or 
more of these post-transcriptional mechanisms (Kennedy et al., 1991, Furth 
et al., 1994, Koffa et al., 2000, McGuire et al., 2002).
I hypothesized that identifying short sequence elements that relieved the 
inhibitory activity of the NRE and using this information to correlate loss of 
NRE-function with changes in the pattern of protein binding to the NRE might 
give some insight as to the nature of the RNA processing mechanisms 
involved in the control of viral late gene expression. I generated a series of 
site-directed mutations throughout the NRE and compared the inhibitory 
activity of each mutant to a wild type NRE control in a reporter gene assay. 
Surprisingly, however, I found that none of the mutations introduced into the 
NRE relieved the inhibitory activity of this element, suggesting that the 
inhibitory activity of the NRE is mediated by larger sequence elements. The 
ability of the NRE mutants to interact with HeLa nuclear proteins was also 
compared with a wild type NRE control following UV cross-linking at 
increasing salt concentrations, but the pattern of protein binding to this 
element remained unchanged. This observation suggests that the NRE- 
binding proteins may make contact with the element at more than one 
position and therefore, loss of one binding site, through mutation, does not 
significantly affect the overall ability of the NRE to bind protein complexes
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and so the protein-binding profile remains similar. It should be noted that 
nucleic acid-binding proteins are usually part of complexes.
Additionally, each of the weak 5’ splice sites was disrupted with random 
point mutations, however, as indicated above, none of these appeared to 
relieve NRE inhibition. Initially, this might suggest that none of the splice 
sites, including the second site, which had been previously suggested to be 
critical for NRE activity, are functionally important for NRE repression. 
However, since the NRE was mutated in non-overlapping 5nt groups this 
means that only one splice site was altered at any time and each of the 
mutated splice site constructs M3, M4, M6 and M7 contained three 
undisrupted splice sites and a wild type GU-rich region, which may be 
sufficient to maintain NRE-mediated repression of reporter gene expression.
Thus it appears that, in contrast to the situation in HPV-1 and BPV-1, short 
sequence elements in the HPV-16 NRE do not determine the inhibitory 
activity of this element, or its ability to interact with a range of HeLa nuclear 
proteins. This observation is supported by additional NRE deletion 
mutagenesis studies carried out in our laboratory (Cumming et al., 2002b).
As an alternative approach to identifying important sequence elements within 
the NRE, NRE-deletion mutants were tested in reporter gene assays similar 
to those used to functionally test the site-directed NRE-mutants. This 
approach revealed that although the full 79nt element is required for maximal 
inhibition, both the 5’ and 3’ portions of the NRE have independent inhibitory 
activity: While deletion of the 3’ portion resulted in a 3-fold increase in the 
level of reporter gene expression, removal of the 5’ portion of the NRE 
relieved the inhibition on reporter gene expression 10-fold (Cumming etal., 
2002b). Moreover, further mutational studies have indicated that the four 
weak 5’ splice sites act together and are responsible for the inhibitory activity 
of this portion of the NRE; the putative stem loop structure was not required 
for inhibition (Cumming et al., 2002b). However, while the 5’ portion is
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functionally more important than the 3’ portion, it appears to bind less protein 
than the GU-rich region (Cumming etal., 2002b). Surprisingly, however, the 
pattern of protein binding to the 5’ and 3’ portions was very similar, albeit 
with variations in band intensity, despite a lack of any sequence similarity 
between these constructs. Competition experiments using up to a 16-fold 
molar excess of unrelated RNA did not affect the NRE protein binding profile, 
confirming that protein binding to the NRE is specific (Cumming et al., 
2002b).
Each of the NRE-binding proteins identified to date, U2AF65, CstF-64 and 
HuR would be predicted to interact predominantly with the GU-rich 3’ region 
of the NRE by virtue of the U-rich nature of their consensus binding sites 
(Koffa et al., 2000). Obviously, it is possible that the 5’ portion of the NRE 
binds different cellular proteins and any similarities in size are purely 
coincidental. Alternatively, UV cross-linking may irreversibly fix an interaction 
that is normally transient in vivo. However, this is an unlikely explanation 
since increasing salt concentrations and competition assays did not disrupt 
the protein binding profile. A more plausible explanation is that the 5’ and 3’ 
parts of the NRE, despite lacking sequence similarity, can act in a 
cooperative manner to mediate the formation of a dynamic, NRE-bound, 
multi-protein complex. One could imagine that a number of cellular proteins, 
interacting specifically with the 5’ and 3’ regions of the NRE, in turn recruit 
additional factors, eventually forming a complex held together by extensive 
RNA-protein and protein-protein interactions.
Given the fact that the cellular environment changes with differentiation, and 
the potential effects of these changes on the activity and distribution of 
cellular proteins (Fuchs, 1990), it is highly likely that the components of any 
putative NRE-bound multi-protein complex would be influenced by 
differentiation. I have not directly tested this hypothesis but a recent report 
by Koffa et al., and results presented in chapter 5, do suggest that the level
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of expression of NRE-bound proteins is influenced by differentiation. It is 
tempting to speculate that these differentiation-dependent changes in NRE- 
bound proteins may be partly responsible for the relief of the inhibitory 
activity of this element in terminally differentiated keratinocytes, thereby 
facilitating viral late protein expression in these cells. Interestingly, Dietrich- 
Goetz et al., (1997) reported that PMA treatment of HPV-16 positive W12 
cells, transiently transfected with NRE constructs, relieves the inhibitory 
activity of this element. PMA acts as an activator of the protein kinase C 
pathway and can induce epithelial differentiation (Meyers et al., 1992). PMA 
treatment of the W12 line was also shown to bring about a differential 
decrease in binding of the 65kDa protein to the NRE and an increase in 
binding of a predominantly cytoplasmic 40kDa protein, possibly HuR; 
indicating that protein binding to the NRE is subject to differential changes 
(Dietrich-Goetz et al., 1997).
In summary, analysis of substitution and deletion mutants of the HPV-16 
NRE has revealed that, while no short sequences alone determine the 
inhibitory activity of this element, the 5’ and 3’ regions each contribute 
independently to the negative effect, and the full-length 79nt element is 
required for maximal inhibition.
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Chapter 5 - Results
CHAPTER 5 -  Protein binding to the NRE
The expression of late HPV proteins is tightly controlled and despite several 
reports of the presence of late viral transcripts in undifferentiated cells, late 
viral proteins are detected only in terminally differentiating keratinocytes 
(Stoler et al., 1989, Doorbar et al., 1990, Ozbun et al., 1997). The switch 
from early (P97) to late promoter (P67o) usage in differentiating cells is partly 
responsible for controlling late gene expression (Grassmann et al., 1996). 
However, post-transcriptional RNA processing mechanisms including 
alternative splicing, polyadenylation, nuclear export, and cytoplasmic 
stability, are also believed to play an important role in preventing translation 
of any late transcripts present in undifferentiated cells. The HPV-16 negative 
regulatory element (NRE), located in the late 3’ untranslated region, was first 
identified due to its ability to repress reporter gene expression in 
undifferentiated epithelial cells (Kennedy et al., 1990). Further to this, the 
NRE has been implicated in mRNA instability, disruption of terminal exon 
definition, nuclear retention and poly(A) site selection (Kennedy et al., 1991, 
Furth et al., 1994, Koffa et al., 2000, McGuire et al., 2002). The coding 
potential of the HPV-16 genome is limited to 8 open reading frames, and 
therefore it is likely that the NRE is dependent on interactions with cellular 
factors in order to exert its inhibitory effects. In support of this, the element 
has been shown to bind a number of cellular proteins both by UV 
crosslinking and RNA affinity chromatography; a number of these proteins 
have been identified and include the auxiliary splicing factor U2AF65, the 
polyadenylation factor CstF-64 and the shuttling protein HuR (Dietrich-Goetz 
et al., 1997, Koffa et al., 2000). Taken together this evidence suggests that 
the NRE has a central role to play in the post-transcriptional control of viral 
late gene expression, however, the exact role of the NRE remains unclear.
In an attempt to address this problem, I decided to look at the involvement of 
the NRE in RNA processing, and more specifically, the ability of the NRE to 
interact with cellular factors involved in splicing. I chose to concentrate on
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splicing, since removal of introns from pre-mRNAs is a crucial step in 3’end 
processing, and alternative splicing is known to play an important role in 
developmentally regulated and tissue-specific patterns of gene expression in 
a range of organisms including Drosophila, C. elegans, and vertebrates 
(reviewed in Wang et al., 1997). Moreover, alternative splicing in viruses 
may facilitate the expression of a larger number of proteins from a relatively 
small genome. The aim of this work was two-fold; firstly I wanted to confirm 
that the NRE could bind the auxiliary splicing factor, U2AF65, the 
polyadenylation factor, CstF-64, and the elav-like, shuttling protein HuR, as 
previously reported and secondly I hoped to identify other cellular proteins 
capable of interacting with the NRE, specifically cellular factors involved in 
splicing.
5.1.1 Binding of U2AF65, CstF-64 and HuR to the HPV-16 NRE
Binding of U2AF65, CstF-64 and HuR to the HPV-16 NRE had previously 
been demonstrated by UV cross-linking experiments and electrophoretic 
mobility shift assays (EMSA) (Dietrich-Goetz et al., 1997, Koffa et al., 2000). 
The NRE can bind several cellular proteins in UV cross-linking experiments 
using nuclear extracts from HeLa cells, the most abundant of which is a 
65kDa protein band (Fig. 5.1 A, lane 1), which is believed to contain U2AF65 
and CstF-64. A protein band of approximately 40kDa is also clearly visible 
within this protein binding profile and may be HuR. In order to confirm that 
the NRE could bind these cellular proteins UV cross-linking was carried out 
using a radiolabelled NRE probe incubated with HeLa nuclear extract (Fig.
5.1 A, lane 1), nuclear extract only (Fig. 5.1 A, lane 2), and NRE probe only 
(Fig. 5.1A, lane 3). HeLa cells are a useful source of basal cell-like proteins 
despite their highly transformed nature. Western blot analysis of the UV 
cross-linked separated proteins using the MC3 antibody, directed against 
U2AF65, identified a single protein band at approximately 65kDa (Fig. 5.1B 
lanes 1,2) which when overlaid on the NRE protein binding profile (Fig. 5.1 A,
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lane 1) was found to co-migrate with the strong 65kDa protein band 
indicating that U2AF65 can be cross-linked to the NRE and is most likely one 
of the 65kDa proteins bound by this element. Similarly, Western blotting with 
a64k, an antibody directed against CstF-64, pulled out a single band when 
the NRE probe was incubated with nuclear extract (Fig. 5.1C, lane 1) which 
also appeared to co-migrate with the strong 65kDa protein band (Fig. 5.1 A, 
lane 1) indicating that CstF-64 can bind the NRE and is also one of the 
65kDa proteins interacting with the NRE. On this occasion, a CstF-64 
specific band was not detected in the nuclear extract lane; this may indicate 
that not enough nuclear extract was loaded since a strong CstF-64 band was 
usually detected in nuclear extracts (Fig. 5.3B). Western blotting with 16A5, 
an anti-HuR antibody, indicated that the 40kDa protein band identified in the 
UV cross-linking protein binding profile quite possibly is HuR since the HuR 
specific protein band (Fig. 5.1D, lanes 1,2) could be overlaid directly onto 
this band, demonstrating that the NRE can bind HuR.
5.1.2 Identification of NRE binding proteins using a novel RNA binding 
assay
In order to further confirm that U2AF65, CstF-64 and HuR can bind the HPV- 
16 NRE and to identify other cellular proteins that can interact with this 
element I developed an alternative method based on an RNA binding assay 
that had previously been used to identify cellular proteins required for the 
inhibition of HIV-1 pre-mRNA splicing (Caputi et al., 1999). This technique is 
considered to be an improvement on the biotin/streptavidin binding assay 
since there is no longer a risk of Western blot contamination with streptavidin 
washed from the column. Also, the secondary structure of the target RNA is 
not disrupted in this method since the covalent link to the agarose beads 
involves the 3’ end of the RNA only, similar to the poly(A) tailing approach. 
The RNA binding assay is based on an affinity chromatography approach 
and involves in vitro transcribing RNA corresponding to the full-length NRE
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or first and second half NRE constructs (Fig. 1.10). This RNA is then 
covalently linked to agarose beads and the beads are used to affinity-purify 
factors from HeLa cell nuclear extracts that can assemble onto the HPV-16 
NRE. Unbound proteins are removed by washing the beads four times in 
buffer D (20mM HEPES-KOH pH7.6, 5% glycerol, 0.1 M KCI, 0.2mM EDTA, 
0.5mM DTT) with 4mM MgCI2. Poly U RNA linked to sepharose beads was 
used as a control since this reflects the U-rich nature of the 3’ half of the 
NRE. A number of RNA processing factors, such as U2AF65 are known to 
bind strongly to U-rich sequences (Green, 1991). In addition, agarose beads 
that had not been linked to RNA were also incubated with nuclear extract as 
a negative control. Nuclear proteins that bound to the immobilized RNAs 
were eluted into protein loading buffer by heating the beads to 90°C for 5 
min, separated on a 12% SDS-PAGE gel and visualised by silver staining 
(Fig. 5.2B) since Coomassie blue staining was found not to be sensitive 
enough (data not shown). As with UV cross-linking, this method 
demonstrated that the NRE is capable of interacting with a range of cellular 
proteins (Fig. 5.2B, lane 2). However, the protein binding profile generated 
by UV cross-linking (Fig. 5.2A) is strikingly different from the profile produced 
by the RNA affinity chromatography approach despite the fact that the NRE 
RNA target is identical in both methods. In particular, the strong 65kDa band 
seen following UV cross-linking appears not to be pulled out in the RNA 
binding assay. In contrast, a number of smaller protein bands, ranging in 
size from 25 to 40kDa, are identified by affinity chromatography. Since polyU 
RNA would be predicted to bind a number of cellular proteins I was surprised 
that silver staining did not appear to identify proteins that could interact with 
this target (Fig. 5.2B, lane 3) however, in practice, it seems that it is 
generally difficult to detect polyU-bound cellular proteins (Baker, personal 
communication). Few proteins appeared to be bound by the unlinked 
agarose beads (Fig. 5.2B, lane 4). Unlike UV cross-linking, in which only 
cellular proteins that directly contact the target RNA can be irreversibly 
bound, the affinity chromatography approach allows the identification of
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proteins that touch the NRE directly, and also proteins that are constituents 
of NRE-bound protein complexes but do not themselves bind to the NIRE. 
This technical difference might help to explain the contrasting protein binding 
profiles generated by these assays.
5.1.3. The HPV-16 NRE can bind U2AF65, CstF-64 and HuR
The RNA affinity chromatography method was used to confirm that U2AF65, 
CstF-64 and HuR could bind to the NRE by immunoblotting with monoclonal 
antibodies directed against these cellular proteins (Fig. 5.3 A, B and G, lane 
1). The three cellular proteins could also be affinity purified from HeLa 
nuclear extracts using polyU RNA (Fig. 5.3 A, B, C, lane 2). It is interesting 
to note that despite the fact that polyU RNA bound proteins could not be 
visualised by silver staining (Fig. 5.2B, lane 2) each of the antibodies used in 
the Western blot analysis identified a strong specific band in the polylll 
samples. No bound proteins were identified in the agarose beads and 
nuclear extract sample using this technique (Fig. 5.3 A, B, C, lane 3).
Nuclear extract was included as a positive control for the Western blot (Fig. 
5.3 A, B, C, lane 4) and gave a strong specific band for each antibody tused.
5.1.4. The HPV-16 NRE can bind ASF/SF2 and Sm proteins
Silver staining of the affinity purified proteins identified a number of smiall 
nuclear proteins that could interact with the NRE. In an attempt to identtify 
these small proteins Western blot analysis was carried out using the 
monoclonal antibody, aSF2 96, directed against the 28kDa cellular proltein 
ASF/SF2, a member of the serine-arginine (SR) protein family of pre-rmRNA 
splicing factors. SR proteins are a family of nuclear proteins, 10 of which 
have been identified so far, with important roles in all aspects of pre-mRNA 
splicing (Zahler et al., 1992). As seen in Fig. 5.4A, ASF/SF2 can bind tthe 
NRE (lane 1), is unable to bind polyU RNA (Fig. 5.4A, lane 2), and was; not
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purified by unlinked agarose beads (Fig. 5.4A, lane 3). Nuclear extract was 
included as a positive control for the Western blot and produced a strong 
specific band (Fig. 5.4A, lane 4).
Western blot analysis was also performed using Y12, a monoclonal antibody 
directed against Sm proteins, which recognizes a band of approximately 
28kDa. Sm proteins range in size from 9 to 29kDa and form a complex that 
binds to several small nuclear RNAs (snRNAs), including the spliceosomal 
U1, U2, U4 and U5 snRNAs, which are essential for splicing (reviewed in 
Will etal., 1997). The FIPV-16 NRE can bind Sm proteins (Fig. 5.4B, lane 1), 
however, polyU RNA did not bind Sm proteins (Fig. 5.4B, lane 2) which is 
surprising given that, although their binding sites on each sn RNA differ, the 
conserved sequences of the Sm site are generally U-rich (Will et al., 1997). 
As with ASF/SF2, unlinked agarose beads could not bind Sm proteins (Fig. 
5.4B, lane 3) and again, nuclear extract was included as a positive control 
for the Western blot (Fig. 5.4B, lane 4). This experiment was repeated 
several times with each antibody and similar results were obtained.
5.1.5. The HPV-16 NRE does not bind the 70kDa subunit of UlsnRNP
Previous reports have demonstrated a specific protein-protein interaction 
between the 70kDa subunit of U1 snRNP (U1 70k) and ASF/SF2, which in 
turn can interact directly with U2AF35 (reviewed in Caceres etal., 1997). The 
primary role of U1 snRNP is in the recognition of 5’ splice sites. Western blot 
analysis of the RNA affinity purified proteins using H111, an antibody raised 
against the a70kDa subunit of U1 snRNP, was performed to establish if this 
protein interacts with the NRE. As shown in Fig. 5.5 A, the NRE was unable 
to bind this cellular protein (Fig. 5.5 A, lane 1). In addition, U1 70k does not 
appear to bind to poly U RNA (Fig. 5.5 A, lane 2), and the unlinked beads 
were also unable to bind this protein (Fig. 5.5 A, lane 3). The Western blot 
was successful as indicated by bands in the nuclear extract only sample
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(Fig. 5.5 A, lane 4), but there are clearly two bands present in this track, 
running between 65 and 70kDa; I am unable to account for the presence of 
the two bands but I have observed this pattern on other occasions (data not 
shown). It has previously been reported that the HPV-16 NRE is unable to 
bind U1 70k (Dietrich-Goetz et al., 1997). This experiment was repeated on 
at least three occasions with similar results (data not shown) leading us to 
conclude that U1 70k cannot bind to the NRE.
5.1.6. Binding of the U1 snRNP-A protein to the HPV-16 NRE
Since the NRE does not appear to bind the a70kDa subunit of U1 snRNP, 
attention shifted to another component of U1 snRNP, the U1 snRNP-A 
protein (U1A); the size of this cellular protein (32kDa) suggested that it might 
be a good candidate for one of the smaller nuclear proteins identified by the 
RNA affinity chromatography method. Western blot analysis with anti-U1A 
antiserum was used to determine if this protein could interact with the HPV- 
16 NRE. The results of this experiment were somewhat ambiguous (Fig. 5.5 
B and C); on at least two occasions U1A did not appear to bind the NRE 
(Fig. 5.5 B, lane 1). However, in at least two separate experiments the HPV- 
16 NRE did appear to bind U1A (Fig. 5.5 C, lane 1) and this was further 
complicated by the observation that while the first half of the NRE was 
unable to bind this protein (Fig. 5.5 C, lane 2), the second half of the NRE 
bound U1A quite strongly (Fig. 5.5 C, lane 3).
In order to clarify the situation with regards to the binding of U1A to the NRE 
an experiment, similar to that described in section 5.1.1, was carried out. A 
radiolabelled NRE probe was incubated with HeLa nuclear extract and 
following UV cross-linking the nuclear proteins bound to the NRE RNA probe 
were analysed by immunoblotting with anti-U1A antiserum. Samples of 
nuclear extract only and NRE-probe only were included as controls. Fig.
5.6A shows the protein binding profile generated using this method, while
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Fig. 5.6B indicates that U1A can be cross-linked to the HPV-16 NRE and this 
U1A specific band co-migrates with a protein band of approximately 35kDa 
in Fig. 5.6 A, lane 1.
This experiment was repeated using a radiolabelled full-length NRE and first 
half and second half NRE constructs (Fig. 5.7 A lanes 1, 2, 3). As controls, 
the full length NRE probe only (lane 4) and nuclear extract only (lane 5) were 
also subjected to UV irradiation. Following cross-linking, the proteins were 
separated on a 15% SDS-PAGE gel and Western blotted with anti-U1A 
antiserum. U1A could be cross-linked to the full-length and half constructs of 
the HPV-16 NRE (Fig. 5.7 A, lanes 1, 2, 3). U1A was also detected in the 
nuclear extract only sample as expected (Fig. 5.7 A, lane 5) but not in the 
NRE probe only sample (Fig. 5.7 A, lane 4). An additional band is visible on 
this blot running at approximately 25kDa but I am unsure of its identity or 
significance. This nitrocellulose membrane was then stripped to remove the 
primary and secondary antibodies and reprobed with 6CS, an antibody 
against the housekeeping protein, GAPDH, as a control for the amount of 
nuclear extract present in each sample. Since the nuclear extract sample 
that had been cross-linked (Fig. 5.7A, lane 5) was positive for U1A, one 
could argue that the presence of U1A in the samples containing the full- 
length or half NRE constructs was simply a result of the presence of nuclear 
extract. However, if the levels of GAPDH are compared in Fig. 5.7B, 
particularly in lanes 2, 3 and 5, it is clear that while the levels of GAPDH in 
these samples are very similar, the levels of U1A protein in the same 
samples in Fig. 5.7A differ, such that there appears to be more U1A protein 
binding in lanes 2 and 3 compared to lane 5 (first half and second half NRE 
constructs and nuclear extract only, respectively) suggesting that U1A can 
be cross-linked to the HPV-16 NRE. Nevertheless, it remains possible that 
the detection of U1A in the UV cross-linked samples containing the full- 
length or half-NRE constructs (Fig. 5.7A, lanes 1-3) merely reflects the 
presence of nuclear extract, particularly since the data generated using the 
RNA binding assay suggested that U1A was unable to bind to the first half of
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the NRE (Fig. 5.5C, lane 2). However, I feel that despite the shortcomings of 
these experiments the data indicates that U1A can interact with the HPV-16 
NRE, although this interaction may be of a transient nature.
5.1.7. Comparison of protein binding to the full-length and half NRE 
constructs
As mentioned previously, the HPV-16 NRE can be roughly divided into two 
halves: the first or 5’ half containing the putative stem loop structure and the 
four weak 5’ splice sites, and the second, 3’ half made up of the GU rich 
region (Fig. 1.10). Recent work in our laboratory has demonstrated that while 
the second half of the NRE is important for cellular protein binding, the first 
half is responsible for more of the inhibitory activity of the element (Cumming 
et al., 2002b). RNA corresponding to the full-length NRE, and the first and 
second halves was linked to agarose beads and incubated with HeLa 
nuclear extracts as previously described. Bound proteins were fractionated 
by SDS-PAGE and visualised by silver staining (Fig. 5.8). In agreement with 
previous observations, the 2nd half NRE construct appeared to bind more 
protein that the 1st half construct and, surprisingly, also bound more protein 
than the full-length NRE, although the overall profile was similar (Cumming 
et al., 2002b). This experiment was repeated a number of times with similar 
results. Some proteins in particular appeared to be bound particularly 
strongly by the second half of the NRE compared to the full-length construct, 
these included a protein, or possibly two proteins as a doublet, running at 
approximately 35kDa. In an attempt to identify this protein, Western blot 
analysis was carried out on the fractionated RNA bound proteins. Two 
proteins in particular, HuR and ASF/SF2, were considered good candidates 
given the size of the protein band and immunoblotting with antibodies 
against these proteins revealed that the ASF/SF2 was probably one of the 
proteins strongly bound by the second half of the NRE. HuR appears to 
require the full-length NRE for efficient binding (Fig. 5.9A, lane 1), whereas
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ASF/SF2 binds more strongly to the second half of the NRE than the first 
half or full-length constructs, (Fig. 5.9B, lanes 3, 2 and 1, respectively), 
possibly suggesting that efficient binding of this protein to the full-length NRE 
is blocked by binding of other cellular proteins.
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It was recently reported that upon induction of epithelial differentiation the 
levels of the NRE binding proteins U2AF65 and CstF-64 alter such that 
U2AF65 levels decrease and levels of CstF-64 increase with differentiation. 
Although the levels of HuR were unaffected by differentiation, accumulation 
of this protein in the cytoplasm was observed (Koffa et al., 2000). This work 
was carried out using the HPV-16 positive epithelial cell line, W12, and 
confluent cell monolayers were maintained in a high calcium and serum 
medium for 10 days to induce differentiation (Koffa et al., 2000). Conversely, 
a previous report had indicated that the level of expression of CstF-64 
decreased with differentiation in a HPV-31 positive cell line, LKP-31 
(Terhune et al., 1999). In this paper the authors induced differentiation by 
suspending the cells in semisolid methylcellulose medium for up to 24 h; this 
method has previously been shown to result in the activation of the viral late 
promoter, transcription of late genes and viral DNA amplification (Reusch et 
al., 1998). As previously discussed, in Chapter 3 ,1 have shown that epithelial 
cells differentiate spontaneously if grown in monolayer culture for 10 days. 
This observation might suggest that the undifferentiated cell population 
utilised by Koffa et al., had in fact begun to differentiate and therefore they 
were comparing cells at different stages of differentiation rather than 
undifferentiated cells with differentiated cells. If this were the case then this 
might help explain the difference between the reports concerning the 
expression of CstF-64.
The aim of the work presented here was to elucidate the changes in the level 
of expression of the NRE-binding proteins with differentiation, by comparing 
undifferentiated HPV-16 genome containing cell populations with 
differentiating HPV-16 genome containing populations. The effect of the 
status of the viral genome on these differential changes was compared using 
subclones of the W12 cell line containing episomal HPV-16 genomes i.e. the 
20863 line, and integrated copies of the HPV-16 genome i.e. the 20861 line 
(Jeon et al., 1995a).
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Previous reports have shown that integration of the HPV genome alters the 
differentiation programme of the infected cell (McCance etal., 1988, Rader 
et al., 1990, Merrick et al., 1992). This integration event frequently disrupts 
the early coding region and results in the loss of expression of all viral 
proteins, with the exception of the oncogenic proteins, E6 and E7. The E6 
and E7 proteins have many roles in the viral life cycle but their combined 
action can maintain the proliferative activity of infected cells, thus modifying 
the normal cellular differentiation programme (reviewed in Mantovani et al., 
2001, Munger etal., 2001). The HaCaT cell line contains no papillomavirus 
genomes and was used as a control for the differentiation of epithelial cells 
since this immortalised line has retained the ability to differentiate as 
demonstrated in Fig. 3.5B and as previously reported (Boukamp et al., 1988, 
Schoop et al., 1999).
Epithelial cells were grown in monolayer culture for 5 days and harvested as 
undifferentiated cells, and cells grown for 10 days were harvested as 
differentiating cells. Protein extracts were prepared and 10p.g of each 
extract, as calculated by Bradford assay, was fractionated by SDS-PAGE 
and the proteins visualised by Coomassie blue staining to confirm that 
comparable amounts of protein extract had been loaded in each lane.
Typical protein extracts from day 5 (undifferentiated) and day 10 
(differentiating) 20863 cells are shown in Fig. 5.10A, the protein profiles 
appear very alike indicating that each tract contains similar amounts of 
protein extract. In addition, a comparison of day 5 and day 10 protein 
extracts from 20863 and 20861 cells is shown in Fig. 5.10B, it appears that 
similar amounts of protein extract have been loaded and there does not 
appear to be any significant differences in the protein profile in these 
different lines, at least at the level of sensitivity provided by Coomassie blue 
staining. Day 5 and day 10 extracts from each line were analysed by 
Western blotting with the SY5 antibody, directed against involucrin (Fig.
5.11). From this figure we can see that in each line the level of expression of 
this differentiation maker increases between day 5 and day 10 extracts.
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However, it appears that the increase in expression of involucrin between 
day 5 and day 10 extracts of the 20861 line (Fig. 5.11B) is less significant 
than that observed in the 20863 and HaCaT samples (Fig. 5.11A and C).
This would tend to suggest that day 10 20861 cells are slightly less 
differentiated than similarly treated samples of 20863 and HaCaT cells, 
indicating that the integration of the HPV-16 genome in the 20861 line has 
disrupted the differentiation programme of these cells, in agreement with 
previous reports (McCance et al., 1988, Rader et al., 1990, Merrick et al., 
1992).
5.2.1. Differential expression of U2AF65 in monolayer cultures of 
epithelial cells
Fractionated protein extracts (10pg) prepared from day 5 and day 10 20863 
cells (Fig. 5.12A), 20861 cells (Fig. 5.12B), and HaCaT cells (Fig. 5.12C) 
were Western blotted with MC3, an antibody directed against U2AF65 In Fig. 
5.12A, lanes 1 and 2, U2AF65 appears to be moderately upregulated with 
differentiation in 20863 cells, while in 20861 cells (Fig. 5.12B, lanes 1 and 2), 
and HaCaT cells (Fig. 5.12C, lanes 1 and 2), this cellular protein is 
downregulated with differentiation. This experiment was repeated at least 
five times using different extracts from each cell line and while the level of 
U2AF65in differentiating 20861 cells was consistently downregulated, the 
level of this protein in differentiating 20863 cells and HaCaT cells varied, 
although the majority of blots indicated that U2AF65 expression increased in 
differentiating 20863 cells and decreased in differentiating HaCaT cells. As a 
control, a number of the nitrocellulose membranes were stripped after 
immunoblotting for U2AF65 and reprobed with 6CS, an anti-GAPDH 
antibody. A comparison of day 5 and day 10 extracts in each blot, (Fig.
5.12A, B, C, lanes 3 and 4), indicates that the samples contain similar 
amounts of protein and therefore the differences in the level of expression of 
U2AF65are not a result of uneven sample loading.
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5.2.2. Differential expression of CstF-64 in monolayer cultures of 
epithelial cells
Day 5 and day 10 protein extracts prepared from monolayer cultures of 
20863, 20861 and HaCaT cell lines were analysed by Western blot using the 
anti-CstF-64 antibody, a64k. The level of CstF-64 protein in 20863 cells 
appeared to decrease with differentiation (Fig. 5.13A, lanes 1 and 2); 
increase with differentiation in 20861 cells (Fig. 5.13B, lanes 1 and 2); and 
decrease moderately in the differentiating HaCaT cell line (Fig. 5.13C, lanes 
1 and 2). This experiment was repeated on at least three occasions for each 
cell line and with different samples. When the blots shown here where 
stripped and reprobed with an anti-GAPDH antibody, 6CS, each lane 
appeared to contain similar amounts of protein extracts (Fig. 5.13A, B and C, 
lanes 3 and 4), indicating that sample loading was equal. Our results tend to 
support the observations of Terhune et al., (1999) in that CstF-64 expression 
appears to decrease with differentiation in cells where the papillomavirus 
genome remains episomal.
5.2.3. Differential expression of HuR in monolayer cultures of epithelial 
cells
Western blotting with 16A5, an antibody directed against the shuttling protein 
HuR, indicated that 20863 cell differentiation leads to a modest decrease in 
the level of expression of HuR (Fig. 5.14A, lanes 1 and 2). In 20861 cells 
HuR is up regulated with differentiation (Fig. 5.14B, lanes 1 and 2), while in 
HaCaT cells the level of HuR protein appears unaffected by differentiation 
(Fig. 5.14C, lanes 1 and 2). Different extracts from each cell line were used 
to repeat this experiment at least three times, (data not shown), and the blots 
shown in Fig. 5.14 are representative of the majority of results obtained. In 
addition, the GAPDH protein levels appear comparable in the day 5 and day 
10 samples of each stripped and reprobed blot shown (Fig. 5.14A, B and C 
lanes 3 and 4).
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5.2.4. Differential expression of ASF/SF2 in monolayer cultures of 
epithelial cells
The aSF2 96 monoclonal antibody directed against ASF/SF2 was used to 
determine if epithelial cell differentiation affected the level of expression of 
this protein and this experiment was repeated at least three times. In Fig. 
5.15A, lanes 1 and 2, ASF/SF2 appears to be substantially upregulated with 
differentiation in 20863 cells, but appears to be downregulated in 
differentiating 20861 cells (Fig. 5.15B, lanes 1 and 2). In HaCaT cells, 
ASF/SF2 expression is slightly decreased with differentiation (Fig. 5.15C, 
lanes 1 and 2). Similar amounts of protein were loaded for each sample as 
indicated by the anti-GAPDH blots (Fig. 5.15B and C, lanes 3 and 4), 
however, Fig. 5.15A, lanes 3 and 4, indicates a lower level of GAPDH 
protein in day 10 20863 cells than the day 5 sample suggesting that the 
differential increase in ASF/SF2 expression may be even more pronounced 
than appears in Fig. 5.15A, lanes 1 and 2.
5.2.5. Differential expression of Sm proteins in monolayer cultures of 
epithelial cells
Based on the results obtained from three separate experiments, the level of 
Sm protein expression appears to be moderately upregulated with 
differentiation in both the HPV-16 positive cell lines, (Fig. 5.16A and B, lanes 
1 and 2), but in differentiating HaCaT cells, Sm proteins are slightly 
downregulated (Fig. 5.16C, lanes 1 and 2), as shown by Western blot 
analysis using Y12, an antibody directed Sm proteins. The blots shown are 
representative of the repeated experiments, which gave consistent results. 
When the levels of GAPDH were analysed in the stripped blots similar 
amounts of protein were found in day 5 and day 10 lanes in the 20861 and 
HaCaT blots (Fig. 5.16B and C, lanes 3 and 4), however, GAPDH levels in 
day 10 20863 cells were slightly higher than in the day 5 track (Fig. 5.16A, 
lanes 3 and 4) but I feel that this difference is not large enough to account for
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the differential increase in the level of Sm proteins observed in this line (Fig. 
5.17A, lanes 1 and 2).
5.2.6. Differential expression of U1A in monolayer cultures of epithelial 
cells
The effect of differentiation on the level of expression of U1A was analysed 
on three occasions by immunoblotting with rabbit antiserum raised against 
the protein. The level of U1A in 20863 and 20861 cells does not appear to 
be affected by differentiation, (Fig. 5.17A and B, lanes 1 and 2), and this was 
a consistent observation. However, differentiation of HaCaT cells results in a 
down regulation of this protein (Fig. 5.17C, lanes 1 and 2). The membranes 
shown in Fig. 5.17A, B and C (lanes 1 and 2) were stripped and reprobed 
with 6CS, an anti-GAPDH antibody, to check that the samples on each had 
comparable amounts of protein (Fig. 5.17A, B and C, lanes 3 and 4).
5.3.1. Expression of NRE-binding proteins in 20863 organotypic raft 
cultures
Total protein extracts were prepared from 20863 cells cultivated on 
organotypic raft cultures to enable us to analyse the level of expression of 
the NRE-binding proteins in a differentiating system that closely resembles 
the in vivo situation. Rafts were untreated (U), or treated with 10pM C8:0 
(C8) for 12 days at the air-liquid interface. Treatment with C8:0 (1, 2- 
dioctanoyl-sn-glycerol) is thought to facilitate a more complete differentiation 
programme through the activation of the protein kinase C pathway (Meyers 
etal., 1992, Ozbun etal., 1997). When the HPV-31 line, CIN 612 9E, is 
cultivated on the raft system, treatment with C8:0 is required for the 
synthesis of the late viral capsid proteins (Meyers et al., 1992). Based on our 
observations, however, C8:0 treatment of 20863 organotypic rafts, while 
perhaps enhancing the production of HPV-16 capsid proteins, is not 
necessary, since late proteins are also clearly detected in untreated rafts 
(Fig. 3.11). Protein extracts were fractionated by SDS-PAGE, transferred to
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membranes and immunoblotted with antibodies directed against each of the 
cellular proteins previously found to bind the NRE: U2AF65, CstF-64, HuR, 
ASF/SF2, Sm, and U1A (Fig. 5.18 A to F respectively). These experiments 
were repeated at least three times for each protein, and although the results 
varied between blots, it eventually became apparent, through repetition and 
by comparing sample loading by probing for GAPDH, that the level of 
expression of each of these cellular proteins appeared to be comparable 
between the untreated and C8 treated extracts. A number of the 
nitrocellulose membranes were stripped and reprobed with 6CS and a 
typical GAPDH blot is shown in Fig. 5.18G.
At first these results were quite surprising and appeared to contradict the 
observations I had previously made using protein extracts prepared from the 
same cell line grown in monolayer culture. However, I now believe that I 
detected no change in the level of expression of these proteins between 
untreated and C8:0 treated extracts because, unlike the material harvested 
from monolayer culture, I was not comparing undifferentiated with 
differentiating but rather like with like, in that, both samples were cultivated 
on the raft system and had therefore a large percentage of cells has 
commenced terminal differentiation i.e. as a heterologous cell population 
there was a low percentage of basal epithelial cells. This suggests that while 
C8 treatment of HPV-16 organotypic rafts may increase the expression of 
late viral proteins, as seen when E1AE4 and L1 proteins levels were 
compared between untreated and C8 treated rafts (Fig. 3.11), it has no 
obvious effect on the expression of the cellular proteins I have analysed. I 
have previously shown that C8:0 treatment does not affect the level of 
expression of the differentiation marker, involucrin (Fig. 3.7B, 3.9B). 
However, I did not attempt to detect changes in the level of expression of 
cellular markers expressed in more differentiated epithelial layers, such as 
filaggrin. Tissue harvested from organotypic rafts is a heterogeneous 
population of undifferentiated, differentiating and terminally differentiated 
cells that make up the various layers of the stratifying epithelium. I attempted
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to overcome this problem by soaking harvested raft tissue overnight in 
trypsin at 4°C to separate the uppermost cornified layer from the lower 
epithelial layers, this technique had previously been used successfully with 
biopsy tissue (David Millen, Histopathology, Western Infirmary, Glasgow 
personal communication). Unfortunately I succeeded only in floating the 
epithelial tissue from the collagen support; this experiment was repeated 
several times with varying concentrations of trypsin but with similar results 
(data not shown). Another shortcoming of this experiment is that the extracts 
prepared from the rafts contain so much protein that any small differences 
between the samples are masked, it may have been possible to identify 
subtle differences between untreated and C8 treated extracts if I had 
compared serial dilutions of the samples; unfortunately, however, I did not 
attempt this experiment due to a lack of time.
5.3.2. Expression of CstF-64 and U2AF65 in CIN 612 9E organotypic 
rafts
It is well established that C8:0 treatment of HPV-31, CIN 612 9E, rafts is 
required for efficient viral late protein production and therefore it is possible 
that, unlike HPV-16 rafts as discussed above, a comparison of untreated and 
C8 treated HPV-31 raft material would be equivalent to comparing 
differentiating protein extracts with terminally differentiated extracts. As HPV- 
31 positive cells, induced to differentiate with methylcelluose, show a 
differential decrease in expression of CstF-64 (Terhune et al., 1999), I 
decided to use CIN 612 9E cells grown on organotypic rafts for 12 days at 
the air-liquid interface in the presence of C8:0 (C8), or without treatment (U), 
to further investigate the changes in CstF-64 expression. In addition, I 
wanted to clarify the effect of C8 treatment on the expression of another 
cellular protein, U2AF65, in light of the observations I had made using C8- 
treated and untreated HPV-16 raft material. Moreover, it has recently been 
demonstrated that an NRE-like element (NLE) in the late 3’UTR of HPV-31 
can bind the cellular proteins CstF-64, U2AF65, and HuR (Cumming et al.,
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2002a). Protein extracts prepared from HPV-31 rafts were analysed by 
Western blotting using a64k and MC3 antibodies against CstF-64 and 
U2AF65 respectively. In agreement with Terhune et al., (1999) the level of 
CstF-64 in C8-treated CIN 612 9E cells was found to be less than that in 
untreated rafts (Fig. 5.19A). This also agrees with the result I generated for 
HPV-16 using 20863 monolayer cultures (Fig. 5.12A). The level of U2AF65 
was also found to decrease in C8-treated CIN 612 9E cells (Fig. 5.19B). 
These observations imply that C8:0 treatment of CIN 612 raft cultures is 
important not only for efficient expression of late viral proteins but also has 
an appreciable difference on the level of expression of at least two cellular 
proteins known to interact with the HPV-31 NLE, CstF-64 and U2AF65.
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5.4. Discussion
Since the discovery of the HPV-16 NRE, efforts have been focused on 
identifying the cellular proteins that interact with this element in an attempt to 
understand more fully the role it plays in the post-transcriptional control of 
viral late protein expression. Previously, the cellular proteins U2AF65, CstF- 
64 and HuR had been shown to bind directly to the HPV-16 NRE (Dietrich- 
Goetz et al., 1997, Koffa et al., 2000). Alternative approaches, described 
herein, have confirmed that these proteins do indeed bind the NRE. In 
addition, it has been shown that the NRE can also bind the cellular proteins 
ASF/SF2, Sm proteins and U1 A, but in agreement with previously published 
work, the NRE does not appear to bind the 70kDa subunit of U1 snRNP (U1 
70K) (Dietrich-Goetz et al., 1997). I specifically focused on cellular factors 
involved RNA processing, which obviously has the potential to be an 
important control mechanism in differential gene expression. Following the 
identification of these NRE-binding proteins, changes in the level of 
expression of each protein during epithelial cell differentiation were 
compared in the 20863, 20861 and HaCaT cell lines. The HaCaT cell line 
was used to establish the effect of epithelial differentiation on the expression 
of the cellular proteins in the absence of any HPV genomes. HaCaT cells 
have been shown to form almost regular epidermal architecture when 
transplanted onto subcutaneous tissue of athymic mice and also when 
grown on organotypic raft cultures and are therefore a very useful paradigm 
for skin keratinocytes In vitro (Boukamp et al., 1988, Schoop et al., 1999). 
Whilst terminally differentiating keratinocytes retain metabolic activity, this is 
generally restricted to regulating the pattern of keratin gene expression, and 
cellular proteins not directly involved in this process are believed to be 
downregulated with differentiation (Fuchs et al., 1994). As expected, the 
level of expression of all the cellular proteins tested decreased with 
differentiation in HaCaT cells, with the exception of HuR which appeared to 
be unaffected by differentiation. This observation is in agreement with a
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previous report in which the authors observed no change in expression of 
HuR following differentiation of spontaneously transformed A/J mouse lung 
tissue (Blaxall et al., 2000). A comparison of the HaCaT cell line with the 
HPV-16 positive 20863 and 20861 lines allows us to establish the effect of 
viral infection on the differential expression of the NRE-binding factors and 
also how the state of the viral DNA (i.e. episomal versus integrated) 
influences this pattern of expression (Table 5.1). Interestingly, I observed 
that 3 cellular proteins, with well-documented roles in splicing, U2AF65, 
ASF/SF2 and Sm proteins, were up regulated in differentiated 20863 cells, 
compared to the HaCaT controls. CstF-64 and HuR were downregulated 
with 20863 differentiation and the levels of U1A appeared to be unaffected.
In contrast to these observations, a previous study on the expression of 
U2AF65, CstF-64 and HuR in the W12 line had reported a differential 
decrease in U2AF65, an increase in CstF-64 and a redistribution of HuR with 
differentiation. There are a number of possible explanations for these 
differences: Firstly, the methods used to induce differentiation differ between 
the studies; we used prolonged growth in monolayer culture to induce 
differentiation, whereas differentiation was induced by increasing the calcium 
and serum concentration of the culture medium in the previous report. 
Furthermore, for the first time we were able to use a cell population that had 
characteristics of truly undifferentiated epithelial cells. Secondly, in the 
original report the state of the viral DNA was not analysed in the W12 cells. 
Since the cells used had reached quite a high passage number, (>40), it is 
likely that the HPV-16 genome had become integrated in these cells causing 
further disruption of the differentiation programme. I used a clonal derivative 
of the parental W12 line, the 20863 line, which stably maintains the virus 
genome as an episome when the cells are at low passage. Typically cells 
ranging in passage number from 15 to 18 were used and Southern blot 
analysis confirmed that the virus was episomal in these cell populations. 
When protein levels were analysed in the 20861 line, another clonal 
derivative of the W12 line in which the viral DNA is known to be integrated,
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U2AF65 expression decreased whereas CstF-64 expression increased with 
differentiation, in agreement with the original report by Koffa et al., (2000) 
indicating that the viral genome most likely was integrated in the late 
passage W12 cells used in that study. HuR appeared to be increased with 
differentiation in the 20861 line, however, we analysed nuclear extracts only 
and did not investigate the subcellular distribution of this protein following 
differentiation.
In contrast to what was observed in 20863 cells, ASF/SF2 levels decreased 
in differentiating 20861 cells, however, Sm protein expression was 
upregulated in both day 10 20861 and 20863 cells. In the 20861 line, 
integration of the HPV-16 genome leads to a specific increase in the 
expression of CstF-64 and HuR, when compared to cells harbouring 
episomal virus (20863) and no virus (HaCaT). Further analysis of differential 
gene expression in the 20861 line might provide interesting insights on the 
effect of viral integration on the expression of RNA processing factors, albeit 
in vitro. Much attention has been focused recently on delineating the 
molecular profile of various human tumours including lung cancer and 
prostate cancer by comparing differential gene expression profiles of normal 
and cancerous tissue (Blaxall et al., 2000, Dhanasekaran et al., 2001). It is 
hoped that by identifying the so-called ‘molecular signature’ of individual 
cancers this information could be used to improve detection rates through 
molecular classification and also aid the design of specific anti-cancer 
therapies.
It appears that differentiation of 20863 cells results in a specific increase in 
expression of two cellular factors U2AF65 and ASF/SF2, albeit slight for the 
former. Both of these proteins are known to play important roles in the 
regulation of splicing (reviewed in Caceres et al., 1997), and it is possible 
that a differential increase in expression of these factors is necessary to 
meet the demands of the increased rate of RNA processing during the 
productive stage of the viral life cycle. Alternatively, these proteins may be
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important in overcoming the negative effects of the NRE in differentiated 
cells. Either way, these results suggest that HPV-16 can circumvent the 
normal cellular differentiation programme to ensure these proteins are 
expressed when needed during the viral life cycle. A number of recent 
reports have noted altered expression of general splicing factors both during 
differentiation and also as a result of various modes of cellular 
transformation (Chabot et al., 1992, Hanamura etal., 1998, Maeda etal., 
1999, Shinozaki et al., 1999). In addition, it has been proposed that 
variations in the expression and activity of splicing factors during viral 
infection is important for the regulated expression of viral proteins. For 
example, it has been demonstrated that ASF/SF2 is partially inactivated 
during adenovirus infection to allow the early to late shift in viral mRNA 
expression (Molin et al., 2000). Also, the HIV Rev response element (RRE) 
has been shown to bind ASF/SF2 and this interaction is believed to facilitate 
the Rev mediated inhibition of HIV RNA splicing (Powell et al., 1997).
Clearly, RNA-processing events in mammalian cells are highly regulated to 
ensure appropriate and accurate gene expression.
Splicing is an integral event in RNA processing and involves the recognition 
of conserved intron sequences at the 5’ splice site, the 3’ splice site, and the 
branchpoint. The auxiliary splicing factor U2AF65 is an essential non-snRNP 
splicing factor which binds specifically to the pyrimidine tract upstream of a 3’ 
splice site, and facilitates the recruitment of U2 snRNP to the upstream 
branch site, thus triggering spliceosome assembly (reviewed in Green,
1991). U1 snRNP is primarily involved in the recognition of 5’ splice sites, but 
has also been shown to bind directly or indirectly at or near 3’ splice sites 
and may interact with U2 snRNP. Niwa et al., proposed an unconventional 
model, referred to as exon definition, to help explain splice site selection; 
they suggested that the exon, not the intron, is the unit of splice site 
recognition and that factors binding at the 3’ splice site of an upstream intron 
communicate across the exon with factors bound at the 5’ splice site of the 
downstream exon, resulting in definition of the exon (Niwa et al., 1992).
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Interactions between factors bound at the 3’ splice site and the 5’ splice site 
are thought to be mediated by SR (serine-arginine) proteins (reviewed in 
Benoit, 1996). In support of this, ASF/SF2, a member of the SR proteins, has 
been shown to interact simultaneously with the 35kDa subunit of U2AF and 
the 70kDa subunit of U1 snRNP (reviewed in Chabot, 1996, Caceres et al., 
1997). However, the exon definition model is challenged by definition of the 
final exon since at the 3’ end of a pre-mRNA, the terminal exon does not 
contain a downstream 5’ splice site but instead contains a polyadenylation 
site; therefore, it has been proposed that the 3’ terminal exon is defined by 
the presence of an upstream 3’ splice site and a downstream 
polyadenylation signal (Berget, 1995). This model therefore predicts that 
splicing factors bound to the 3’ splice site can communicate across a 
terminal exon with factors recognizing the polyadenylation signal and much 
evidence has accumulated in support of a physical linkage between splicing 
and polyadenylation (Zhao et al., 1999). The HPV-16 NRE is located 
upstream of the late polyadenylation signal of the terminal exon which 
encodes the viral capsid protein L1 and it is tempting to speculate that 
binding of RNA processing factors to the NRE might somehow promote 
definition of this final exon and improve the efficiency of polyadenylation of 
late mRNAs in differentiated cells by coupling the processes of splicing and 
polyadenylation. U2AF65 has been shown to interact directly with the 
carboxyl terminus of poly(A) polymerase (PAP), thus providing evidence of 
the coupling of splicing and polyadenylation (Vagner et al., 2000). Although 
U2AF65 is not normally known to bind 3’ UTR sequences, the U-rich nature 
of the second half of the NRE may be sufficient to enable binding of the 
protein to this element. Binding of U2AF65 to the NRE, and the elevated level 
of expression of this protein in differentiated 20683 cells, may improve the 
efficiency of polyadenylation of NRE-containing late mRNAs. Binding of 
ASF/SF2 to pre-mRNA has been shown to result in the recruitment of U1 
snRNP and facilitate enhanced binding of this factor to the target mRNA 
(Eperon et al., 1993). An increase in the level of expression of ASF/SF2 in
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differentiated 20863 cells might act to stabilize the binding of U1 snRNP in 
the region of the NRE, via the interaction between the 70kDa U1 snRNP 
subunit and ASF/SF2. In addition, ASF/SF2 can modulate the selection of 
alternative splice sites in a concentration-dependent manner, such that, an 
increase in ASF/SF2 can switch splice-site selection to the most proximal 5’ 
splice site (Lamond, 1991), in the absence of a 5’ splice site, as in the L1 
terminal exon, a differential increase in ASF/SF2 might promote a switch in 
poly(A) site usage from LP2 in undifferentiated cells to the weaker, NRE- 
proximal, LP1 in differentiated cells as observed by McGuire et al., (2002).
Efficient recognition of a polyadenylation signal is dependent not only on the 
highly conserved AAUAAA hexanucleotide but also requires RNA sequences 
surrounding this site, including both upstream and downstream efficiency 
elements (USEs and DSEs). USEs have been described in a variety of 
viruses including SV40, ground squirrel hepatitis virus, cauliflower mosaic 
virus, adenovirus type 2, and HIV 1, at a distance of 10-51nt upstream of the 
AAUAAA hexanucleotide, and although these elements are functionally 
similar, they share no apparent sequence homology apart from U-richness 
(Schek et al., 1992). The position of the NRE relative to the late poly(A) 
signal and its U-rich nature suggest that this element may act as a USE 
(McGuire et al., 2002). The U1A protein subunit of U1 snRNP has been 
shown to bind to an USE in the SV40 late poly(A) signal (Wassarman et al., 
1993, Lutz et al., 1994). Binding of U1A to this USE enhances 
polyadenylation at this site through efficient terminal exon definition and 
coupling of splicing and polyadenylation brought about by the direct 
interaction of U1A and the 160kDa subunit of the cleavage-polyadenylation 
specificity factor (CPSF), (Lutz et al., 1996). Further to this, it was reported 
that U1A increased polyadenylation of the SV40 late mRNA at lower 
concentrations but increasing the concentration of U1A had an inhibitory 
effect on polyadenylation (Lutz et al., 1996). It had previously been shown 
that free U1A protein could inhibit polyadenylation of its own pre-mRNA
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through an interaction with PAP (Boelens et al., 1993). We found that the 
level of U1A protein expression was unaffected by differentiation in 20863 
cells and it is likely that the cell avoids having an excess of free 111A in order 
to evade the possible negative effects of this situation on polyadenylation.
U1 snRNP can also be cross-linked to a site upstream of the USE in the late 
poly(A) region of SV40 and it has been suggested that this pattern of binding 
may be functionally important for communication across large terminal exons 
(Wasserman et al., 1993). Binding of U1 snRNP upstream of the SV40 USE 
brings U1A closer to the USE and thus avoids the possibility of U1A 
becoming dissociated from the pre-mRNA as it scans this large exon 
(Wasserman et al., 1993). Terminal exons are generally much larger that 
internal exons, which have an average size of 137 nucleotides, and the L1 
terminal exon is no exception at 1625nt. In the case of the HPV-16 late 
polyadenylation region, it is possible that the U1A protein, tethered at the 3’ 
splice site of the terminal exon via the interaction between U1 snRNP and 
U2 snRNP, diffuses along the terminal exon in search of the polyadenylation 
complex and the NRE acts as a USE-like reassociation point to aid in U1A 
diffusion. If the NRE was acting as a reassociation point for U1A as it 
scanned the exon this would be particularly useful during vegetative viral 
replication when late pre-mRNAs are being transcribed at a high rate and 
efficient processing is vital. The binding of U1A to this type of reassociation 
point would, by necessity, be weak and transient in nature and this might 
help explain the ambiguous data we obtained when attempting to analyse 
U1A binding to the NRE in that, UV cross-linking, on occasion, fixed a 
normally fleeting interaction between U1A and the NRE.
Once the poly(A) signal has been recognised, polyadenylation proceeds as a 
two step process involving cleavage of the primary transcript and addition of 
a poly(A) tail to the free 3’ end. CstF-64 is a polypeptide component of the 
cleavage stimulation factor (CstF) and this factor is known to bind 3’UTR 
sequences through its N-terminal RNA recognition motif, and this factor 
usually binds to U-rich or GU-rich downstream efficiency elements (DSEs) to
151
Chapter 5 - Results
regulate the specificity and efficiency of polyadenylation (Wahle et al., 1999). 
CstF-64 can also bind GU-rich elements upstream of the poly(A) site and 
binding of CstF upstream of the C2 complement gene AAUAAA 
hexanucleotide stimulates cleavage and poly(A) addition at this site (Moreira 
et al., 1998). In addition, the level of activity or abundance of CstF-64 has 
been implicated in the regulation of poly(A) site selection. For example, an 
increase in expression of CstF-64 upon B cell activation permits preferential 
use of the weaker upstream poly(A) site of IgM thus promoting a switch from 
the membrane bound to the secreted form of IgM (Takagaki et al., 1998). 
Conversely, during adenovirus infection the binding activity of CstF-64 
decreases, resulting in a switch from the use of the weak L1 mRNA poly(A) 
site to preferential usage of the stronger downstream L3 poly(A) site (Mann 
et al., 1993). In HPV-16, early viral transcripts are polyadenylated at a 
poly(A) site located at the end of the early region while the late viral 
transcripts are transcribed through this early polyadenylation site into the late 
polyadenylation region (Kennedy et al., 1990). In HPV-31 a differential 
decrease in the level of CstF is thought to increase early poly(A) site read- 
through, allowing transcription to proceed to the stronger late 
polyadenylation signal (Terhune etal., 1999). However, unlike HPV-31, the 
late poly(A) region of HPV-16 contains three potential polyadenylation 
signals LP1, LP2 and LP3 (Seedorf et al., 1985, Kennedy et al., 1990). In 
undifferentiated cells the stronger LP2 site is preferentially used but with 
differentiation polyadenylation is found to switch to the weaker, NRE- 
proximal, LP1 site (McGuire et al., 2002). A decrease in the levels of CstF- 
64, as observed in differentiating day 10 20863 cells, would normally result 
in the preferential usage of a stronger poly(A) signal e.g. LP2. Although 
changes in the RNA binding activity of CstF-64 were not investigated in this 
experiment, it is possible that a differential decrease in CstF-64 promotes 
early poly(A) site read-through, as in HPV-31, and another, HPV-16 specific, 
possibly NRE-controlled mechanism controls the switch in late poly(A) site 
usage.
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Following polyadenylation the message must be transported to the 
cytoplasm for translation. Interestingly, correct 3’ end formation is thought to 
be important for efficient mRNA export, which is believed to occur through 
nuclear pores (Green, 1991). Mounting evidence has implicated RNA- 
binding proteins as possible mediators of export. HuR is a ubiquitously 
expressed member of the Hu family of RNA-binding proteins related to 
Drosophilia ELAV and selectively binds AU-rich elements (AREs) in the 
3’UTR of mRNAs through one or more of its three RNA recognition motifs 
(reviewed in Brennan et al., 2001). ARE-containing transcripts are normally 
rapidly degraded, however, binding of HuR to ARE-containing mRNAs 
stabilizes these messages, although the mechanism is not yet fully 
understood (Brennan et al., 2001). HuR is a predominantly nuclear protein 
but has been found to shuttle between the nucleus and cytoplasm via a 
novel shuttling sequence (reviewed in Brennan et al., 2001). HuR’s ability to 
shuttle has led to the suggestion that this protein may initially bind mRNAs in 
the nucleus and accompany them into the cytoplasm, providing ongoing 
protection from the degradation machinery (Sokolowski et al., 1999). The 
HPV-16 NRE lacks the HuR consensus binding site, an AUUUA tandem 
repeat, but the presence of a tandem repeat of GUUUG might be sufficient 
to enable the protein to bind to this element. The apparent down regulation 
of HuR in the nuclear extracts of differentiated 20863 cells may be the result 
of a differentiation-induced redistribution of this protein to the cytoplasm 
resulting in the efficient export of HuR-bound late mRNA transcripts which 
would otherwise be prematurely degraded. For example, binding of HuR, 
and hnRNPC1/C2, to AU-rich elements in the late mRNAs of HPV-1 
stabilizes these messages and improves the efficiency of translation of these 
late proteins (Sokolowski et al., 1999). ASF/SF2 has also been shown to 
shuttle continuously between the nucleus and cytoplasm, and this protein 
appears only to exit the nucleus when bound to RNA, thus raising the 
possibility that, in addition to its role in splicing, ASF/SF2 may be able to
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mediate the export of mRNAs to which it is bound, such as HPV-16 late 
mRNAs, possibly in cooperation with HuR (Caceres et al., 1998).
I did not specifically address the basis of the inhibitory effect of the NRE in 
undifferentiated cells, however, I feel that the expression of late viral proteins 
in differentiated cells, and conversely the absence of late protein expression 
in undifferentiated cells, is controlled by a combination of differentiation- 
dependent events in which the NRE plays a pivotal role. Firstly, the switch 
from early promoter to late promoter usage in differentiated cells is crucial 
and leads to an abundance of late pre-mRNAs which might serve to titrate 
out inhibitory factors present in undifferentiated cells that possibly prevent 
binding of RNA processing factors necessary for late protein expression to 
the NRE. Secondly, although it has not yet been demonstrated for HPV-16, it 
is highly likely, by analogy with HPV-31 that the early polyadenylation 
sequence allows read-through in undifferentiated cells, but the transcripts 
are either prematurely terminated or rapidly turned over. Upon differentiation, 
read-through increases and transcription is allowed to proceed to the late 
polyadenylation region and this may be mediated by a decrease in the level 
of expression of CstF-64, as observed in differentiated 20863 cells. The 
early polyadenylation signal of HPV-16 contains a very weak CstF binding 
site and therefore a differential decrease in CstF expression would be 
expected to promote a switch to the stronger late poly(A) site. In combination 
with the increased read-through, it is probable that late messages are 
polyadenylated more efficiently in differentiated cells since the NRE may be 
acting as a USE-like element thereby promoting efficient polyadenylation of 
NRE-containing late mRNAs through the coupling of NRE-bound splicing 
factors with the polyadenylation complex. Stabilisation and rapid export of 
late mRNAs to the cytoplasm, mediated by NRE-bound HuR and ASF/SF2, 
thus avoids the degradation machinery that possibly functions in 
undifferentiated cells to degrade unstable late messages and facilitates 
expression of late viral proteins, Fig. 5.20.
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Fig. 5.2. Comparison o f the protein binding profiles of NRE RNA 
probes using UV cross-linking and affin ity chromatography. A.
UV cross-linking with an NRE RNA probe and HeLa nuclear extracts. 
B. Silver staining of NRE RNA linked agarose beads (lane 2), poly U 
linked sepharose beads (lane 3) and agarose beads (lane 4) following 
incubation with HeLa nuclear extract. Lane 1 contains rainbow protein 
molecular weight marker.
Fig. 5.3. Western blot analysis of proteins binding to the NRE 
following an RNA binding assay. NRE RNA linked agarose beads 
(lane 1), poly U RNA linked sepharose beads (lane 2) and agarose 
beads (lane 3) were incubated with HeLa nuclear extract, unbound 
proteins were removed by washing, bound proteins were eluted and 
separated on a 12% SDS-PAGE gel together with nuclear extract 
(lane 4) and transferred to nitrocellulose membrane. A. Western 
blotting using MC3, an antibody directed against U2AF65. B. Western 
blotting with an anti CstF-64 antibody, a64k. C. Western blotting with 
an antibody against HuR, 16A5.
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Fig. 5.4. The HPV-16 NRE can bind ASF/SF2 and Sm proteins.
NRE RNA-linked agarose beads (lane 1), poly U RNA linked 
sepharose beads (lane 2) and agarose beads (lane 3) were incubated 
with HeLa nuclear extract, unbound proteins were removed by 
washing, bound proteins were eluted and separated by SDS-PAGE 
together with nuclear extract (lane 4) and transferred to nitrocellulose 
membrane. A. Western blotting with an antibody directed against 
ASF/SF2, aSF2 96. B. Western blotting with Y12, an anti-Sm protein 
antibody.
Fig. 5.5.Binding o f U1 snRNP subunits to the NRE. NRE RNA
linked agarose beads (lane 1), poly U RNA linked sepharose 
beads (lane 2) and agarose beads (lane 3) were incubated with 
HeLa nuclear extract, unbound proteins were removed by 
washing, bound proteins were eluted and separated by SDS- 
PAGE together with nuclear extract (lane 4) and transferred to 
nitrocellulose membrane. A. Western blotting with H111, an 
antibody directed against the a 70kDa subunit of U1 snRNP. B. 
Western blotting with anti-U1A antiserum. C. Agarose beads 
linked with full-length NRE RNA (lane 1), RNA corresponding to 
the 1st half of the NRE (lane 2) and RNA corresponding to the 
2nd half of the NRE (lane 3) Western blotted with anti-U1A 
antiserum.
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Fig. 5.7. Western blot analysis of U1A binding to the NRE 
follow ing UV cross-linking. A. Radiolabelled RNA probes 
corresponding to the full-length NRE (lane 1), the 1st half NRE (lane 
2) and the 2nd half NRE (lane 3) were incubated with 2pl of HeLa 
nuclear extract, UV irradiated, and separated on a 15% SDS-PAGE 
gel together with the NRE probe (lane 4) and HeLa nuclear extract 
(lane 5) and transferred to nitrocellulose membrane. A. 
Immunoblotting with anti-U1A antiserum. B. The nitrocellulose 
membrane was stripped and reprobed with 6CS, an antibody directed 
against GAPDH.
kDa
-97.4
- 66.0
-46.0
-30.0
"21.5
Fig. 5.8. Comparison of protein binding to full-length and half 
NRE RNA constructs. Full-length NRE RNA (lane 1), RNA 
corresponding to the 1st half of the NRE (lane 2) and RNA 
corresponding to the 2nd half of the NRE was linked to agarose 
beads and incubated with HeLa nuclear extracts, together with 
unlinked beads (lane 4). Bound proteins were separated by SDS- 
PAGE and visualised by silver staining. Lane 5 contains rainbow 
protein molecular weight marker.
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Figures 5.12-5.17. Western blot analysis of protein 
expression in monolayer cultured cells. Protein extracts were 
prepared from 20863 cells (A), 20861 cells (B), and HaCaT cells 
(C), grown in monolayer culture for 5 days (lanes 1 and 3) and 10 
days (lanes 2 and 4); 10pg of each extract were separated by 
SDS-PAGE and transferred to nitrocellulose membrane:
5.12 A, B and C, lanes 1 and 2. Western blotting with MC3, an 
anti-U2AF65 antibody
5.13 A, B and C, lanes 1 and 2. Western blotting with a64k, an 
antibody against CstF-64
5.14 A, B and C, lanes 1 and 2. Western blotting with 16A5, an 
anti-HuR antibody
5.15 A, B and C, lanes 1 and 2. Western blotting with aSF2 96 
an antibody directed against ASF/SF2
5.16 A, B and C, lanes 1 and 2. Western blotting with Y12, an 
antibody against Sm proteins
5.17 A, B and C, lanes 1 and 2. Western blotting with anti-U1A 
antiserum
5.12-5.17 A, B and C, lanes 3 and 4. Blots were stripped and 
reprobed with an antibody against GAPDH, 6CS.
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Fig. 5.18. Analysis of protein expression in C8 treated and 
untreated raft material by Western blotting. 10 pi of protein 
extracts were prepared from 20863 cells grown on organotypic rafts 
either untreated (U), or treated with 10pM C8:0 (C8), for 12 days at 
the air-liquid interface, each extract was separated by SDS-PAGE 
and transferred to nitrocellulose membrane. A. Western blotting with 
anti-U2AF65’ MC3. B. Western blotting with a64k, an anti CstF-64 
antibody. C. Western blotting with 16A5, anti-HuR antibody. D. 
Western blotting with aSF2 96, an anti-ASF/SF2 antibody. E. 
Western blotting with an anti-Sm antibody, Y12. F. Western blotting 
with anti-U1A antiserum G. A number of nitrocellulose membranes 
were striped and reprobed with 6CS, an antibody directed against 
GAPDH.
A U2AF6S B CstF-64 c
kDa ,, „ „  kDa
U C8 U C8
kDa
97.4 -  97.4 -  97.4
6 6 . 0 “  w  6 6 . 0 “  66.0
46.0 ”  46.0 “  46.0
30.0 ”  30.0 -  3o.o
2 1 .5 -  2 1 .5 -  215
ASF/SF2 Sm
D E
kDa U C8 kDa U C8
66.0 -66.0 -
46.0 -
30.0 -  
21.5 -
46.0 -
30.0 -
21.5 -
p U1A GAPDH
kDa U C8 U C8
66.0 "
97.4 -
66.0 "  46  0 ”
46.0 ~ 30 0 “
30.0 ~ 21.5 _
HuR
U C8
h
•  •
1 2
1 2 1 2
B
CstF-64 U2AF65
kDa c o 00 kDa c o 00
97.4 - 97.4 -
• g
I
66.0 - 66.0 -
46.0 - 46.0 -
30.0 - 30.0 -
21.5 _
1 2
21.5 _
1 2
Figure 5.19. Protein expression in CIN 612 9E organotypic raft 
cultures. Protein extracts were prepared from CIN 612 9E cells 
grown on organotypic rafts either untreated (U), or treated with 
10pM C8:0 (C8), for 12 days at the air-liquid interface. 10 pi of each 
extract was separated by SDS-PAGE gel and transferred to 
nitrocellulose membrane. A. Western blotting with aCstF-64. B. 
Western blotting with MC3, an antibody directed against U2AF65.
U2AF65 ASF/
SF2
Sm CstF-64 HuR U1A
20863 0 4 4
20861 u i 0 t f —
HaCaT 4 i 1 4 — 4
Upregulated j^Downregulated c— ^ Unchanged
Table 5.1: Results of Western blot analysis of day 5 (undifferentiated) and day 
10 (differentiated) protein extracts using antibodies directed against each of the 
NRE-binding proteins.
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G eneral Discussion
CHAPTER 6: General Discussion
In this study I have described the development of a tissue culture system in 
which to study the differentiation of HPV-16 positive epithelial cell lines in 
monolayer culture. I have found that continued growth of both the parental 
W12 cell line and the 20863 subclone of this line, as well as the HaCaT cell 
line, in monolayer cultures for up to 10 days, in the absence of phorbol ester 
treatment, results in the initiation of differentiation, as indicated by a 
substantial increase in the level of expression of the keratinocyte-specific 
marker of differentiation, involucrin. Furthermore, a low level of expression of 
the HPV-16 late viral proteins E1AE4 and L1 was detected in day 10 
monolayer cultures of the W12 and 20863 lines. While several previous 
studies have reported the detection of late viral transcripts in monolayer 
cultures, this is this first report, to our knowledge, of the detection of viral 
capsid protein expression in such cultures. In contrast, it appears that if the 
W12 and 20863 lines are maintained in monolayer culture for up to 5 days 
they remain essentially undifferentiated, as indicated by a low level of 
expression of involucrin, and little or no viral late protein expression. I believe 
that we now have a reliable, reproducible system capable of generating 
undifferentiated and differentiating populations of HPV-positive cells for use 
in the study of the regulation of HPV-16 late protein expression in response 
to epithelial differentiation.
I have also characterised the growth of HPV-16 positive epithelial cells on 
the organotypic raft culture system. This method has been used extensively 
to study other HPV-positive cell lines, since this system can faithfully mimic 
the epithelial differentiation programme as seen in vivo, and is therefore a 
useful tissue culture system in which to study the complete viral life cycle, 
which is exclusively linked to the keratinocyte differentiation programme. I 
found that after 12 days at the air-liquid interface, HPV-16 positive tissue 
expressed readily detectable levels of L1 mRNA; amplification of viral DNA
155
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was also observed by Southern blot analysis. Moreover, E1AE4 and L1 
protein expression was detected both by Western blot analysis of protein 
extracts prepared from harvested rafts and also by immunocytochemistry on 
harvested raft sections. It appears that while phorbol ester treatment of the 
biopsy-derived HPV-16 positive W12 line, and the 20863 subclone, 
enhances late protein expression it is not necessary; this contrasts with 
previous reports concerning the biopsy-derived HPV-31 cell line, CIN 612, 
for which phorbol ester treatment is required for virion synthesis on 
organotypic rafts (Meyers e ta l., 1992, Ozbun etal., 1997). However, our 
observations are supported by additional reports using HPV-positive lines 
established using cloned viral DNA, in which completion of the viral life cycle 
on organotypic rafts is not dependent on PKC-induced changes in the 
differentiation programme (Frattini etal., 1996, 1997, Meyers etal., 1997, 
Thomas etal., 2001). Taken together, the results presented herein, using 
both the monolayer and raft culture systems, support the concept that the 
productive stage of the HPV life cycle is dependent on epithelial 
differentiation.
The requirement of host tissue differentiation for efficient viral replication is 
not unique to papillomaviruses and has been described for a number of 
other viral systems including cytomegalovirus (Weinshenker et a i, 1988), 
Epstein-Barr virus (Li etal., 1992), human immunodeficiency virus (Cullen et 
al., 1989), measles virus (Schneider-Schaulies et a!., 1993), and Rift valley 
fever virus (Lewis et al., 1989). The process by which differentiation 
activates the productive HPV life cycle is an area of great interest and the 
identification of the mechanisms controlling the differential expression of the 
late viral proteins has been a longstanding challenge in the study of HPV 
biology. In the case of HPV-16, a 79nt negative regulatory element (NRE) 
located within the late 3’ untranslated region (UTR) is believed to play a 
central role in controlling the pattern of viral late protein expression (Kennedy 
et al., 1990, 1991, Dietrich-Goetz etal., 1997, Koffa etal., 2000, McGuire et
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al., 2002). This c/s-acting element can inhibit reporter gene expression 
following transient transfection in basal epithelial cells (Kennedy et al.,
1990). Moreover, this element has been shown to act as a general regulator 
of polyadenylation; it appears to control the differential usage of late 
polyadenylation signals as well as acting as a transcriptional pause site 
(McGuire et al., 2002). I have carried out saturating site-directed 
mutagenesis of the NRE and the results tend to suggest that no single short 
sequence is responsible for the inhibitory activity of this element or its ability 
to interact with a range of cellular proteins. In fact, it appears that while each 
half of this element has independent inhibitory activity, the full 79nt are 
required for maximal inhibition (Cumming et al., 2002b). This contrasts with 
the situation in both BPV-1 and HPV-1, where the inhibitory activity of 
negative elements within the late 3’ UTR of these viruses has been mapped 
to distinct short sequences (Furth et al., 1994, Tan et al., 1995a).
Given the putative role of the NRE in post-transcriptional control 
mechanisms, it is not surprising that this element has been shown to interact 
with a range of cellular proteins (Dietrich-Goetz et al., 1997). These include 
the auxiliary splicing factor, U2AF65, the polyadenylation factor CstF-64, and 
the elav-like HuR protein (Koffa etal., 2000). It seems likely, given the 
limited coding potential of the papillomavirus genome, that the virus is 
dependent on interactions with cellular factors, such as these, to direct the 
pattern of late gene expression. In this report I have confirmed that the NRE 
can bind U2AF65, CstF-64 and HuR using an affinity-chromatography based 
RNA binding assay. Furthermore, I have used this assay to show that the 
NRE can interact with three additional cellular proteins, ASF/SF2, Sm and 
U1A, which are primarily involved in pre-mRNA splicing: ASF/SF2 is a 
member of the splicing-related (SR) protein family and has also been 
reported to shuttle between the nucleus and cytoplasm. Sm proteins form a 
complex that binds to several small nuclear RNAs (snRNAs), including U1 
snRNP, the primary function of which is the recognition of 5’ splice sites;
157
G eneral Discussion
U1A is a subunit of U1 snRNP (reviewed in Will etal., 1997, Caceres etal., 
1997).
In addition, using undifferentiated and differentiating cell populations from 
monolayer cultures of HPV-16 positive cell lines and the HaCaT cell line, I 
have shown that differential changes in the level of expression of these 
NRE-bound cellular proteins are dependent on the status of the viral genome 
in the infected cell: In the absence of HPV-16 infection, each of the NRE- 
binding proteins is downregulated with differentiation, with the exception of 
HuR, which remains unchanged. However, when the HPV-16 genome is 
episomal, as it is in the 20863 and W12 cell lines, a specific upregulation of 
the splicing factors U2AF65 and ASF/SF2 was observed upon differentiation. 
In contrast, when the viral genome is integrated, as is the case in the 20861 
cell line, as well as many cervical carcinomas, a specific upregulation of the 
polyadenylation factor CstF-64, and the shuttling protein HuR, was detected 
following differentiation. While it is possible that a differential increase in the 
expression of NRE-bound splicing factors in the 20863 cell line facilitates the 
increase in viral RNA processing during the productive phase of the viral life 
cycle, I favour the hypothesis that these splicing factors are important in 
overcoming the negative effects of the NRE in differentiated cells. Similarly, 
changes in the expression and activity of splicing factors during the life cycle 
of other viruses, including adenovirus and HIV, regulates the expression of 
viral proteins in these infections (Powell et al., 1997, Molin et al., 2000). I 
propose that the differential increase in expression of these cellular splicing 
factors during the late stages of the HPV-16 life cycle improves the efficiency 
of polyadenylation of late messages through enhanced terminal exon 
definition, brought about by direct interactions between splicing factors 
bound by the NRE, and the downstream polyadenylation complex. While 
direct interactions between splicing and polyadenylation factors in the late 3’ 
UTR of BPV-1 have been shown to reduce polyadenylation of late messages 
in this system (Furth etal., 1994, Gunderson etal., 1998), interactions
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between the splicing and polyadenylation machinery in the late 
polyadenylation region of SV40 promotes 3’ end processing of these 
messages (Lutz et al., 1994, 1996). Moreover, it is possible that the late 
HPV-16 messages are more stable and exported more efficiently from the 
nucleus to the cytoplasm, in differentiating cells, as a result of the shuttling 
activity of NRE-bound HuR and ASF/SF2 (Caceres et al., 1998, Brennan et 
al., 2001).
While I have reported the identification of several additional NRE-binding 
proteins, there are a still a large number of cellular factors capable of 
interacting with this element that remain unidentified. Identification of other 
NRE-binding proteins will help elucidate the precise mechanisms by which 
the NRE regulates HPV-16 late gene expression. To this end, a limited 
proteomics approach is currently being undertaken in our laboratory which 
aims to identify as many proteins as possible that bind to the NRE, both in 
undifferentiated and differentiating epithelial cells. This information could 
also help with the characterisation of protein complexes that form upon the 
NRE. In addition, use of the organotypic raft culture system to follow the 
pattern of expression of NRE-binding proteins during epithelial differentiation 
will be very useful in understanding the basis of the tight linkage of epithelial 
differentiation and viral late protein expression.
Attempts to construct an NRE-deletion mutant in the context of the viral 
genome were unsuccessful during the course of the work presented here, as 
described in section 4.2. Nevertheless, this objective is still being actively 
pursued in the laboratory and additional cloning strategies are currently 
being tested. An alternative approach to negating the NRE in the context of 
the viral genome might be to construct plasmids with the potential to express 
anti-sense NRE RNA molecules, either constitutively, or under the control of 
a differentiation inducible promoter. Stable transfection of these plasmids
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into HPV-16 epithelial cell lines might give some insight to the role of this 
element in vivo, during the epithelial differentiation programme.
At present, only a small number of groups world wide study the mechanisms 
controlling the tight linkage between the differentiation programme of HPV- 
infected cells and completion of the viral life cycle, and the role(s) of virally 
encoded cis-acting factors in this process. There are number of reasons for 
this, one of which is the sheer volume of research efforts currently focused 
on the study of the HPV oncoproteins E6, E7, and to a lesser extent, E5. The 
importance of these studies can not be over emphasized since the 
information they generate gives invaluable insights to cellular control 
mechanisms. Moreover, since these oncoproteins are the only viral proteins 
expressed in cervical carcinoma cells they can be exploited as cell-type 
specific targets of therapeutic cancer vaccines. However, it is also important 
to bear in mind that any treatment which could specifically disrupt the pattern 
of viral late gene expression would be a powerful tool in eliminating 
transmission of infectious HPV virions, thus precluding the need for 
therapeutic cancer vaccines. For example, if late protein expression could 
be induced earlier in the HPV-life cycle i.e. in the basal cells of the 
epithelium, this might enable the host immune system to mount a successful 
attack on the virus. Alternatively, if late protein expression could be blocked 
completely then mature virions could not assemble. Clearly, the 
development of either of these strategies is complex and requires a more 
complete understanding of the control of late viral protein expression in 
response to epithelial differentiation. The difficulties associated with 
recreating accurate skin models in vitro, from which populations of 
undifferentiated, differentiating and terminally differentiated HPV-positive 
cells can be produced is one of the major factors impeding progress in this 
field. For HPV-16 in particular, the inability to produce infectious virions from 
organotypic raft cultures of the HPV-16 positive epithelial lines currently 
available has resulted in this subtype being largely ignored in favour of, one
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might argue, less-clinically important but more user-friendly PV types such 
as BPV-1, HPV-1 and HPV-31. Nonetheless, studies utilising these viral 
types provide much needed general information about control mechanisms 
that may be conserved amongst papillomaviruses. However, these studies 
also highlight the diversity of regulatory mechanisms employed by this viral 
family. Therefore, it is crucial that we continue to identify the specific 
methods used by individual HPV types to control the pattern of late gene 
expression, particularly in the clinically relevant types, such as HPV-16. Only 
by understanding the intricacies of the HPV life cycle more fully will we be 
able to design effective treatments to eliminate HPV-associated disease in 
the future.
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